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1Summary of the Thesis 
Aromatic organic compounds are ubiquitous in the modern society as medicines and 
functionalized materials. Heteroaromatic compounds have attracted considerable 
attention in these areas. Heterocycles are one of the most important organic structural 
motifs in a myriad of pharmaceutically active compounds and organic materials.  
Therefore, the efficient synthesis of heterocycles and their derivatives has been a topic of 
great interest from the perspective of medicinal chemistry and organic synthesis. The 
simplest approach among the synthetic strategies is the arylation of heterocyclic C-H 
bonds. Palladium-catalyzed transformations possess an interesting and remarkable power 
for C-C bond formation. 
The aim of the present dissertation is to enhance the scope of palladium-catalyzed 
reactions. This paragraph outlines the tasks of this thesis. A more detailed introduction is 
given at the beginning of each chapter. 
The first task was to synthesize 1-deazapurines from primary amines and 1,3-
electrophilic reagents. After that Pd/Cu catalysed reactions afforded arylated products of 




























In Prof. Langer’s research group, a number of di- and trihalogenated molecules or the 
corresponding triflates have already been studied with regard to the site-selectivities of 
Pd(0)-catalysed cross-coupling reactions. 
2In continuation to that work, Pd(0)-catalysed reactions were carried out on 5,7-dichloro-












Another task was to study the regioselective cross-coupling reactions of 2,6-
dichloroquinoxaline. These reactions afforded mono- and diarylated quinoxaline 








In addition, 2,4-dichloro-1-trifluoromethylbenzene was also studied for Pd(0)-catalysed 
cross coupling reactions. These reactions afforded the desired arylated products with 










3Chapter 1: Synthesis of arylated 1-deazapurines via C-H bond activation
1 Pd/Cu Catalysed Arylation of 1-Deazapurines via C-H Bond Activation 
1.1 General Introduction 
Heterocyclic compounds play a role of immense importance in human life because of 
their widespread applications, medicinal value in particular. Nitrogen heterocycles 
possess diverse medicinal potential that’s why these compounds have received special 
attention in pharmaceutical chemistry.1 Nitrogen-containing heterocycles are integral 
components of natural products, dyes, agrochemicals, and pharmaceuticals.2  
Benzimidazoles are amongst the nitrogen containing pharmacologically active 
heterocyclic compounds.3 Various compounds with benzimidazole motif possess a broad 
spectrum of biological activities including potent antifungal,4 cytotoxic,5 anticancer and 
antimetastatic (Tilomisole),6 antitumor (TBZ),7 anthelmintic (Albendazole (Abz), 
























































Figure 1. Pharmacologically relevant benzimidazole derivatives 
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Besides, vitamin-B12 contains a benzimidazole moiety.11 Similarly, many commercially 
available drugs and pharmaceuticals contain a benzimidazole motif, such as Pradaxa, 
Astemizole, Omeprazol, Candesartan and Pentostatin.12 Furthermore, benzimidazoles and 
related compounds act as corrosion inhibitors for metals and alloys.13
Purine and its derivatives are structural elements of therapeutic drug molecules. Many 
molecules with purine motif display a wide variety of interesting biological properties. 
Some of them are reported as adenosine receptor ligands,14 modulators of multidrug 
resistance,15 antiviral and antitumor agents,16 antineoplastic agents,17 and enzyme 
inhibitors.18 For the finding of new biologically valuable agents, medicinal chemists and 
biochemists study structural modifications of naturally occurring nucleosides.19 All such 
biological aspects are relevant for deazapurine derivatives. For example, carbocyclic 
nucleosides 3-deazaaristeromycin20 and 3-deazaneplanocin21 are noteworthy motifs 















Figure 2. Pharmacologically relevant 3-deazapurine derivatives 
7-Deazapurine nucleosides with frequent occurrence possess interesting biological 
properties. For example, a number of derivatives have been reported to show antiviral 
activities.22 
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1.2 Introduction 
Imidazo[4,5-b]pyridine (commonly known as 1-deazapurine) is an important 
pharmacophore which leads to the synthesis of a number of biologically relevant targets.  
1-Deazapurines constitute an important class of heterocyclic compounds which exhibit a 
broad spectrum of pharmacological properties.23 1-Deazapurine is a common structural 
motif found in numerous molecules that display antiviral, antifungal, antibacterial and 
antiproliferative activities. The potent biological activities and the prevalence of 1-
desazapurines in both natural products and pharmaceuticals has inspired significant 
interest in the synthesis of these heterocycles.24 1-Deazapurine derivatives have been 
reported as potential phosphodiesterase inhibitors,25 adenosine deaminase (ADA) 
inhibitors,26 GPR4 receptor antagonists,27 aurora-kinase inhibitors (CCT 129202), AT1 
receptor (L-158,809) and AT1 antagonist28 (Figure 3). 
Some derivatives are reported to exhibit antitumor, anti-HIV-1, cytotoxic and adenosine-
deaminase inhibition activities29 along with in vivo activity against mouse leukemia.30 
Additionally, imidazo[4,5-b]pyridin-2-ones have been reported as nonsteroidal anti-
inflammatory and analgesic agents31 (Figure 3) with antidepressant, antiphlogistic, 
cardiotonic, hypotensive, antiarrhythmic and antisecretory biological activities.32 
Furthermore, 1-deazapurine derivatives are also considered as candidates for components 
of unnatural base pairs that are expected to develop novel functional biopolymers.33
















































Figure 3. Pharmacologically relevant imidazo[4,5-b]pyridines (1-deazapurines) 
C-H bond activation is an important area of organometallic chemistry that provides 
improved protocols in synthetic organic chemistry. In recent years, direct C-H activation 
reactions have received prominent attention34 as an alternative method to cross-coupling 
reactions with the use of organometallics. Direct C-H arylation of arenes and 
heterocycles has been achieved by using, e.g., Rh,35 Ru,36 or Pd37 catalysis using different 
bases and many types of aryl halides. I have studied the Pd/Cu catalysed arylation 
reactions of 1-deazapurine. 
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Direct C-H arylation of 1-deazapurine to the 2-position by diverse aryl halides was 
achieved with Pd catalysis in the presence of CuI and Cs2CO3, following a procedure38 
already reported. 
1.3 Results and Discussion 
5-Aminoimidazoles 3a-d were generated in situ by reaction of methyl N-
(cyanomethyl)formimidate (1) with primary amines (2a-d) in continuous argon supply 













Scheme 1. Synthesis of 5-aminoimidazoles 3a-d (generated in situ). Reagents and 
conditions: (i) CH2Cl2, Argon, Reflux, 2h. 
The in situ generated imidazoles 3a-d were treated with an equivalent amount of 1,3-
electrophilic reagents (4a-e) and the reactions afforded the corresponding substituted 
imidazo[4,5-b]pyridines (1-deazapurines) 5a-h in good yields. The best yield was 
obtained when the primary amine 2a and the electrophilic reagent 4c were reacted. 

















Scheme 2. Synthesis of substituted 3H-imidazo[4,5b]pyridines 5a-h. Reagents and 
conditions: (i) CH2Cl2, argon, reflux, 5 h. 
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Table 1. Synthesis of 5a-h 
 aYields of isolated products. 
The substituted 3H-imidazo(4,5-b)pyridines (5a-h) were treated with 2 mmol of aryl 
halides (ArX). The reactions were set up in the presence of argon and were carried out in 
DMF at 150 0C for different time periods. The corresponding arylated products 6a-o were 


















Scheme 3. Synthesis of arylated 3H-imidazo[4,5-b]pyridines 6a-o. Reagents and 
conditions: (i) Pd(OAc)2 (5 mol%), CuI (3 equiv.), Cs2CO3 (2.5 equiv.), ArX (2 equiv.), 
DMF, Argon, 150 0C. 
The reactions of electron poor aryl halides (containing F, CF3) afforded the 
corresponding products in low yields, while electron rich aryl halides (containing Me, Et) 
afforded the corresponding products in higher yields.  
5 2, 3 4 R R1 % (5) a
a a a 4-(MeO)C6H4CH2 CF3 51 
b a b 4-(MeO)C6H4CH2 CH3 65 
c a c 4-(MeO)C6H4CH2 2-Furyl 98 
d b d t-Bu 2-Thienyl 71 
e b b t-Bu CH3 69 
f b e t-Bu C6H5 77 
g c e c-Hex C6H5 70 
h d d PhCH2CH2 2-Thienyl 75 
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The reactions of 3H-imidazo[4,5-b]pyridines 5b with 4-iodotoluene and 5h with 
phenylbromide resulted in the products 6b and 6j, respectively, in the best yields 
(Scheme 3, Table 2). 
Table 2. Synthesis of 6a-n. 
 a Yields of isolated products. 
The structures of all products were established by spectroscopic methods. The structures 
of 6a (Figure 4) and 6b (Figure 5) were independently confirmed by 2D NMR 
correlations using HMBC, HSQC and NOESY. The chemical shift values of the carbon 
atoms were assigned with the help of HSQC experiments. 
Entry 6 5 R R1 ArX t (h) % (6)a
1 a a 4-(MeO)C6H4CH2 CF3 4-MeC6H4I 50 42 
2 b b 4-(MeO)C6H4CH2 CH3 4-MeC6H4I 30 93 
3 c c 4-(MeO)C6H4CH2 2-Furyl 4-MeC6H4I 30 69 
4 d d t-Bu 2-Thienyl 4-MeC6H4I 48 59 
5 e f t-Bu C6H5 4-MeC6H4I 60 31 
6 f e t-Bu CH3 2,4-(Me2)C6H3I 56 50 
7 g e t-Bu CH3 4-EtC6H4I 30 50 
8 h c 4-(MeO)C6H4CH2 2-Furyl C6H5Br 48 58 
9 i d t-Bu 2-Thienyl C6H5Br 30 47 
10 j h PhCH2CH2 2-Thienyl C6H5Br 57 83 
11 k g c-Hex C6H5 2-FC6H4Br 40 43 
12 l f t-Bu C6H5 2-FC6H4Br 60 25 
13 m e t-Bu CH3 3-(CF3)C6H4Br 56 20 
14 n g c-Hex C6H5 4-(CF3)C6H4Cl 30 31 
15 o f t-Bu C6H5 4-EtC6H4I 30 63 
10
Chapter 1: Synthesis of arylated 1-deazapurines via C-H bond activation
In the HMBC spectrum of 6a, the aromatic protons at  = 7.73 showed a strong 
correlation with C-2 (133.4). In the NOESY spectrum of 6a, the aromatic protons ( = 
7.73) showed an interaction with the methylene protons ( = 5.65) attached with the 
carbon resonating at  = 47.1. The clear correlations and information from 2D NMR 
studies on 6a (Figure 4) and 6b (Figure 5) unambiguously confirmed that the 4-MeC6H4




































































Figure 5. 2D-NMR correlations (HMBC, HSQC, NOESY and COSY) of 6b. 
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The C-H bond at position 2 is more reactive because the proton is more acidic. The 
proton at C-6 is less acidic and is more sterically hindered. In conclusion, Pd/Cu easily 

















Scheme 4: Possible explanation for the C-H activation reactions of 5 
1.4 Conclusion 
I have successfully synthesized derivatives of 3H-imidazo[4,5-b]pyridines (1-
deazapurines) by the methodology of C-H bond activation following a procedure already 
reported. But this is the first time to synthesize arylated products of 3H-imidazo[4,5-
b]pyridines. 
In conclusion, a general Pd-catalyzed arylation of purines with aryl iodides by C-H 
activation in position 2 was developed by using Cs2CO3 and CuI as additives. Though the 
reaction conditions are rather harsh, the method can be efficiently applied in the synthesis 
of diverse 2-aryl-1-deazapurines. 
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2 Regioselective Palladium(0)-Catalysed Cross-Coupling Reactions of 5,7-
Dichloro-1,6-naphthyridine. 
2.1 General Introduction 
Pd-catalysed cross-coupling reactions with their tremendous enabling ability are modern, 
marvelous and powerful synthetic tools for the formation of highly substituted 
heterocycles39 with their key role in total synthesis.40 The regioselectivity of 
polyhalogenated heterocycles in Pd-catalysed cross-coupling reactions has been broadly 
studied and can provide a versatile and feasible way for the design and synthesis of 
libraries containing highly functionalized substituents in specific positions of a 
heterocyclic scaffold.41 
The Suzuki-Miyaura reaction is a palladium-catalyzed cross-coupling of aryl halides (or 
pseudo halides) with organoboron reagents and is undoubtedly a most powerful, essential 
and versatile platform for catalytic transformations in organic chemistry. The Suzuki-
Miyaura cross-coupling reaction has become one of the most widely utilized method for 
the formation of C(sp2)-C(sp2) bonds because of its mild reaction conditions and its 
compatibility with a broad range of functional groups. The Suzuki-Miyaura reaction is 
currently a fundamental and interesting reaction for the preparation of diversified biaryls, 
which have a myriad of applications of worth in polymer, agricultural, agrochemical, 
pharmaceutical and material chemistry. Biaryls are present in a wide variety of 
compounds such as natural products, advanced materials, liquid crystals and more 
importantly ligand molecular probes for biological processes. Mostly, arylboronic acids 
are used as nucleophilic organoboron reagents in Suzuki-Miyaura reactions.42 
In 1979, the seminal paper of Miyaura, Yamada, and Suzuki laid the basis for the Suzuki-
Miyaura reaction which now emerged as an extremely powerful and valuable method for 
C-C bond formation by cross coupling of aryl bromides, iodides, chlorides and triflates 
with boronic acids. The reactivity order is ArI >ArBr>ArOTf>>ArCl.43 
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The Suzuki-Miyaura reaction has proven to be a practical way to generate C-C bonds by 
coupling an organic halide with an organoboron molecule, in the presence of a palladium 
catalyst (Scheme 5). The reaction proceeds in a basic medium, thus a boronate is the 







Scheme 5. Suzuki-Miyaura coupling reaction 
The Suzuki-Miyaura reaction involes three steps in its mechanism. Firstly, oxidative 
addition of RX to Pd(0) takes place to form organopalladium halides. Then, in the 
transmetalation step, the halide is substituted by the organic R group of the organoboron 
species that provides a diorganopalladium complex, finally, in the reductive elimination, 



















Figure 6. Simplified mechanism 
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The reaction proceeds in basic medium and a variety of bases can be used in this reaction, 
e.g. K3PO4, K2CO3, and Cs2CO3, which enhances the rate of transmetallation by 
increasing the nucleophilicity of the organoboran species by formation of an 
organoborate. The process can occur with a mono or dicoordinated Pd complex, with 
phosphines as the most common ligands, e.g. Pd(OAc)2 together with phosphine ligands 
(such as PPh3, PCy3, SPhos and XPhos), Pd(PPh3)2Cl2, or Pd (PPh3)4.44
Prof. Peter Langer’s research group has carried out site-selective Suzuki-Miyaura 
reactions of polyhalogenated heteroaromatic and aromatic compounds or their triflates in 
a couple of years.  
In this context, regioselective Suzuki-Miyaura reactions of tribromopyrazoles (a),45 2,3,4-
tribromothiophene (b),46 2,3,5-tribromothiophene (c),47 2,3-dibromobenzofuran (d),48
1,2-dibromo-3,5-difluorobenzene (e),49 1,4-dibromo-2-fluorobenzene (f),50 2,4,5,6-
tetrachloropyrimidine (g),51 and tetrabromobenzoquinone (h)52 have already been 




































Figure 7. Suzuki-Miyaura reactions of vicinal halides studied in Prof. Langer’s group 
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The Langer group has also reported regioselective Suzuki-Miyaura cross coupling 
reactions of several substrates containing triflate groups, such as bis(triflates) of dimethyl 
4-fluoro-3,5-dihydroxphthalate (i),53 3,4-dihydroxbenzoate (j),54 phenyl 1,4-
dihydroxnaphthoate (k),55 2,4-bis(hydroxy)di- phenylsulfone (l),56 1,2-
dihydroxyanthraquinone (m),57 and methyl-2,5-dihydroxbenzoate (n)58 (Figure 8). All 

































Figure 8. Dihydroxy substrates which were transformed into their triflates and 
subsequently reacted in Suzuki reractions (Langer group) 
2.2 Introduction 
Naphthyridines are nitrogen containing heterocycles in which two pyridine rings, each 
ring with one nitrogen atom, are joined through two adjacent carbon atoms. Arnold 
Reissert, in 1893, obtained the first derivative (1,8-naphthyridine) of the new heterocyclic 
system and suggested the common name naphthyridine to such heterocycles. 
Naphthyridines are also known as “pyridinopyridines” and “benzodiazines”. There are 
generally six isomeric possible structures for naphthyridine heterocycles: 1,5- (1), 1,6- 
(2), 1,7- (3), 1,8- (4), 2,6- (5) and 2,7- naphthyridine (6) (Figure 9).  
16











Figure 9. Isomeric structures of naphthyridine 
In the literature some other terms have also been found, such as, “isonaphthyridine” [for 
1,5-naphthyridine (1)], ”benzodiazines”, “pyridopyridines”, “2,5-naphthyridine” [for 1,6-
naphthyridine (2)], and “copyrin(e)” or copurine [for 2,7-naphthyridine (6)]. In 1927 the 
1,5- and 1,8-naphthyridines were described as the first representatives of unsubstituted 
naphthyridines. The other isomers, 1,6-, 1,7- and 2,7-naphthyridines, were prepared in 
1958 and 2,6-naphthyridine was synthesized in 1965.59 
Pyridines and pyrido-fused derivatives, e.g. naphthyridines, are considered to be very 
interesting for their chemical reactivity and biological properties and these heterocycles 
possess wide range of pharmaceutical and agrochemical applications. Various 
naphthyridine derivatives exhibit a wide spectrum of biological activity such as 
bactericidal, fungicidal, antitumor, anti-inflammatory and carcinostatic. On behalf of 
such biological properties, naphthyridines have received considerable attention over the 
past years. The compounds incorporating naphthyridine motif have been reported useful 
in the treatment of cardiac arrhythmia, hypertention, rheumatoid arthritis, hyperlipidemia 
and mycocardial infarction.60 1,8-Naphthyridines have been reported to possess a wide 
range of biological activities such as antibacterial,61 antitumor,62 neurotoxic,63
neuroprotective,64 anticonvulsant and cardiac65 activities (Figure 10). 
17



































Figure 10. Pharmacologically relevant 1,8-naphthyridine derivatives. 
Additionally several other naphthyridine derivatives exhibit inhibition of protein kinase D 
(PKD),66 and acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE),67 and 




























Figure 11.  Naphthyridine inhibitors and antagonists 
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1,6-Naphthyridine derivatives also exhibit interesting biological properties, such as 
activity as antinociceptive agents,69 HIV-1 integrase inhibitors,70 and anti-human 
cytomegalovirus (HCMV) agents.71  
Some other compounds with 1,6-naphthyridine motif have been reported for the 
inhibition of fibroblast growth factor receptors (FGFR). Fibroblast growth factors are 
major factors for some tumors and angiogenesis is essential for the growth and survival 
of solid tumors. The inhibition of FGFR tyrosine kinases is considered to be an effective 





























Figure 12.  Pharmacologically relevant 1,6-naphthyridine derivatives 
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2.3 Results and Discussion 
The commercially available 5,7-dichloro-1,6-naphthyridine (7) was studied for site-
selective Suzuki-Miyaura cross-coupling reactions.  The reactions of 7 with arylboronic 
acids 8a-l (1.3 equiv.) afforded the 5-aryl-7-chloronaphthyridines 9a-l in 33-96% yield 
(Scheme 6, Table 3).  
The reaction conditions were systematically optimized for derivatives 9a-l (Table 6). 
Both electron-poor and electron-rich arylboronic acids could be successfully employed. 
The best yields were obtained using the solvent system 1,4-dioxane / toluene (1:1),  
Pd(PPh3)4 (5 mol%) as the catalyst and 2M K2CO3 as the base. The reactions were carried 
out at 70 °C for 8 h (entry 12, Table 6). The reactions carried out at temperatures higher 
than 70 °C afforded a mixture of products. Therefore, the optimized conditions given in 













Scheme 6. Synthesis of 9a-l. Reagents and conditions: (i) 7 (1 equiv), Ar1-B(OH)2 (1.3 
equiv), Pd(PPh3)4 (5 mol%), 2M K2CO3 (1 mL), 1,4-dioxane / toluene (1:1), 70 0C, 8 h. 
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Table 3: Synthesis of 9a-l. 
 aYields of isolated products. 
The Suzuki-Miyaura reactions of 5,7-dichloro-1,6-naphthyridine 7 with 2.5 equiv. of 
arylboronic acids 10a-i gave 5,7-diaryl-1,6-naphthyridines 11a-i in good yields. The best 
yields were obtained using 2.5 equiv. of the arylboronic acid, 5 mol% of Pd(PPh3)4 and 2 
mL of 2M K2CO3 as base (1,4-Dioxane, 110 0C, 12 h). The reactions could be 
successfully carried out with both electron-rich and electron-poor arylboronic acids. The 
reaction of 7 with arylboronic acid 10c afforded product 11c in excellent yield (Scheme 













Scheme 7. Synthesis of 11a-i. Reagents and conditions: (i) 7 (1 equiv), Ar1-B(OH)2 (2.5 
equiv), Pd(PPh3)4 (5 mol%), 2M K2CO3 (2 mL), 1,4-dioxane, 110 0C, 12 h. 
Entry 8, 9 Ar1 % a (9)
1 a 4-MeC6H4 70 
2 b 3,5-Me2C6H3 80 
3 c 2-(MeO)C6H4 74 
4 d 4-FC6H4 54 
5 e 2,3,4-(MeO)3C6H2 67 
6 f 2,3-(MeO)2C6H3 96 
7 g 2-MeC6H4 70 
8 h 4-ClC6H4 33 
9 i 4-(CF3)C6H4 65 
10 j 4-(MeO)C6H4 79 
11 k 4-(Et)C6H4 79 
12 l 4-(tBu)C6H4 67 
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Table 4: Synthesis of 11a-i. 
 a Yields of isolated products. 
The Suzuki-Miyaura reactions of 5-aryl-7-chloronaphthyridines 9e,f in with 1.3 equiv. of 
arylboronic acids 12a-d afforded disubstituted products 13a-d in good yields. The 
reaction of 9e with arylboronic acid 12a afforded the product 13a in excellent yield 













Scheme 8. Synthesis of 13a-d. Reagents and conditions: (i) 9 (1 equiv), Ar2-B(OH)2 (1.3 
equiv), Pd(PPh3)4 (5 mol%), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 110 0C, 8 h. 
Entry 10, 11 Ar1 % a (11)
1 a 2-(MeO)C6H4 71 
2 b 4-MeC6H4 74 
3 c 3,5-Me2C6H3 94 
4 d 4-(Et)C6H4 67 
5 e 4-(tBu)C6H4 79 
6 f 2,3,4-(MeO)3C6H2 49 
7 g 4-(CF3)C6H4 64 
8 h 3-FC6H4 74 
9 i 4-(MeO)C6H4 73 
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Table 5: Synthesis of 13a-d. 
 a Yields of isolated products. 
Table 6. Reaction conditions optimization for synthesis of 9a 
Entry Solvent Base Temp. Time 9a 
1 1,4-Dioxane 2 equiv. K3PO4 80 °C 6h mixture 
2 1,4-Dioxane 2M K2CO3 100 °C 6h mixture 
3 THF 2M K2CO3 80 °C 6h mixture 
4 THF 2 equiv. K3PO4 80 °C 6h mixture 
5 Toluene 2 equiv. K3PO4 70 °C 6h mixture 
6 Toluene 2M K2CO3 80 °C 6h mixture 
7 Toluene 2 equiv. Cs2CO3 65 °C 6h mixture 
8 THF 2 equiv. Cs2CO3 70 °C 6h mixture 
9 DME 2M K2CO3 65 °C 10h 49 
10 1,4-Dioxane 2M K2CO3 65 °C 6h No Reaction
11 DMF 2M K2CO3 100 °C 6h mixture 
12 1,4-Dioxane:Toluene (1:1) 2M K2CO3 70 °C 8h 70 
a Pd(PPh3)4 was used as catalyst in all reactions. 
Entry 12, 13 9 Ar1 Ar2 % a (13)
1 a e 2,3,4- (MeO)3C6H2 3,5-Me2C6H3 89 
2 b e 2,3,4- (MeO)3C6H2 4-MeC6H4 64 
3 c e 2,3,4- (MeO)3C6H2 4-(tBu)C6H4 54 
4 d f 2,3-(MeO)2C6H3 2-MeC6H4 47 
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The structures of all products were established by NMR, MS and IR data. The structures 
of 9f (Figure 13) and 11c (Figure 14) were independently confirmed by X-ray 
crystallography.  
Figure 13. ORTEP view of the crystal structure of 9f  
Figure 14. ORTEP view of the crystal structure of 11c
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The site-selective synthesis of 9a-l could be explained on the basis of steric and 
electronic effects. The 1H NMR chemical shift of the molecules in which the halide is 
replaced by a hydrogen usually gives a good possibility to estimate the electronic 
character and the site-selectivity of Pd catalyzed cross-coupling reactions of 
polyhalogenated substrates.100c The position C-5 (1H NMR, 9.15 ppm) is more electron 
deficient as compared to position C-7 (1H NMR, 8.45 ppm). Therefore, the first attack 














Scheme 9: Possible explanation for the site-selectivity of cross-coupling reactions of 7 
2.4 Conclusion 
I have successfully synthesized derivatives of 5,7-dichloro-1,6-naphthyridine by site-
selective Suzuki-Miyaura cross-coupling reactions. The monoarylated products were 
isolated with good site-selectivity, employing electron-rich and electron-poor arylboronic 
acids. 
In conclusion, a general Pd(0)-catalyzed arylation of 5,7-dichloro-1,6-naphthyridine with 
a number of arylboronic acids was achieved by Suzuki-Miyaura reactions. The first 
attack occurred at position 5 which is more electron-deficient and less sterically hindered. 
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3 Regioselective Palladium(0)-Catalysed Cross-Coupling Reactions of 2,6-
Dichloroquinoxaline 
3.1 Introduction 
Quinoxaline is a benzo-fused six-membered nitrogen containing heterocycle containing 
benzene ring and pyrazine ring. Quinoxaline is related to naphthalene but with less 
aromaticity. Quinoxalines are also called as benzopyrazines.73 Different quinoxaline 
derivatives show a broad spectrum of biological activities including antibacterial and 
antifungal,74 antihistamic, antioxidant and antiinflammatory,75 antimicobacterial,76
antiamoebic,77 antiproliferative,78 fungicidal and algicidal,79 antimalarial and 
antileishmanial,80 cytotoxic,81 anticancer,82 anti HIV and anti HCV,83 anti-tuberculosis,84
potent and selective class III tyrosine kinase inhibitory,85 and potential influenza NS1A 
protein inhibitory activity.86
Certain quinoxaline antibiotics of octadepsipeptide type have been reported as 
antibacterial, antitumor and potent inhibitors of RNA synthesis; examples are 































































Figure 15. Quinoxaline antibiotics 
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Furthermore, some derivatives are reported as high-performance thermoplastics88 and 
some other quinoxaline derivatives display bipolar characters that are reported as 
potential emissive and electron-transport moieties, hence they act as potential building 
blocks for the synthesis of organic semiconductors.89 
3.2 Results and discussion 
Pd-catalysed cross-coupling reactions are powerful tools for the formation of highly 
substituted heterocycles. The commercially available 2,6-dichloroquinoxaline (14) was 
studied for site-selective Suzuki-Miyaura cross-coupling reactions. The reactions of 14 
with arylboronic acids 15a-t (1.3 equiv.) afforded the 2-aryl-6-chloroquinoxalines 16a-t
in 23-97% yield. The reaction conditions were systematically optimized for derivatives 
16a-t (Table 6) in order to isolate the products in better yields. Both electron-poor and 
electron-rich arylboronic acids could be successfully employed. In case of arylboronic 
acids 15d,l,r,t, the yields were low because of their lower reactivity as compared to 14. 
The best yields were observed using THF as the solvent, Pd(PPh3)4 (5 mol%) as the 
catalyst and K3PO4 (2 equiv) as the base. The reactions were carried out at 90 °C for 8 h 
in a sealed tube (entry 6, Table 10). The reactions of highly reactive electron-rich 
arylboronic acids, carried out in THF, were carried out for 4 h at 85 °C (entry 3, Table 
10). The reactions carried out in toluene or 1,4-dioxane needed higher temperature and 
afforded the products in lower yield (entry 6, Table 10). Therefore, the optimized 
conditions given in entry 6 allowed to prepare 2-aryl-6-chloroquinoxalines 16a-t in good 









Scheme 10. Synthesis of 16a-t. Reagents and conditions: (i) 14 (1 equiv), 15 (1.3 equiv), 
Pd(PPh3)4 (5 mol%), K3PO4 (2 equiv), THF (8 mL), 90 0C, 8 h. 
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Table 7: Synthesis of 16a-t. 
 a Yields of isolated products. 
15, 16 Ar1 % a (16)
a 2-MeC6H4 77 
b 3-MeC6H4 67 
c 4-MeC6H4 75 
d 2,6-Me2C6H3 37 
e 3,5-Me2C6H3 90 
f 2,4,6-Me3C6H2 96 
g 2-(MeO)C6H4 72 
h 4-(MeO)C6H4 63 
i 2,3-(MeO)2C6H3 65 
j 2,6-(MeO)2C6H3 97 
k 2,3,4-(MeO)3C6H2 53 
l 3-FC6H4 23 
m 4-FC6H4 62 
n 2-C4H3S 45 
o 4-(Et)C6H4 96 
p 4-(tBu)C6H4 77 
q 4-(CF3)C6H4 52 
r 4-(Vinyl)C6H4 30 
s 2-ClC6H4 78 
t 3-ClC6H4 25 
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The Suzuki-Miyaura reactions of 2,6-dichloroquinoxaline (14) with 2.5 equiv. of 
arylboronic acids 17a-f gave 2,6-diarylquinoxalines 18a-f in good yields. The best yields 
were obtained using 2.5 equiv. of the arylboronic acid, 5 mol% of Pd(PPh3)4 and 2 mL of 
2M K2CO3 as the base (1,4-dioxane, 120 0C, 12 h). The reaction of 14 with arylboronic 









Scheme 11. Synthesis of 18a-f. Reagents and conditions: (i) 14 (1 equiv), 17 (2.5 equiv), 
Pd(PPh3)4 (5 mol%), 2M K2CO3 (2 mL), 1,4-Dioxane (8 mL), 120 0C, 12 h. 
Table 8: Synthesis of 18a-f. 
a Yields of isolated products. 
The Suzuki-Miyaura reactions of 2-aryl-6-chloroquinoxalines 16c,h,m-o with 1.3 equiv. 
of arylboronic acids 19a-g afforded disubstituted products 20a-g in good yields. The 
reactions were carried out in 1,4-dioxane using Pd(PPh3)4 (5 mol%) and 2M K2CO3 (1 
mL) at 120 0C for 8 h. The reaction of 16n with arylboronic acid 19f afforded product 20f
in 91% yield (Scheme 12, Table 9). 
17, 18 Ar % a (18)
a 2-MeC6H4 64 
b 4-(Me)C6H4 51 
c 3,5-Me2C6H3 94 
d 2-(MeO)C6H4 49 
e 4-(Et)C6H4 47 
f 4-(tBu)C6H4 26 
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Scheme 12. Synthesis of 20a-g. Reagents and conditions: (i) 16 (1 equiv), 19 (1.3 equiv), 
Pd(PPh3)4 (5 mol%), 2M K2CO3 (1 mL), 1,4-dioxane, 120 0C, 8 h. 
Table 9: Synthesis of 20a-g. 
 a Yields of isolated products. 
Table 10. Reaction conditions optimization for synthesis of 3. 
Entry Solvent Catalyst Temp. (°C) Time (h) 3c (%) 
1 1,4-Dioxane (PPh3)4Pd 85 3 No reaction
2 1,4-Dioxane (PPh3)4Pd 110 6 69 
3 THF (PPh3)4Pd 85 4 71 
4 Toluene (PPh3)4Pd 85 4 29 
5 Toluene (PPh3)4Pd 110 6 66 
6 THF (PPh3)4Pd 90 8 75 
 a 2 equiv. K3PO4 was used as base in each reaction 
19, 20 16 Ar1 Ar2 % a (20)
a c 4-MeC6H4 3,5-Me2C6H3 70 
b c 4-MeC6H4 4-(tBu)C6H4 78 
c c 4-MeC6H4 2-(MeO)C6H4 47 
d h 4-(MeO)C6H4 4-FC6H4 76 
e m 4-FC6H4 3,5-Me2C6H3 63 
f n 2-C4H3S 3,5-Me2C6H3 91 
g o 4-(Et)C6H4 4-MeC6H4 54 
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The structures of all products were established by NMR, MS and IR data. The structures 
of 16g (Figure 16) and 20e (Figure 17) were independently confirmed by X-ray 
crystallography.  
Figure 16. ORTEP view of the crystal structure of 16g 
Figure 17. ORTEP view of the crystal structure of 20e 
The monoarylated products 16a-t were synthesised by Suzuki-Miyaura reactions in good 
yield. The position 2 of 2,6-dichloroquinoxaline (14) is more electron-deficient as 
compared to position 6. The products were obtained with good site-selectivity.  
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Scheme 13: Possible explanation for the site-selectivity of cross-coupling reactions of 14 
3.3 Conclusion 
In conclusion, the Pd(0)-catalyzed Suzuki-Miyaura cross-coupling reactions of 2,6-
dichloroquinoxaline (14) have been successfully carried out with good site-selectivity. 
The mono- and diarylated products were obtained in good yield. The first attack occurred 
at position C-2 that is more electron deficient as compared to position C-6. 
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4 Regioselective Palladium(0)-Catalysed Cross-Coupling Reactions of 2,4-
Dichloro-1-(trifluoromethyl)benzene 
4.1 Introduction 
The trifluoromethyl (CF3) group is a significant structural motif in many 
pharmaceutically relevant molecules90 and with a wide range of important and interesting 
applications in organic, material, medicinal, and agricultural chemistry, due to its unique 
physical, chemical, and biological properties.91 
Various compounds with CF3 motif have been reported to exhibit biologically interesting 
properties such as antimalarial agents;92 malaria which is still a worldwide problem of 
public health, affecting 300 million people and causing about 2.5 million deaths annually, 
mainly among children less than 5 years old93 (Figure 18).
























Figure 18. Antimalarial agents containing a CF3 motif 
Some more compounds with CF3 motif act as potential antituberculosis agents 
(mafloquine),94 antiviral agents,95 in vitro androgen receptor antagonists and in vivo 
antiandrogenic agents,96 amebicidal and trichomonacidal agents.97  
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Some other compounds with CF3 moiety, such as JNJ-1930942, have also been reported 
as positive allosteric modulator of the 7 nicotinic acetylcholine receptor (nAChR) which 
is a potential therapeutic target for the treatment of cognitive deficits associated with 
schizophrenia, Alzheimer’s disease, Parkinson’s disease, and attention-
deficit/hyperactivity disorder.98 , boxidine is the most effective, nonsteroidal, 
nonestrogenic and potent hypocholesteremic agent that is reported to inhibit the 



































































in vitro androgen receptor antagonist
In vivo antiandrogenic agent
Figure 19. Pharmacologically relevant CF3 motif containing compounds 
4.2 Results and Discussion 
The Suzuki-Miyaura cross-coupling reactions of commercially available 2,4-dichloro-1-
(trifluoromethyl)benzene 21 with 1.3 equiv. of arylboronic acids 22a-m afforded the 
biphenyls 23a-m in moderate to good yields (Scheme 14, Table 11) with excellent site-
selectivity.  
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The best yields were obtained using 1.3 equiv. of the arylboronic acid, Pd(PPh3)4 (0.05 
equiv.) as the catalyst and 2M K2CO3 as the base (1,4-dioxane, 80 0C, 6 h). The 











Scheme 14. Synthesis of 23a-m. Reagents and conditions: (i) 21 (1 equiv), 22 (1.3 
equiv), Pd(PPh3)4 (5 mol%), 2M K2CO3 (1 mL), 1,4-dioxane, 80 0C, 6 h. 
Table 11: Synthesis of 23a-m 
 a Yields of isolated products. 
22,23 Ar1 % a (23)
a 2-MeC6H4 93 
b 3-MeC6H4 95 
c 4-MeC6H4 97 
d 2,6-Me2C6H3 36 
e 3,5-Me2C6H3 72 
f 4-EtC6H4 49 
g 2-(MeO)C6H4 56 
h 2,3-(MeO)2C6H3 74 
i 2,3,4-(MeO)3C6H2 60 
j 2-ClC6H4 47 
k 4-FC6H4 46 
l 4-(CF3)C6H4 35 
m 3-(CF3)C6H4 32 
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The Suzuki-Miyaura reactions of 2,4-dichloro-1-(trifluoromethyl)benzene 21 with 2.5 
equiv. of arylboronic acids 24a-d gave 2,4-diaryl-1-(trifluoromethyl)benzene derivatives 
25a-d in good yields. The reactions were carried out at 110 0C in 1,4-dioxane using 2.5 
equiv. of the arylboronic acid, 5 mol% of Pd(PPh3)4 and 2 mL of 2M K2CO3 as base. 











Scheme 15. Synthesis of 25a-d. Reagents and conditions: (i) 21 (1 equiv), Ar1-B(OH)2
(2.5 equiv), Pd(PPh3)4 (5 mol%), 2M K2CO3 (2 mL), 1,4-Dioxane (8 mL), 110 0C, 8 h. 
Table 12: Synthesis of 25a-c 
a Yields of isolated products. 
The Suzuki-Miyaura reactions of 3-chloro-4'-methyl-4-(trifluoromethyl)biphenyl 23c
with 1.3 equiv. of arylboronic acids 26a-d afforded unsymmetrical disubstituted products 
27a-d in moderate to good yields. The reactions were carried out in 1,4-dioxane using 
Pd(PPh3)4 (5 mol%) and 2M K2CO3 (1 mL) at 110 0C for 8 h (Scheme 16, Table 13). 
24, 25 Ar1 % a (25)
a 2-MeC6H4 57 
b 3-MeC6H4 39 
c 4-MeC6H4 60 
d 4-FC6H4 49 
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Scheme 16. Synthesis of 27a-c. Reagents and conditions: (i) 23c (1 equiv), Ar2-B(OH)2
(1.3 equiv), Pd(PPh3)4 (5 mol%), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 110 0C, 8 h. 
Table 13: Synthesis of 27a-c 
  
 a Yields of isolated products. 
The structures of all products were established by NMR, MS and IR data. The structure 
of 23c (Figure 20) was independently confirmed by X-ray crystallography.  
Figure 20. ORTEP view of the crystal structure of 23c 
26,27 23 Ar1 Ar2 % a (27)
a c 4-MeC6H4 4-FC6H4 25 
b c 4-MeC6H4 4-(MeO)C6H4 59 
c c 4-MeC6H4 3,5-Me2C6H3 64 
d c 4-MeC6H4 4-EtC6H4 40 
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The site-selective formation of 23a-m can be explained by steric and electronic reasons. 
Generally, the first attack of palladium(0)-catalyzed cross-coupling reactions favours the 
more electron-deficient and less sterically hindered position.100 The position at C-4 of 
2,4-dichloro-1-(trifluoromethyl)benzene 21 is sterically less hindered and more electron 








Scheme 17: Possible explanation for the site-selectivity of cross-coupling reactions of 21 
4.3 Conclusion 
In conclusion, I have synthesised mono- and diarylated (both symmetrical and 
unsymmetrical) products via site-selective Suzuki-Miyaura cross-coupling reactions. 
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5 Abstract 
The Pd/Cu catalyzed reactions of 3H-imidazo[4,5-b]pyridines (1-deazapurines) via C-H 
bond activation provided arylated 1-deazapurines. The arylation took place at position 2 
of the 1-deazapurines. Pd(0)-catalysed Suzuki-Miyaura cross coupling reactions of 5,7-
dichloro-1,6-naphthyridine, 2,6-dichloroquinoxaline and 2,4-dichloro-1-
(trifluoromethyl)benzene with different arylboronic acids afforded aryl-substituted 
naphthyridines, quinoxalines and trifluoromethyl-substituted di- and terphenyls with 
excellent site-selectivity. The first attack occurred at the more electronically deficient and 
sterically less hindered position. 
Die Pd / Cu-katalysierten Reaktionen von 3H-Imidazo[4,5-b]pyridinen (1-
Desazapurinen) via C-H-Aktivierung lieferte arylierte 1-Deazapurine. 
Die Arylierung fand an Position 2 des 1-Desazapurins statt. Suzuki-Miyaura-
Kupplungen von 5,7-Dichlor-1,6-naphthyridin, 2,6-Dichlorchinoxalin und 2,4-Dichlor-1-
(trifluormethyl)benzol mit verschiedenen Arylboronsäuren  
ergab arylsubstituierte Naphthyridine, Chinoxaline, Trifluormethyl-substituierte 
Biphenyle und Terphenyle mit ausgezeichneter Regioselektivität. Der erste 
































































General Scheme.  Palladium-catalyzed reactions developed in this thesis. 
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6 Experimental Section 
6.1 General: Equipment, chemicals and work technique 
1H NMR Spectroscopy:  
Bruker: AM 250, Bruker ARX 300, Bruker ARX 500;  = 0.00 ppm for 
Tetramethylsilane;  = 7.26 ppm for (CDCl3); Characterization of the signal fragmen- 
tations: s = singlet, d = doublet, dd = double of doublet, t = triplet, q = quartet, m = 
multiplet, br = broadly. All coupling constants are indicated as (J). 2D NMR techniques 
(NOESY, COSY, HSQC, and HMBC) were used for the confirmation of structure. 
13C NMR Spectroscopy: 
Bruker: AM 250, (62.9 MHz); Bruker: ARX 300, (75 MHz), Bruker: ARX 500, 
(125 MHz) Ref: 29.84 ± 0.01 ppm and 206.26 ± 0.13 ppm  = 77.00 ppm for CDCl3. The 
multiplicity of the carbon atoms was determined by the DEPT 135 and APT technique 
(APT = Attached Proton Test) and quoted as CH3, CH2, CH and C for primary, 
secondary, tertiary and quaternary carbon atoms. Characterization of the signal 
fragmentations: quart = quartet the multiplicity of the signals was determined by the 
DEPT recording technology and/or the APT recording technology. 
Mass Spectroscopy:
AMD MS40, Varian MAT CH 7, MAT 731 (EI, 70 eV), Intecta AMD 402 (EI, 70 eV 
and CI), Finnigan MAT 95 (CI, 200 eV).  
High Resolution mass spectroscopy:  
Finnigan MAT 95 or Varian MAT 311; Bruker FT 
CIR, AMD 402 (AMD Intectra). 
Infrared spectroscopy (IR):  
Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet Protege 460, Nicolet 360 
Smart Orbit (ATR); KBr, KAP, Nujol, and ATR; Peaks are given following 
assignments: w = weak, m = medium, s = strong, br = broad. 
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Elemental Analysis  
LECO CHNS-932, Thermoquest Flash EA 1112.  
X-ray crystal structure analysis:  
Crystallographic data were collected on a Bruker X8Apex, Diffractometer with CCD-
Kamera (MoKa und Graphit Monochromator, = 0.71073 Å). The structures were solved 
by direct methods using SHELXS-97 and refined against F2 on all data by full matrix 
least-squares with SHELXL-97. 
Melting points:  
Micro heating table HMK 67/1825 Kuestner (Büchi apparatus). 
Column chromatography:  
Chromatography was performed over Merck silica gel 60 (0,063 -0,200 mm, 70 - 230 
mesh) as normal and/or over mesh silica gel 60 (0,040 - 0,063 mm, 200 -400 mesh) as 
Flash Chromatography. All solvent were distilled before use. 
Thin Layer Chromatography (TLC):  
Merck DC finished foils silica gel 60 F254 on aluminum foil and Macherey finished 
foils Alugram® Sil G/UV254. Detection under UV light with 254 nm and/or 366 nm 
without dipping reagent, as well as with anisaldehyde sulfuric acid reagent (1 mL 
anisaldehyde consisting in 100 mL stock solution of 85% methanol, 14% acetic acid and 
1% sulfuric acid).   
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6.2 Pd/Cu Catalysed Arylation of 1-deazapurines via C-H Bond Activation 
General Procedure for the Synthesis of Compounds 5a-h: To a Schlenk flask, CH2Cl2, 
the primary amine (2a-d), and methyl N-(cyanomethyl)-formimidate (1) were added 
under an argon atmosphere at r.t. The reaction mixture was refluxed for 2 h and after that, 
the mixture was cooled down to r.t., and then to 0°C using an ice bath. Afterwards, the 
1,3-electrophilic reagent (4a-e) was added, and the mixture continued to stir at the same 
temperature for 15–20 min and was then refluxed for 5 h. The solvent was evaporated to 
dryness, and the residue was purified by column chromatography (n-heptane – EtOAc), 
to give 5a-h as solid products. 
3-(4-Methoxybenzyl)-5,7-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine (5a): 
Starting with CH2Cl2 (6 mL), 1 (0.47 mL; 5.33 mmol), 2a (0.68 mL, 5.33 mmol), 4a
(0.74 mL, 5.33 mmol), 5a was isolated as yellowish solid 
(1.018 g, 51%); m.p. 108-110 °C. 1H NMR (300.13 MHz, 
CDCl3): δ = 3.72 (s, 3H, OCH3), 5.40 (s, 2H, -CH2-), 6.82 
(d, 3J = 8.7 Hz, 2H, ArH), 7.26 (d, 3J = 8.7 Hz, 2H, ArH), 
7.80 (s, 1H), 8.22 (s, 1H). 13C NMR (62.89 MHz, CDCl3), δ
= 47.6 (-CH2-), 55.3 (OCH3), 111.5 (q, 3JCF = 4.40 Hz, CH), 114.6 (2CH), 121.8 (q, 1JCF = 
274.0 Hz, CF3), 125.4 (q, 1JCF = 274.0 Hz, CF3), 126.41 (C), 129.5 (C, q, 2JCF = 35.2 Hz), 
129.9 (2CH), 133.37 (C), 142.8 (q, 2JCF = 35.7 Hz, C), 148.0 (C), 148.1 (CH), 160.04 (C); 
19F NMR (282.40 MHz, CDCl3): δ = -66.10 (ArCF3), -62.13 (ArCF3); IR (ATR, cm-1): ~ν
= 3069 (w), 3011 (w), 2958 (w), 2934 (m), 2912 (w), 2839 (w), 1611 (w), 1585 (w), 1513 
(m), 1489 (w), 1464 (w), 1455 (w), 1441 (w), 1407 (w), 1390 (w), 1381 (w), 1352 (w), 
1327 (w), 1306 (w), 1271 (s), 1255 (s), 1191 (m), 1174 (s), 1129 (s), 1109 (w), 1098 (w), 
1033 (m), 964 (w), 940 (w), 940 (w), 921 (w), 903 (w), 880 (s), 842 (w), 833 (w), 804 
(w), 759 (w), 748 (w), 728 (w), 709 (w), 681 (w), 666 (w), 655 (m), 632 (w), 597 (w), 
564 (w); GC-MS (EI, 70 eV): m/z (%): 375 (M+, 60), 360 (4), 340 (1), 312 (1), 360 (4), 
178 (2), 121 (100), 91 (4), 78 (6) 51 (1). HRMS (EI): calcd for C16H11F6N3O [M+]: 








Starting with CH2Cl2 (6 mL), 1 (0.56 mL, 6.23 mmol), 2a
(0.81 mL, 6.23 mmol), 4b (0.75 mL, 6.23 mmol), 5b was 
isolated as brown solid (1.3 g, 65%); m.p. 95-97 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 2.64 (s, 3H, CH3), 3.69 (s, 
3H, OCH3), 5.31 (s, 2H, -CH2-), 6.78 (d, 3J = 8.6 Hz, 2H, 
ArH), 7.18 (d, 3J = 8.6 Hz, 2H, ArH), 7.24 (s, 1H), 7.95 (s, 1H). 13C NMR (75.46 MHz, 
CDCl3), δ = 19.2 (CH3), 46.8 (-CH2-), 55.3 (OCH3), 114.3 (q, 3JCF = 4.40 Hz, CH), 114.4 
(2CH), 122.9 (CF3, q, 1JCF = 273.44 Hz), 127.5 (C), 128.6 (C, q, 2JCF = 34.11 Hz), 129.1 
(C), 129.5 (2CH), 144.6 (CH), 148.0 (C), 154.2 (C), 159.7 (C). 19F NMR (282.40 MHz, 
CDCl3): δ = -62.17 (ArCF3); IR (ATR, cm-1): ~ν  = 3076 (w), 3031 (w), 2956 (w), 2918 
(m), 2842 (w), 1782 (w), 1741 (w), 1679 (w), 1613 (m), 1595 (w), 1585 (w), 1562 (w), 
1555 (w), 1510 (m), 1495 (w), 1484 (w), 1465 (w), 1443 (w), 1433 (w), 1420 (w), 1397 
(m), 1385 (m), 1363 (s), 1289 (s), 1272 (w), 1242 (m), 1231 (m), 1206 (w), 1184 (w), 
1178 (w), 1165 (w), 1152 (m), 1123 (s), 1104 (s), 1027 (m), 976 (w), 963 (w), 928 (w), 
915 (w), 895 (m), 871 (m), 843 (w), 827 (w), 817 (m), 793 (w), 762 (m), 725 (w), 716 
(m), 675 (m), 667 (w), 636 (m), 623 (w), 566 (s), 537 (m); GC-MS (EI, 70 eV): m/z (%): 
321 (M+, 68), 306 (9), 214 (1), 151 (1), 121 (100), 106 (1), 91 (4), 77 (6), 65 (1), 51 (1); 
HRMS (EI): calcd for C16H14F3N3O [M+]: 321.10835; found: 321.108154 
5-(Furan-2-yl)-3-(4-methoxybenzyl)-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine 
(5c):
Starting with CH2Cl2 (6 mL), 1 (0.28 mL, 3.12 mmol), 2a (0.41 mL, 
3.12 mmol), 4c (0.46 mL, 3.12 mmol), 5c was isolated as yellowish 
solid (0.992 g, 98); m.p. 144-146 °C. 1H NMR (300.13 MHz, CDCl3): 
δ = 3.71 (s, 3H, OCH3), 5.36 (s, 2H, -CH2-), 6.50 (dd, J  = 1.70 Hz, J  
= 3.40 Hz, 1H, CHfuryl), 6.80 (d, 3J = 8.6 Hz, 2H, ArH), 7.09-7.11 (m, 
1H, CHfuryl), 7.25 (d, J = 8.6 Hz, 2H, ArH), 7.50-7.52 (m, 1H, 
CHfuryl), 7.85 (s, 1H, ArH), 8.01 (s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3): δ = 47.0 (-
CH2-), 55.3 (OCH3), 109.3 (CHfuryl), 110.3 (q, 3JCF = 4.40 Hz, CH), 112.3 (CHfuryl), 114.5 













(2CH), 130.1 (C), 143.7 (CHfuryl), 145.5 (CH), 148.2 (C), 153.2 (C), 159.8 (2C); 19F 
NMR (282.40 MHz, CDCl3): δ = -62.32 (ArCF3); IR (ATR, cm−1): ~ν  = 3120 (w), 3065 
(m), 3013 (w), 2942 (w), 2912 (w), 2838 (w), 1613 (m), 1586 (w), 1513 (s), 1493 (m), 
1464 (w), 1454 (w), 1440 (w), 1425 (w), 1396 (m), 1386 (w), 1360 (s), 1313 (w), 1305 
(m), 1287 (w), 1261 (w), 1243 (s), 1226 (w), 1201 (m), 1169 (s), 1153 (m), 1127 (s), 
1098 (m), 1070 (w), 1031 (s), 1005 (m), 962 (s), 943 (w), 932 (w), 912 (m), 885 (w), 873 
(w), 863 (m), 846 (w), 835 (w), 821 (m), 777 (m), 744 (s), 714 (w), 682 (w), 666 (m), 
632 (s), 595 (m), 534 (m); GC-MS (EI, 70 eV): m/z (%): 373 (M+, 61), 358 (1), 224 (4), 
207 (1), 173 (2), 150 (1), 121 (100), 91 (3), 77 (6), 51 (1); HRMS (ESI) calcd for 
C19H14F3N3O2 [M+H]+: 374.11109 found 374.1108. 
3-tert-Butyl-5-(thiophen-2-yl)-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine (5d):
Starting with CH2Cl2 (6 mL), 1 (0.55 mL, 6.15 mmol), 2b (0.65 mL, 
6.15 mmol), 4d (1.37 g, 6.15 equiv.), 5d was isolated as pink solid 
(1.42 g, 71%); m.p. 143-145 °C. 1H NMR (300.13 MHz, DMSO-d6): 
δ = 1.83 (s, 9H, 3CH3), 7.20 (dd, J = 3.78 Hz, J = 1.13 Hz, 1H, 
CHthienyl), 7.69 (d, 3J = 5.0 Hz, 1H, CHthienyl), 7.02 (d, 3J = 3.7 Hz, 1H, CHthienyl), 8.12 (s, 
1H, ArH), 8.62 (s, 1H, ArH); 13C NMR (75.46 MHz, DMSO-d6): δ = 28.4 (3CH3), 57.5 
(C), 109.1 (q, 3JCF = 4.40 Hz, CH), 122.8 (q, 1JCF = 273.99 Hz, CF3), 126.3 (CH), 127.3 
(q, 2JCF = 33.56 Hz, C), 128.7 (CH), 130.8 (C), 143.9 (C), 145.4 (CH), 146.2 (2C), 147.9 
(C); 19F NMR (282.40 MHz, DMSO-d6): δ = -60.85 (ArCF3); IR (ATR, cm−1): ~ν  = 3125 
(m), 3071 (w), 2976 (m), 2916 (w), 2874 (w), 1597 (s), 1540 (s), 1511 (w), 1482 (s), 
1471 (m), 1433 (m), 1409 (w), 1388 (s), 1370 (s), 1350 (m), 1338 (m), 1303 (s), 1281 
(w), 1264 (m), 1247 (m), 1224 (s), 1175 (s), 1149 (m), 1132 (s), 1082 (w), 1074 (w), 
1063 (w), 1029 (w), 1020 (w), 931 (s), 900 (m), 872 (s), 846 (m), 826 (s), 818 (w), 791 
(m), 770 (w), 749 (w), 723 (m), 702 (s), 666 (w), 658 (m), 647 (m), 635 (s), 618 (w), 611 
(w), 589 (w), 570 (w), 554 (m), 530 (m); GC-MS (EI, 70 eV): m/z (%): 325 (M+, 31), 
269 (100), 250 (2), 224 (2), 205 (1), 146 (1), 57 (1), 41 (2), 29 (1); HRMS (ESI) calcd for 








Starting with CH2Cl2 (6 mL), 1 (0.69 mL, 7.78 mmol), 2b (0.82 mL, 7.78 
mmol), 4b (0.94 mL, 7.78 mmol), 5e was isolated as white solid (1.38 g, 
69%); m.p. 100-102 °C. 1H NMR (300.13 MHz, CDCl3): δ = 1.77 (s, 9H, 
3CH3), 2.64 (s, 3H, CH3), 7.21 (s, 1H, ArH), 8.10 (s, 1H, ArH); 
13C NMR (62.89 MHz, CDCl3): δ = 24.7 (CH3), 29.1 (3CH3), 57.5 (C), 113.6 (q, 3JCF = 
4.12 Hz, CH), 122.9 (q, 1JCF = 273.74 Hz, CF3), 128.1 (q, 2JCF = 33.42 Hz, C), 130.3 (C), 
142.9 (CH), 148.4 (C), 152.8 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.23 (ArCF3); 
IR (ATR, cm−1): ~ν  = 3119 (s), 2984 (m), 2922 (s), 2877 (w), 2854 (w), 1813 (w), 1731 
(w), 1673 (w), 1596 (s), 1478 (s), 1464 (w), 1435 (w), 1401 (w), 1382 (m), 1371 (m), 
1359 (m), 1336 (s), 1302 (w), 1282 (w), 1264 (m), 1228 (s), 1220 (w), 1197 (w), 1164 
(m), 1125 (s), 1077 (m), 1031 (m), 997 (w), 968 (m), 934 (w), 910 (m), 892 (s), 863 (s), 
834 (w), 809 (m), 758 (w), 724 (s), 680 (m), 669 (m), 638 (s), 627 (w), 563 (m), 547 (w), 
533 (w); GC-MS (EI, 70 eV): m/z (%): 257 (M+, 28), 242 (3), 201 (100), 182 (10), 154 
(2), 132 (8), 105 (1), 78 (1), 57 (3), 41 (4), 29 (2); HRMS (ESI) calcd for C12H15F3N3 
[M+H]+: 258.12126 found 258.12141. 
3-tert-Butyl-5-phenyl-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine (5f):
Starting with CH2Cl2 (6 mL), 1 (0.84 mL, 9.4 mmol), 2b (0.99 mL, 
9.4 mmol), 4e (2.03 g, 9.4 equiv.), 5f was isolated as white solid 
(2.32 g, 77%); m.p. 130-132 °C. 1H NMR (300.13 MHz, CDCl3): δ
= 1.84 (s, 9H, 3CH3), 7.35-7.47 (m, 3H, ArH), 7.85 (s, 1H, ArH), 
8.03 (d, 3J = 8.3 Hz, 2H, ArH), 8.19 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3): δ = 
29.2 (3CH3), 57.8 (C), 111.1 (q, 3JCF = 4.12 Hz, CH), 122.9 (CF3, q, 1JCF = 274.02 Hz), 
127.0 (2CH), 128.8 (q, 2JCF = 33.42 Hz, C), 128.9 (2CH), 129.2 (CH), 131.5 (C), 138.6 
(C), 143.9 (CH), 148.8 (C), 151.7 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.24 
(ArCF3); IR (ATR, cm−1): ~ν  = 3117 (m), 3089 (w), 3027 (w), 2979 (m), 2912 (w), 2882 
(w), 1812 (w), 1737 (w), 1603 (m), 1580 (w), 1536 (w), 1490 (s), 1476 (s), 1441 (m), 
1373 (s), 1339 (m), 1291 (m), 1259 (s), 1228 (s), 1182 (w), 1172 (w), 1163 (w), 1147 
(w), 1130 (s), 1085 (w), 1062 (m), 1027 (m), 1001 (w), 969 (w), 943 (s), 910 (w), 869 (s), 










620 (s), 555 (m), 531 (w); GC-MS (EI, 70 eV): m/z (%): 319 (M+, 22), 300 (1), 264 (17), 
263 (100), 242 (2), 215 (1), 193 (2), 158 (1), 140 (2), 57 (1), 41 (1); HRMS (ESI) calcd 
for C17H17F3N3 [M+H]+: 320.13691 found 320.13715. 
3-Cyclohexyl-5-phenyl-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine (5g):
Starting with CH2Cl2 (6 mL), 1 (0.52 mL, 5.79 mmol), 2c (0.66 mL, 
5.79 mmol), 4e (1.25 g, 5.79 equiv.), 5g was isolated as reddish 
solid (1.4 g, 70%); m.p. 120-122 °C. 1H NMR (300.13 MHz, 
CDCl3): δ = 1.31-2.04 (m, 8H, 4-CH2-), 2.27-2.33 (m, 2H, -CH2-), 
4.68-4.78 (m, 1H, CH), 7.45-7.58 (m, 3H, ArH), 7.94 (s, 1H, ArH), 
8.10-8.14 (m, 2H, ArH), 8.27 (s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3): δ = 25.3 
(CH2), 25.6 (2CH2), 33.3 (2CH2), 54.5 (CH), 111.7 (q, 3JCF = 4.40 Hz, CH), 122.9 (q, 1JCF 
= 273.45 Hz, CF3), 127.2 (2CH), 128.93 (2CH), 128.94 (q, 2JCF = 34.1 Hz, C) 129.3 
(CH), 130.5 (C), 138.6 (C), 143.9 (CH), 148.2 (C), 152.5 (C); 19F NMR (282.40 MHz, 
CDCl3): δ = -62.21 (ArCF3); IR (ATR, cm−1): ~ν  = 3102 (w), 3075 (w), 3027 (w), 3039 
(w), 2938 (m), 2922 (m), 2857 (w), 1781 (w), 1748 (w), 1603 (w), 1493 (m), 1478 (m), 
1456 (w), 1450 (w), 1399 (w), 1387 (m), 1377 (s), 1346 (w), 1310 (m), 1288 (m), 1265 
(s), 1207 (s), 1147 (m), 1140 (w), 1124 (s), 1010 (w), 1084 (w), 1068 (w), 1054 (w), 
1029 (w), 1001 (w), 994 (w), 985 (w), 966 (w), 941 (m), 918 (w), 890 (m), 873 (s), 852 
(w), 838 (w), 821 (m), 790 (w), 765 (s), 714 (m), 689 (s), 672 (w), 664 (w), 634 (m), 620 
(w), 615 (m), 576 (w), 532 (m); GC-MS (EI, 70 eV): m/z (%): 345 (M+, 33), 290 (8), 276 
(4), 263 (100), 244 (3), 140 (1), 102 (1), 77 (1), 55 (2), 41 (2); HRMS (ESI) calcd. for 







Starting with CH2Cl2 (6 mL), 1 (0.48 mL, 5.36 mmol), 2d (0.68 mL, 
5.36 mmol), 4d (1.2 g, 5.36 equiv.), 5h was isolated as light brown 
solid (1.5 g, 75%); m.p. 99-101 °C. 1H NMR (300.13 MHz, CDCl3): 
δ = 3.19 (t, J = 7.17, 2H, -CH2-), 4.51 (t, J = 7.17, 2H, -CH2-), 7.04-
7.09 (m, 3H, ArH), 7.12-7.25 (m, 3H, ArH), 7.37 (d, J = 5.0 Hz, 1H, 
CHthienyl), 7.61 (d, J = 3.5 Hz, 1H, CHthienyl), 7.75 (s, 1H, ArH), 7.81 
(s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3): δ = 36.1 (-CH2-), 45.7 (-CH2-), 110.5 (q, 
3JCF = 4.40 Hz, CH), 122.7 (q, 1JCF = 273.45 Hz, CF3), 125.5 (CH), 127.1 (CH), 128.2 
(CH), 128.3 (CH) 128.7 (2CH), 128.9 (2CH), 129.6 (q, 2JCF = 34.11 Hz, C), 137.3 (C), 
144.0 (C), 145.6 (CH), 147.9 (C), 148.3 (2C); 19F NMR (282.40 MHz, CDCl3): δ = -
62.27 (ArCF3); IR (ATR, cm−1): ~ν  = 3103 (w), 3084 (w), 3031 (w), 2942 (w), 2869 (w), 
1769 (w), 1596 (s), 1538 (m), 1496 (m), 1476 (w), 1454 (w), 1431 (s), 1397 (m), 1375 
(s), 1349 (m), 1306 (w), 1298 (w), 1276 (m), 1261 (s), 1202 (s), 1123 (s), 1102 (m), 1027 
(m), 1003 (w), 934 (m), 907 (w), 889 (w), 867 (s), 847 (w), 827 (m), 772 (w), 737 (m), 
693 (s), 655 (m), 632 (m), 615 (w), 590 (w), 566 (w), 535 (w); GC-MS (EI, 70 eV): m/z 
(%): 373 (M+, 30), 354 (2), 269 (100), 208 (2), 104 (5), 91 (4), 77 (2), 65 (1); HRMS 







General Procedure for the Synthesis of Compounds 6a-o: DMF (6 mL) was added to an 
argon-purged pressure tube containing 3H-midazo[4,5-b]pyridine 5a-h (1 mmol), 
Pd(OAc)2 (0.05 mmol, 5 mol %), CuI (3 mmol), aryl halide (2 mmol), and Cs2CO3 (2.5 
mmol). The reaction mixture was stirred at 150 °C for 30-60 h and, after cooling to r.t., 
the solvent was evaporated under reduced pressure. The products were isolated and 
purified by column chromatography (gradient elution n-heptane/ethyl acetate, ethyl 
acetate/isopropanol). 
3-(4-Methoxybenzyl)-2-p-tolyl-5,7-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine (6a): 
Starting with 5a (0.25 g, 0.67 mmol), ArX (4-MeC6H4I) 
(0.145 g, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI 
(0.382 g, 3 equiv.), Cs2CO3 (0.544 g, 2.5 equiv.), DMF (6 
mL), reaction time 50 h, 6a was isolated as brownish solid 
(0.132 g, 42%); mp 106–108 °C; 1H NMR (250.12 MHz, 
DMSO-d6): δ = 2.40 (s, 3H, CH3), 3.67 (s, 3H, OCH3), 5.65 
(s, 2H, -CH2-), 6.80 (d, 3J = 8.82 Hz, 2H, ArH), 6.96 (d, 3J = 8.82 Hz, 2H, ArH), 7.37 (d, 
3J = 8.19 Hz, 2H, ArH), 7.73 (d, 3J = 8.19 Hz, 2H, ArH), 8.11 (s, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3): δ = 21.5 (CH3), 47.1 (-CH2-), 55.2 (OCH3), 111.6 (CH), 114.2 
(2CH), 121.9 (q, 1JCF = 274.2 Hz, CF3), 125.8 (C), 126.3 (q, 1JCF = 274.2 Hz, CF3), 127.5 
(C), 128.2 (q, 2JCF = 34.8 Hz, C), 128.7 (2CH), 129.5 (2CH), 129.6 (2CH), 129.9 (C), 
133.4 (C), 141.7 (q, 2JCF = 35.7 Hz, C), 141.8 (C), 150.1 (C), 159.4 (C); 19F NMR 
(282.40 MHz, DMSO-d6): δ = -64.38 (ArCF3), -60.52 (ArCF3); IR (ATR, cm−1): 
~ν  = 2962 (w), 2926 (w), 2844 (w), 1613 (m), 1586 (w), 1513 (s), 1466 (s), 1417 (m), 
1376 (w), 1361 (w), 1322 (w), 1274 (s), 1249 (m), 1228 (m), 1176 (w), 1161 (w), 1130 
(s), 1107 (m), 1087 (w), 1034 (m), 1018 (w), 993 (m), 948 (m), 920 (w), 886 (s), 843 (w),  
826 (m), 809 (w), 776 (w), 732 (s), 710 (w), 671 (s), 626 (w), 573 (w), 536 (m); GC-MS 
(EI, 70 eV): m/z (%): 465 (M+, 31), 446 (1), 232 (1), 121 (100), 77 (4); HRMS (EI) calcd 










Starting with 5b (0.2 g, 0.62 mmol), ArX (4-MeC6H4I) 
(0.27 g, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI 
(0.353 g, 3 equiv.), Cs2CO3 (0.5 g, 2.5 equiv.), DMF (6 
mL), reaction time 30 h, 6b was isolated as deep brown 
solid (0.237 g, 93%); mp 114–116 °C; 1H NMR 
(250.13 MHz, DMSO-d6): δ = 2.36 (s, 3H, CH3), 2.66 (s, 
3H, CH3), 3.65 (s, 3H, OCH3), 5.57 (s, 2H, -CH2-), 6.79 (d, 3J = 8.75 Hz, 2H, ArH), 6.92 
(d, 3J = 8.75 Hz, 2H, ArH), 7.32 (d, 3J = 8.00 Hz, 2H, ArH), 7.54 (s, 1H, ArH), 7.66 (d, 
3J = 8.12 Hz, 2H, ArH); 13C NMR (62.89 MHz, CDCl3): δ = 21.4 (CH3), 24.5 (CH3), 46.3 
(-CH2-), 55.2 (OCH3), 114.2 (2CH), 114.4 (q, 3JCF = 4.12 Hz, CH), 123.0 (q, 1JCF = 
273.74 Hz, CF3), 126.7 (C), 127.7 (q, 2JCF = 33.42 Hz, C), 128.3 (2CH), 128.8 (C), 129.1 
(C), 129.4 (2CH), 129.5 (2CH), 140.7 (C), 149.9 (C), 153.3 (C), 156.1 (C), 159.1 (C); 19F 
NMR (300.13 MHz, CDCl3): δ = -61.83 (ArCF3); IR (ATR, cm−1): ~ν  = 3066 (w), 3038 
(w), 3009 (w), 2957 (w), 2921 (m), 2839 (w), 1613 (m), 1597 (w), 1584 (w), 1511 (s), 
1468 (m), 1449 (m), 1426 (w), 1407 (m), 1388 (m), 1372 (w), 1362 (w), 1300 (m), 1279 
(m), 1261 (w), 1245 (s), 1225 (w), 1190 (w), 1175 (w), 1162 (m), 1124 (s), 1097 (m), 
1031 (s), 961 (w), 927 (w), 896 (s), 871 (s), 834 (w), 820 (s), 802 (w), 776 (m), 749 (w), 
730 (s), 719 (s), 708 (w), 695 (w), 679 (s), 665 (w), 648 (m), 638 (w), 629 (w), 621 (w), 
592 (s), 555 (m), 535 (w); GC-MS (EI, 70 eV): m/z (%): 411 (M+, 49), 392 (1), 290 (2), 
270 (1), 206 (1), 161 (1), 121 (100), 77 (4); HRMS (ESI) calcd for C23H20F3N3O [M + 










Starting with 5c (0.2 g, 0.54 mmol), ArX (4-MeC6H4I) 
(0.235 g, 2 equiv.), Pd(OAc)2 (0.006 g, 0.05 equiv.), CuI 
(0.308 g, 3 equiv.), Cs2CO3 (0.439 g, 2.5 equiv.), DMF (6 
mL), reaction time 30 h, 6c was isolated as brown solid 
(0.171 g, 69%); mp 98–100 °C; 1H NMR (300.13 MHz, 
CDCl3): δ = 2.36 (s, 3H, CH3), 3.68 (s, 3H, OCH3), 5.48 
(s, 2H, -CH2-), 6.49 (dd, J = 1.70 Hz, J = 3.40 Hz, 1H, CHfuryl), 6.71 (d, 3J = 8.87 Hz, 2H, 
ArH), 7.01 (d, 3J = 8.87 Hz, 2H, ArH), 7.04-7.06 (m, 1H, CHfuryl), 7.21 (d, 3J = 8.31 Hz, 
2H, ArH), 7.48-7.50 (m, 1H, CHfuryl), 7.54 (d, 3J = 8.31 Hz, 2H, ArH), 7.85 (s, 1H, ArH); 
13C NMR (62.89 MHz, CDCl3): δ = 21.5 (CH3), 46.6 (-CH2-), 55.2 (OCH3), 108.9 
(CHfuryl), 112.3 (CHfuryl), 114.1 (2CH), 122.9 (CF3, q, 1JCF = 272.37 Hz), 124.0 (CH), 
126.6 (C), 128.3 (q, 2JCF = 34.33 Hz, C), 128.6 (CH), 128.7 (2CH), 129.4 (CH), 129.5 
(2CH), 137.9 (C), 140.9 (CHfuryl), 143.5 (C), 144.1 (C), 150.2 (C), 152.4 (C), 153.5 (C), 
155.2 (C), 159.2 (C); 19F NMR (282.40 MHz, CDCl3): δ = -61.97 (ArCF3); IR (ATR, 
cm−1): ~ν  = 3033 (w), 2998 (w), 2956 (w), 2929 (w), 2873 (w), 2837 (w), 1809 (w), 1731 
(w), 1698 (m), 1612 (s), 1586 (w), 1513 (s), 1496 (w), 1463 (s), 1455 (s), 1416 (m), 1406 
(m), 1371 (m), 1270 (w), 1246 (s), 1165 (m), 1134 (s), 1095 (w), 1030 (w), 1019 (w), 944 
(w), 912 (w), 878 (w), 821 (s), 767 (w), 732 (m), 677 (w), 664 (m), 638 (w), 622 (w), 590 
(w), 561 (w), 533 (w); GC-MS (EI, 70 eV): m/z (%): 463 (M+, 50), 444 (1), 342 (3), 121 











Starting with 5d (0.2 g, 0.62 mmol), ArX (4-MeC6H4I) 
(0.27 g, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI 
(0.353 g, 3 equiv.), Cs2CO3 (0.504 g, 2.5 equiv.), DMF (6 
mL), reaction time 48 h, 6d was isolated as light brown 
solid (0.15 g, 59%); mp 190–192 °C; 1H NMR 
(300.13 MHz, CDCl3): δ = 1.66 (s, 9H, 3CH3), 2.35 (s, 3H, CH3), 7.06-7.09 (d, 3J = 3.59 
Hz, 1H, CHthienyl), 7.14-7.19 (m, 2H, ArH), 7.31-7.35 (m, 2H, ArH), 7.54 (d, 3J = 3.78 
Hz, 1H, CHthienyl), 7.58 (dd, J = 3.78 Hz, J = 1.13 Hz, 1H, CHthienyl), 7.74 (s, 1H, ArH); 
13C NMR (75.46 MHz, CDCl3): δ = 21.5 (CH3), 31.0 (3CH3), 61.2 (C), 109.8 (q, 3JCF = 
4.40 Hz, CH), 122.9 (q, 1JCF = 273.99 Hz, CF3), 125.7 (CH), 127.7 (CH), 128.0 (q, 2JCF = 
34.11 Hz, C), 128.3 (CH), 128.6 (2CH), 129.7 (2CH), 131.4 (C), 139.8 (C), 143.5 (C), 
145.0 (C), 146.1 (C), 146.7 (C), 150.1 (C); 19F NMR (282.40 MHz, CDCl3): δ = -61.98 
(ArCF3); IR (ATR, cm−1): ~ν  = 3094 (w), 3069 (w), 3022 (w), 2980 (w), 2960 (w), 2919 
(w), 2871 (w), 1618 (w), 1606 (w), 1589 (m), 1548 (w), 1536 (w), 1510 (w), 1504 (w), 
1467 (s), 1429 (m), 1390 (w), 1381 (s), 1351 (m), 1334 (w), 1304 (w), 1276 (m), 1257 
(m), 1248 (w), 1226 (w), 1218 (w), 1183 (w), 1170 (w), 1155 (w), 1137 (s), 1126 (m), 
1072 (w), 1063 (w), 1053 (m), 1026 (w), 1015 (w), 950 (w), 945 (w), 906 (w), 875 (w), 
864 (m), 849 (w), 827 (w), 817 (m), 798 (w), 761 (w), 750 (w), 727 (s), 709 (w), 682 (m), 
665 (s), 628 (m), 616 (w), 602 (w), 575 (w), 535 (m); GC-MS (EI, 70 eV): m/z (%): 415 
(M+, 8), 359 (100), 338 (3), 196 (1), 146 (2), 118 (2), 91 (1), 57 (1), 41 (2), 29 (1); 
HRMS (ESI) calcd for C22H21F3N3S [M+H]+: 416.14028 found 416.14085. 
3-tert-Butyl-5-phenyl-2-p-tolyl-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine (6e):
Starting with 5f (0.2 g, 0.62 mmol), ArX (4-MeC6H4I) 
(0.27 g, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI 
(0.353 g, 3 equiv.), Cs2CO3 (0.504 g, 2.5 equiv.), DMF 
(6 mL), reaction time 60 h, 6e was isolated as light 
brown solid (0.079 g, 31%); mp 239–240 °C; 1H NMR (300 MHz, CDCl3): δ = 1.68 (s, 











7.48 (m, 2H, ArH), 7.86 (s, 1H, ArH), 8.03-8.07 (m, 2H, ArH); 13C NMR (75.46 MHz, 
CDCl3): δ = 21.5 (CH3), 31.1 (3CH3), 60.9 (C), 111.1 (q, 3JCF = 4.40 Hz, CH), 123.1 (q,
1JCF = 273.45 Hz, CF3), 126.9 (2CH), 127.9 (q, 2JCF = 33.56 Hz, C), 128.6 (2CH), 128.9 
(2CH), 129.1 (CH), 129.6 (2CH), 131.6 (2C), 138.9 (2C), 139.8 (2C), 150.7 (C); 19F 
NMR (282.40 MHz, CDCl3): δ = -61.63 (ArCF3); IR (ATR, cm−1): ~ν  = 3054 (w), 3028 
(w), 2982 (w), 2922 (m), 2853 (w), 1698 (w), 1658 (m), 1619 (w), 1593 (m), 1498 (w), 
1469 (m), 1461 (m), 1381 (s), 1331 (w), 1318 (w), 1302 (w), 1276 (m), 1247 (s), 1184 
(w), 1175 (w), 1147 (w), 1128 (s), 1113 (w), 1082 (w), 1070 (w), 1056 (w), 1017 (w), 
973 (w), 959 (m), 947 (w), 923 (w), 907 (w), 877 (s), 853 (w), 828 (w), 819 (m), 794 (w), 
777 (m), 733 (m), 727 (w), 701 (m), 694 (w), 680 (w), 666 (w), 635 (w), 626 (s), 604 (w), 
575 (w), 534 (w); GC-MS (EI, 70 eV): m/z (%): 409 (M+, 8), 353 (100), 215 (1), 139 (1), 




Starting with 5e (0.2 g, 0.78 mmol), ArX (2,4-Me2C6H3I) 
(0.23 mL, 2 equiv.), Pd(OAc)2 (0.009 g, 0.05 equiv.), CuI 
(0.445 g, 3 equiv.), Cs2CO3 (0.634 g, 2.5 equiv.), DMF (6 
mL), reaction time 56 h, 6f was isolated as light grey gummy 
solid (0.14 g, 50%); 1H NMR (300.13 MHz, CDCl3): δ = 1.60 (s, 9H, 3CH3), 2.26 (s, 6H, 
2CH3), 2.64 (s, 3H, CH3), 7.00-7.02 (m, 3H, ArH), 7.20 (s, 1H, ArH); 13C NMR 
(75.46 MHz, CDCl3): δ = 21.2 (2CH3), 24.7 (CH3), 30.8 (3CH3), 60.6 (C), 113.4 (q, 3JCF
= 4.40 Hz, CH), 123.1 (q, 1JCF = 273.45 Hz, CF3), 127.3 (q, 2JCF = 33.01 Hz, C), 127.6 
(CH), 129.2 (C), 131.0 (CH), 134.7 (2C), 137.4 (CH), 150.3 (C), 151.7 (2C), 156.2 (C); 
19F NMR (282.40 MHz, CDCl3): δ = -61.78 (ArCF3); IR (ATR, cm−1): ~ν  = 2968 (w), 
2922 (m), 2861 (w), 1737 (w), 1604 (w), 1589 (m), 1495 (w), 1476 (w), 1457 (m), 1386 
(s), 1365 (s), 1329 (m), 1309 (w), 1274 (m), 1253 (m), 1224 (s), 1210 (w), 1155 (w), 
1128 (s), 1074 (m), 1049 (m), 1016 (m), 997 (w), 933 (w), 906 (s), 866 (w), 852 (s), 800 






70 eV): m/z (%): 361 (M+, 8), 305 (100), 285 (4), 270 (1), 132 (2), 116 (3), 77 (1), 57 (1), 
41 (1); HRMS (ESI) calcd for C20H23F3N3 [M+H]+: 362.18386 found 362.18417. 
3-tert-Butyl-2-(4-ethylphenyl)-5-methyl-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine 
(6g):
Starting with 5e (0.2 g, 0.78 mmol), ArX (4-EtC6H4I) (0.23 
mL, 2 equiv.), Pd(OAc)2 (0.009 g, 0.05 equiv.), CuI (0.445 
g, 3 equiv.), Cs2CO3 (0.634 g, 2.5 equiv.), DMF (6 mL), 
reaction time 30 h, 6g was isolated as light brown gummy 
solid (0.14 g, 50%); 1H NMR (300.13 MHz, CDCl3): δ = 1.13-1.20 (m, 12H, 4CH3), 1.58 
(s, 3H, CH3), 2.50-2.56 (m, 2H, -CH2-), 7.13-7.17 (m, 3H, ArH), 7.40 (d, 3J = 8.18 Hz, 
2H, ArH); 13C NMR (62.89 MHz, CDCl3): δ = 15.6 (CH3), 24.8 (CH3), 28.6 (-CH2-), 
30.9 (3CH3), 60.7 (C), 113.5 (q, 3JCF = 4.58 Hz, CH), 123.2 (q, 1JCF = 273.74 Hz, CF3), 
126.9 (2CH), 127.4 (q, 2JCF = 33.36 Hz, C), 128.3 (2CH), 132.3 (C), 138.6 (C), 143.1 
(C), 145.9 (C), 151.8 (C), 155.5 (C); 19F NMR (282.40 MHz, CDCl3): δ = -61.74 
(ArCF3); IR (ATR, cm−1): ~ν  = 3023 (w), 2964 (s), 2929 (m), 2872 (w), 2725 (w), 2632 
(w), 2300 (w), 2228 (w), 1905 (w), 1788 (w), 1737 (w), 1659 (w), 1592 (m), 1499 (s), 
1462 (s), 1410 (w), 1386 (s), 1365 (s), 1327 (m), 1306 (m), 1268 (w), 1228 (s), 1169 (w), 
1158 (w), 1136 (s), 1072 (m), 1049 (w), 1019 (m), 1006 (w), 979 (w), 965 (w), 933 (w), 
898 (s), 871 (m), 846 (w), 831 (w), 819 (s), 783 (w), 765 (w), 732 (m), 703 (w), 685 (m), 
669 (w), 646 (w), 634 (w), 615 (w), 690 (m), 554 (w); GC-MS (EI, 70 eV): m/z (%): 361 
(M+, 11), 305 (100), 290 (58), 284 (5), 270 (3), 250 (1), 132 (1), 102 (1), 89 (2), 77 (1), 








Starting with 5c (0.2 g, 0.62 mmol), ArX (C6H5Br) (0.13 mL, 2 
equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI (0.353 g, 3 
equiv.), Cs2CO3 (0.504 g, 2.5 equiv.), DMF (6 mL), reaction 
time 48 h, 6h was isolated as brown solid (0.162 g, 58%); mp 
103–105 °C; 1H NMR (300.13 MHz, CDCl3): δ = 3.67 (s, 3H, 
OCH3), 5.48 (s, 2H, -CH2-), 6.49 (dd, J = 1.89 Hz, J = 3.40 Hz, 
1H, CHfuryl), 6.72 (d, 3J = 8.69 Hz, 2H, ArH), 7.03 (d, 3J = 8.88 Hz, 1H, CHfuryl), 7.26 (d, 
3J = 8.69 Hz, 1H, CHfuryl), 7.37 (d, 3J = 7.92 Hz, 2H, ArH), 7.44 (m, 1H, ArH), 7.61-7.66 
(m, 2H, ArH), 7.73 (d, 3J = 8.50 Hz, 2H, ArH), 7.86 (s, 1H, ArH); 13C NMR (75.46 MHz, 
CDCl3): δ = 46.7 (-CH2-), 55.2 (OCH3), 107.8 (CHfuryl), 111.4 (CHfuryl), 114.3 (2CH), 
121.7 (q, 1JCF = 274.55 Hz, CF3), 124.1 (CH), 126.4 (C), 127.9 (2CH), 128.6 (q, 3JCF = 
4.40 Hz, CH), 128.8 (2CH), 129.6 (2CH), 130.3 (C), 130.6 (CH), 143.6 (CHfuryl), 144.3 
(C), 152.8 (C), 153.5 (C), 154.9 (C), 156.9 (C), 159.2 (C); 19F NMR (282.40 MHz, 
CDCl3): δ = -61.98 (ArCF3); IR (ATR, cm−1): ~ν  = 3063 (w), 3001 (w), 2959 (w), 2934 
(w), 2912 (w), 2837 (w), 1722 (w), 1708 (w), 1693 (w), 1681 (w), 1611 (m), 1513 (s), 
1466 (s), 1452 (w), 1441 (w), 1414 (m), 1376 (m), 1301 (w), 1267 (w), 1246 (s), 1214 
(w), 1165 (w), 1134 (s), 1095 (w), 1027 (m), 945 (w), 919 (w), 903 (w), 880 (w), 821 
(w), 789 (w), 780 (m), 696 (s), 664 (w), 609 (w), 565 (w), 535 (w); GC-MS (EI, 70 eV): 
m/z (%): 449 (M+, 39), 328 (3), 121 (100), 105 (17), 77 (13), 39 (1); HRMS (ESI) calcd 
for C25H19F3N3O2 [M+H]+: 450.10370 found 450.10288. 
3-tert-Butyl-2-phenyl-5-(thiophen-2-yl)-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine 
(6i):
Starting with 5d (0.2 g, 0.62 mmol), ArX (C6H5Br) (0.13 
mL, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI (0.353 
g, 3 equiv.), Cs2CO3 (0.504 g, 2.5 equiv.), DMF (6 mL), 
reaction time 30 h, 6i was isolated as yellow solid (0.117 g, 
47%); mp 208–210 °C; 1H NMR (300.13 MHz, CDCl3): δ = 1.65 (s, 9H, 3CH3), 7.0 (dd, 













7.36 Hz, 2H, ArH), 7.55 (d, 3J = 3.97 Hz, 1H, CHthienyl), 7.58 (m, 1H, ArH), 7.63 (d, 3J = 
7.18 Hz, 2H, ArH), 7.45 (q, 4JHF = 1.89 Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3): 
δ = 30.9 (3CH3), 61.1 (C), 109.7 (q, 3JCF = 4.40 Hz, CH), 122.9 (q, 1JCF = 273.99 Hz, 
CF3), 124.7 (CH), 125.8 (CH),  126.1 (q, 2JCF = 34.66 Hz, C), 127.9 (2CH), 128.3 (CH), 
128.9 (CH), 129.8 (2CH), 134.6 (C), 144.1 (C), 145.0 (C), 146.5 (C), 150.2 (C), 156.7 
(C); 19F NMR (282.40 MHz, CDCl3): δ = -62.00 (ArCF3); IR (ATR, cm−1): ~ν  = 3082 
(w), 2979 (w), 2923 (w), 2871 (w), 1588 (m), 1536 (m), 1515 (w), 1559 (m), 1444 (m), 
1430 (m), 1382 (s), 1367 (w), 1351 (w), 1332 (w), 1305 (m), 1277 (m), 1256 (s), 1227 
(w), 1215 (w), 1165 (s), 1156 (m), 1121 (s), 1073 (m), 1063 (m), 1035 (w), 1027 (w), 
1017 (w), 999 (w), 973 (w), 949 (m), 920 (w), 906 (w), 876 (w), 867 (m), 860 (w), 850 
(w), 828 (w), 789 (w), 773 (m), 753 (m), 735 (w), 723 (m), 699 (s), 688 (w), 666 (m), 
640 (w), 621 (w), 613 (w), 596 (w), 589 (w), 569 (w), 537 (w); GC-MS (EI, 70 eV): m/z 
(%): 401 (M+, 20), 345 (100), 324 (2), 215 (2), 146 (1), 77 (1), 41 (2); HRMS (ESI) calcd 
for C21H19F3N3S [M+H]+: 402.12463 found 402.12507. 
3-Phenethyl-2-phenyl-5-(thiophen-2-yl)-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine 
(6j):
Starting with 5h (0.2 g, 0.54 mmol), ArX (C6H5Br) (0.12 
mL, 2 equiv.), Pd(OAc)2 (0.006 g, 0.05 equiv.), CuI (0.308 
g, 3 equiv.), Cs2CO3 (0.439 g, 2.5 equiv.), DMF (6 mL), 
reaction time 57 h, 6j was isolated as bright yellow solid 
(0.199 g, 83%); mp 137–139 °C; 1H NMR (300.13 MHz, 
CDCl3): δ = 3.14 (t, J = 6.99, 2H, -CH2-), 4.57 (t, J = 7.55, 
2H, -CH2-), 6.99 (d, J = 8.12 Hz, 2H, ArH), 7.12-7.16 (m, 2H, ArH), 7.28-7.44 (m, 5H, 
ArH), 7.51-7.59 (m, 2H, ArH), 7.63 (d, J = 7.18 Hz, 2H, ArH), 7.76 (s, 1H, ArH); 
13C NMR (62.89 MHz, CDCl3): δ = 35.6 (-CH2-), 45.6 (-CH2-), 110.3 (q, 3JCF = 4.12 Hz, 
CH), 122.8 (q, 1JCF = 274.00 Hz, CF3), 124.2 (CH), 125.8 (2CH), 126.0 (CH), 126.9 
(CH), 127.9 (CH), 128.3 (q, 2JCF = 33.88 Hz, C), 128.7 (CH), 128.8 (3CH), 129.0 (CH), 
129.3 (CH), 129.5 (C), 130.4 (CH), 134.2 (C), 137.4 (C), 143.4 (C), 146.6 (C), 149.8 (C), 
156.5 (C); 19F NMR (282.40 MHz, CDCl3): δ = -61.99 (ArCF3); IR (ATR, cm−1): 







1496 (m), 1467 (w), 1453 (w), 1443 (w), 1418 (w), 1384 (s), 1367 (w), 1339 (w), 1329 
(w), 1309 (w), 1271 (m), 1250 (m), 1228 (w), 1155 (w), 1125 (s), 1099 (w), 1073 (w), 
1049 (w), 1029 (w), 1020 (w), 1004 (w), 959 (w), 942 (w), 929 (w), 898 (w), 868 (m), 
846 (w), 833 (w), 809 (s), 779 (w), 755 (m), 739 (w), 696 (w), 684 (m), 666 (w), 618 (w), 
609 (w), 586 (w), 558 (m), 532 (w); GC-MS (EI, 70 eV): m/z (%): 449 (M+, 26), 358 (2), 
345 (100), 324 (1), 242 (1), 208 (2), 186 (1), 146 (1), 105 (1), 91 (1), 77 (2); HRMS 
(ESI) calcd for C25H19F3N3S [M+H]+: 450.12463 found 450.12452. 
3-Cyclohexyl-2-(2-fluorophenyl)-5-phenyl-7-(trifluoromethyl)-3H-imidazo[4,5-
b]pyridine (6k):
Starting with 5g (0.2 g, 0.58 mmol), ArX (2-FC6H4Br) 
(0.13 mL, 2 equiv.), Pd(OAc)2 (0.006 g, 0.05 equiv.), CuI 
(0.331 g, 3 equiv.), Cs2CO3 (0.471 g, 2.5 equiv.), DMF (6 
mL), reaction time 40 h, 6k was isolated as light brown 
solid (0.11 g, 43%); mp 188–190 °C. 1H NMR 
(300.13 MHz, CDCl3): δ = 1.17-1.39 (m, 4H, 2-CH2-), 1.66-1.86 (m, 4H, 2-CH2-), 2.70-
2.82 (m, 2H, -CH2-), 3.97-4.05 (m, 1H, CH), 7.13-7.19 (m, 1H, ArH), 7.23-7.28 (m, 1H, 
ArH), 7.33-7.51 (m, 4H, ArH), 7.57-7.63 (m, 1H, ArH), 7.85 (s, 1H, ArH), 8.01-8.05 (m, 
2H, ArH); 13C NMR (62.89 MHz, CDCl3): δ = 25.3 (-CH2-), 26.1 (2-CH2-), 30.9 (2-CH2-
), 58.4 (CH), 111.2 (q, 3JCF = 4.58 Hz, CH), 115.9 (d, 2JCF = 21.06 Hz, CH), 118.5 (d, 2JCF 
= 15.11 Hz, C), 123.1 (q, 1JCF = 274.20 Hz, CF3), 124.9 (d, 3JCF = 3.66 Hz, CH), 127.0 
(2CH), 128.5 (q, 2JCF = 33.87 Hz, C), 128.9 (2CH), 129.2 (CH), 130.8 (q, 3JCF = 1.83 Hz, 
C), 132.6 (q, 3JCF = 2.29 Hz, CH), 138.8 (C), 149.6 (C), 151.6 (C), 151.9 (C), 158.3 (C), 
162.3 (C); 19F NMR (282.40 MHz, CDCl3): δ = -112.63 (ArF), -61.96 (ArCF3); IR (ATR, 
cm−1): ~ν  = 3054 (w), 2922 (m), 2850 (m), 1616 (w), 1606 (w), 1591 (w), 1506 (w), 1480 
(m), 1446 (s), 1416 (m), 1386 (s), 1355 (w), 1319 (m), 1281 (s), 1252 (s), 1224 (w), 1211 
(m), 1194 (w), 1187 (w), 1154 (s), 1137 (s), 1124 (s), 1109 (w), 1097 (w), 1076 (m), 
1028 (w), 996 (w), 962 (m), 923 (w), 883 (m), 876 (s), 851 (w), 834 (m), 798 (m), 772 
(s), 740 (m), 710 (w), 695 (s), 675 (w), 661 (m), 617 (m), 562 (w), 537 (w); GC-MS (EI, 
70 eV): m/z (%): 439 (M+, 20), 420 (4), 370 (5), 357 (100), 336 (3), 158 (1), 140 (1), 102 








Starting with 5f (0.2 g, 0.63 mmol), ArX (2-FC6H4Br) (0.13 
mL, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), CuI (0.359 
g, 3 equiv.), Cs2CO3 (0.511 g, 2.5 equiv.), DMF (6 mL), 
reaction time 60 h, 6l was isolated as yellow solid (0.065 g, 
25%); mp 156–158 °C; 1H NMR (300.13 MHz, CDCl3): δ = 
1.71 (s, 9H, 3CH3), 7.06-7.22 (m, 3H, ArH), 7.37-7.49 (m, 4H, ArH), 7.88 (s, 1H, ArH), 
8.06 (d, 3J = 8.49 Hz, 2H, ArH); 13C NMR (62.89 MHz, CDCl3): δ = 30.1 (3CH3), 61.1 
(C), 111.2 (q, 3JCF = 4.58 Hz, CH), 115.5 (d, 2JCF = 21.06 Hz, CH), 123.0 (q, 1JCF = 
274.20 Hz, CF3), 123.2 (d, 2JCF = 16.02 Hz, C), 124.1 (d, 3JCF = 3.66 Hz, CH), 127.0 
(2CH), 128.5 (q, 2JCF = 33.88 Hz, C), 128.9 (2CH), 129.1 (CH), 130.5 (q, 3JCF = 1.83 Hz, 
C), 131.6 (d, 3JCF = 2.29 Hz, CH), 131.9 (d, 3JCF = 7.78 Hz, CH), 138.8 (C), 150.5 (C), 
150.9 (C), 151.1 (C), 158.5 (C), 162.5 (C); 19F NMR (282.40 MHz, CDCl3): δ = -111.97 
(ArF), -61.90 (ArCF3); IR (ATR, cm−1): ~ν  = 3466 (w), 3057 (w), 2980 (w), 1737 (w), 
1621 (w), 1580 (w), 1513 (w), 1474 (w), 1455 (m), 1448 (w), 1379 (s), 1366 (w), 1337 
(w), 1320 (w), 1273 (w), 1255 (m), 1169 (s), 1153 (m), 1136 (w), 1113 (m), 1102 (w), 
1067 (w), 1053 (m), 1035 (w), 1022 (w), 1000 (w), 983 (w), 960 (m), 948 (w), 933 (w), 
919 (w), 883 (m), 867 (m), 818 (w), 798 (w), 768 (s), 747 (m), 732 (w), 687 (s), 672 (w), 
620 (m), 602 (w), 591 (w), 529 (w); GC-MS (EI, 70 eV): m/z (%): 413 (M+, 13), 357 
(100), 336 (4), 236 (1), 215 (1), 189 (3), 140 (2), 121 (1), 57 (1), 41 (1); HRMS (ESI) 
calcd for C23H20F4N3 [M+H]+ : 414.15879 found 414.15857. 
3-tert-Butyl-5-methyl-7-(trifluoromethyl)-2-(3-(trifluoromethyl)phenyl)-3H-
imidazo[4,5-b]pyridine (6m):
Starting with 5e (0.2 g, 0.78 mmol), ArX (3-(CF3)C6H4Br) (0.22 
mL, 2 equiv.), Pd(OAc)2 (0.009 g, 0.05 equiv.), CuI (0.445 g, 3 
equiv.), Cs2CO3 (0.634 g, 2.5 equiv.), DMF (6 mL), reaction 
time 56 h, 6m was isolated as deep brown gummy solid (0.062 g, 
20%); 1H NMR (300.13 MHz, CDCl3): δ = 1.60 (s, 9H, 3CH3), 2.67 (s, 3H, CH3), 7.26 (s, 











(3CH3), 60.9 (C), 113.9 (q, 3JCF = 4.40 Hz, CH), 122.9 (q, 1JCF = 273.45 Hz, CF3), 123.7 
(q, 1JCF = 272.35 Hz, CF3), 126.4 (q, 3JCF = 3.85 Hz, CH), 126.8 (q, 3JCF = 3.85 Hz, CH), 
127.8 (q, 2JCF = 32.56 Hz, C), 128.6 (CH), 129.5 (C), 130.5 (q, 2JCF = 32.46 Hz, C), 133.2 
(CH), 135.7 (C), 150.1 (C), 152.6 (C), 153.7 (C); 19F NMR (282.40 MHz, CDCl3): δ = -
62.77 (ArCF3), -62.01 (ArCF3); IR (ATR, cm−1): ~ν  = 2961 (w), 2926 (m), 2855 (w), 
1728 (w), 1591 (w), 1477 (w), 1468 (w), 1433 (w), 1389 (m), 1368 (m), 1335 (w), 1318 
(m), 1304 (m), 1274 (m), 1229 (m), 1162 (m), 1127 (s), 1094 (w), 1072 (m), 1032 (w), 
1003 (w), 984 (w), 933 (w), 901 (m), 970 (w), 853 (w), 808 (m), 742 (w), 729 (w), 706 
(s), 697 (w), 666 (w), 651 (w), 628 (w), 586 (w), 536 (w); GC-MS (EI, 70 eV): m/z (%): 
401 (M+, 3), 382 (2), 345 (100), 326 (4), 172 (3), 152 (1), 145 (1), 146 (1), 57 (2), 41 (2), 
29 (1); HRMS (ESI) calcd for C19H17F6N3 [M+H]+: 402.13994 found 402.1395. 
3-Cyclohexyl-5-phenyl-7-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)-3H-
imidazo[4,5-b]pyridine (6n):
Starting with 5g (0.25 g, 0.73 mmol), ArX (4-
(CF3)C6H4Br) (0.19 mL, 2 equiv.), Pd(OAc)2 (0.008 g, 
0.05 equiv.), CuI (0.413 g, 3 equiv.), Cs2CO3 (0.589 g, 
2.5 equiv.), DMF (6 mL), reaction time 30 h, 6n was 
isolated as light yellow solid (0.11 g, 31%); mp 225–
227 °C; 1H NMR (300.13 MHz, CDCl3): δ = 1.15-1.40 (m, 4H, 2-CH2-), 1.86-1.96 (m, 
4H, 2-CH2-), 2.75-2.93 (m, 2H, -CH2-), 4.22-4.33 (m, 1H, CH), 7.35-7.41 (m, 1H, ArH), 
7.43-7.51 (m, 2H, ArH), 7.73-7.79 (m, 4H, ArH), 7.87 (s, 1H, ArH), 8.02-8.10 (m, 2H, 
ArH); 13C NMR (62.89 MHz, CDCl3): δ = 25.2 (-CH2-), 26.00 (2-CH2-), 31.12 (2-CH2-), 
58.05 (CH), 111.54 (q, 3JCF = 4.58 Hz, CH), 123.4 (q, 1JCF = 274.20 Hz, 2CF3), 125.87 
(q, 3JCF = 4.12 Hz, 2CH), 126.9 (2CH), 128.9 (2CH), 129.3 (CH), 130.1 (2CH), 132.3 (q,
2JCF = 32.96 Hz, 2C), 133.7 (C), 138.6 (2C), 151.8 (C), 153.1 (C), 155.0 (C); 19F NMR 
(282.40 MHz, CDCl3): δ = -62.87 (ArCF3), -62.06 (ArCF3); IR (ATR, cm−1): ~ν  = 3068 
(w), 2945 (m), 2858 (m), 1621 (w), 1592 (w), 1469 (w), 1446 (w), 1426 (m), 1406 (w), 
1385 (s), 1381 (s), 1351 (w), 1317 (s), 1276 (m), 1255 (m), 1227 (w), 1173 (m), 1153 
(m), 1129 (s), 1104 (m), 1078 (w), 1062 (m), 1029 (w), 1015 (m), 994 (w), 962 (m), 922 







(s), 675 (w), 666 (w), 620 (s), 596 (m), 556 (w); GC-MS (EI, 70 eV): m/z (%): 489 (M+, 
16), 470 (3), 434 (2), 408 (24), 407 (100), 344 (1), 236 (1), 140 (1), 55 (2), 41 (2); HRMS 
(EI) calcd for C26H21F6N3 [M+] : 489.16342 found 489.163581. 
3-tert-Butyl-2-(4-ethylphenyl)-5-phenyl-7-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine 
(6o):
Starting with 5f (0.2 g, 0.63 mmol), ArX (4-EtC6H4Br) 
(0.18 mL, 2 equiv.), Pd(OAc)2 (0.007 g, 0.05 equiv.), 
CuI (0.359 g, 3 equiv.), Cs2CO3 (0.512 g, 2.5 equiv.), 
DMF (6 mL), reaction time 30 h, 6o was isolated as 
brown solid (0.168 g, 63%); mp 227–229 °C; 1H NMR (300.13 MHz, CDCl3): δ = 1.20 
(t, J = 7.55 Hz, 3H, CH3), 1.69 (s, 9H, 3CH3), 2.65 (q, J = 15.11, J = 7.55 Hz, 2H, -CH2-
), 7.20 (d, 3J = 8.31 Hz, 2H, ArH), 7.36 (d, 3J = 8.12 Hz, 2H, ArH), 7.39-7.49 (m, 3H, 
ArH), 7.86 (s, 1H, ArH), 8.05 (d, 3J = 8.12 Hz, 2H, ArH); 13C NMR (75.46 MHz, 
CDCl3): δ = 15.6 (CH3), 28.9 (-CH2-), 31.1 (3CH3), 60.9 (C), 110.9 (q, 3JCF = 4.40 Hz, 
CH), 123.1 (q, 1JCF = 273.99 Hz, CF3), 126.9 (2CH), 127.5 (2CH), 127.5 (q, 2JCF = 33.56 
Hz, C), 128.9 (2CH), 129.0 (CH), 129.7 (2CH), 131.9 (C), 139.0 (C), 146.1 (C), 150.6 
(2C), 150.7 (C), 157.3 (C); 19F NMR (282.40 MHz, CDCl3): δ = -61.83 (ArCF3); IR 
(ATR, cm−1): ~ν  = 3086 (w), 2967 (s), 2872 (w), 1915 (w), 1737 (w), 1619 (w), 1598 (w), 
1500 (w), 1463 (m), 1378 (s), 1316 (w), 1285 (w), 1255 (m), 1204 (w), 1176 (m), 1153 
(w), 1127 (s), 1083 (w), 1055 (w), 1016 (w), 1000 (w), 958 (m), 930 (w), 877 (m), 839 
(m), 794 (w), 773 (m), 729 (w), 691 (s), 666 (w), 626 (m), 579 (w), 547 (w); GC-MS (EI, 
70 eV): m/z (%): 423 (M+, 9), 368 (23), 367 (100), 352 (34), 331 (3), 282 (1), 189 (2), 
140 (2), 116 (8), 89 (2), 77 (2), 57 (8), 41 (8), 29 (4); HRMS (ESI) calcd for C25H25F3N3 






6.3 Regioselective Palladium-Catalysed Cross-Coupling Reactions of 5,7-dichloro-
1,6-naphthyridine. 
General procedure for synthesis of 9a-l: A 1,4-dioxane / toluene (1:1) solution (8 mL) of 
7 (1.0 mmol), arylboronic acid 8 (1.3 equiv.), 2M K2CO3 (1 mL), and Pd(PPh3)4 (5 
mol%) was heated at 70 °C for 8 h. After cooling to room temperature, H2O was added 
and the reaction mixture was extracted with CH2Cl2. The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (gradient elution n-heptane/ethyl acetate). 
7-Chloro-5-p-tolyl-1,6-naphthyridine (9a): 
Starting with 7 (0.199 g, 1 mmol), 8a (0.176 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 8 
mL), 9a was isolated as white solid (0.178 g, 70%); mp 138–141 °C; 1H 
NMR (250.13 MHz, CDCl3): δ = 2.36 (s, 3H, CH3), 7.25 (d, 3J = 8.31 
Hz, 2H, ArH), 7.37 (dd, J = 8.69 Hz, J = 4.16 Hz, 1H, ArH), 7.48 (d, 3J
= 8.12 Hz, 2H, ArH), 7.84 (s, 1H, ArH), 8.31-8.35 (m, 1H, ArH), 8.95 
(dd, J = 4.34 Hz, J = 1.70 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (CH3), 
120.2 (CH), 120.8 (C), 122.2 (CH), 129.3 (2CH), 130.0 (2CH), 134.3 (C), 136.2 (CH), 
139.8 (C), 148.3 (C), 152.9 (C), 155.2 (CH), 162.1 (C); IR (ATR, cm−1): ~ν  = 3129 (w), 
3021 (w), 2862 (w), 1914 (w), 1738 (w), 1610 (w), 1549 (s), 1466 (w), 1378 (w), 1340 
(m), 1294 (m), 1182 (m), 1163 (m), 1112 (m), 1068 (s), 1043 (m), 1022 (w), 970 (m), 
950 (w), 880 (m), 867 (s), 858 (s), 828 (s), 813 (s), 782 (s), 768 (m), 725 (m), 696 (w), 
642 (w), 603 (m), 588 (m), 566 (w); GC-MS (EI, 70 eV): m/z (%): 254 (M+, 100), 253 
(73), 239 (87), 217 (42), 203 (30), 190 (23), 177 (8), 127 (8), 108 (11), 96 (13), 75 (13), 






Starting with 7 (0.199 g, 1 mmol), 8b (0.194 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 8 
mL), 9b was isolated as light yellow solid (0.214 g, 80%); mp 155–159 
°C; 1H NMR (250.13 MHz, CDCl3): δ = 2.30 (s, 6H, 2CH3), 7.05 (s, 
1H, ArH), 7.16 (s, 2H, ArH), 7.34 (dd, J = 8.51 Hz, J = 4.10 Hz, 1H, ArH), 7.84 (s, 1H, 
ArH), 8.29-8.34 (m, 1H, ArH), 8.94 (dd, J = 4.26 Hz, J = 1.73 Hz, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 21.3 (2CH3), 120.3 (CH), 120.8 (C), 122.2 (CH), 127.8 (2CH), 
131.2 (CH), 136.3 (CH), 136.9 (C), 138.2 (2C), 148.2 (C), 152.8 (C), 155.2 (CH), 162.5 
(C); IR (ATR, cm−1): ~ν  = 3073 (w), 2953 (w), 2860 (w), 2726 (w), 1597 (m), 1552 (s), 
1519 (w), 1494 (w), 1462 (m), 1429 (m), 1343 (m), 1298 (s), 1240 (w), 1164 (m), 1096 
(w), 1076 (s), 1038 (w), 1015 (w), 975 (m), 904 (m), 879 (m), 849 (s), 822 (m), 782 (w), 
772 (m), 709 (m), 678 (w), 609 (w), 601 (m), 589 (w), 540 (w); GC-MS (EI, 70 eV): m/z
(%): 268 (M+, 75), 255 (32), 253 (100), 231 (19), 217 (26), 190 (13), 163 (4), 139 (3), 
127 (4), 115 (8), 102 (8), 95 (8), 77 (9), 63 (7), 51 (7), 39 (6); HRMS (ESI) calcd for 
C16H14ClN2 [M+H]+: 269.084 found 269.08434. 
7-Chloro-5-(2-methoxyphenyl)-1,6-naphthyridine (9c): 
Starting with 7 (0.1 g, 0.5 mmol), 8c (0.099 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9c was isolated as white solid (0.1 g, 74%); mp 159–161 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 3.62 (s, 3H, OCH3), 6.97 (d, 3J = 
8.50 Hz, 1H, ArH), 7.05 (dt, J = 7.55 Hz, J = 0.94 Hz, 1H, ArH), 7.31-7.37 (m, 2H, 
ArH), 7.39-7.45 (m, 1H, ArH), 7.91-7.97 (m, 2H, ArH), 8.97 (dd, J = 4.16 Hz, J = 1.70 
Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 55.5 (OCH3), 111.1 (CH), 120.8 (CH), 
121.1 (CH), 122.0 (C), 122.1 (CH), 126.3 (C), 131.1 (CH), 131.5 (CH), 136.7 (CH), 
148.4 (C), 152.0 (C), 155.2 (CH), 156.8 (C), 160.5 (C); IR (ATR, cm−1): ~ν  = 3322 (br), 
2989 (w), 2830 (w), 1603 (m), 1582 (w), 1553 (m), 1492 (w), 1432 (m), 1372 (m), 1347 
(w), 1303 (m), 1285 (w), 1238 (m), 1165 (w), 1110 (m), 1065 (w), 1020 (s), 936 (w), 858 
(m), 789 (w), 746 (s), 699 (w), 627 (m), 601 (m), 567 (w), 528 (w); GC-MS (EI, 70 eV): 







(24), 165 (62), 151 (16), 102 (28), 100 (11), 88 (17), 82 (13), 75 (28), 63 (23), 51 (16), 39 
(14), 29 (1); HRMS (ESI) calcd for C15H12ClN2O [M+H]+: 271.06327 found 271.06347. 
7-Chloro-5-(4-fluorophenyl)-1,6-naphthyridine (9d):
Starting with 7 (0.1 g, 0.5 mmol), 8d (0.09 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9d was isolated as white solid (0.07 g, 54%); mp 162–164 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 7.16-7.21 (m, 2H, ArH), 7.41 (dd, J = 
8.69 Hz, J = 4.34 Hz, 1H, ArH), 7.60-7.65 (m, 2H, ArH), 7.92 (s, 1H, 
ArH), 8.30-8.34 (m, 1H, ArH), 9.02 (dd, J = 4.16 Hz, J = 1.51 Hz, 1H, 
ArH); 13C NMR (75.46 MHz, CDCl3), δ = 115.9 (2CH, d, 2JCF = 22.01 Hz), 120.7 (CH), 
122.5 (CH), 122.6 (C), 132.1 (2CH, d, 3JCF = 8.25 Hz), 133.2 (C, d, 4JCF = 3.30 Hz), 
135.8 (CH), 148.4 (C), 152.9 (C), 155.4 (CH), 160.8 (C), 163.7 (C, d, 1JCF = 250.34 Hz);
19F NMR (282.40 MHz, CDCl3): δ = -111.04 (ArF); IR (ATR, cm−1): ~ν  = 3116 (w), 3054 
(w), 1895 (w), 1597 (m), 1577 (w), 1562 (m), 1507 (s), 1434 (w), 1381 (w), 1367 (m), 
1327 (m), 1295 (w), 1220 (s), 1173 (w), 1155 (m), 1093 (w), 1043 (w), 1013 (w), 968 
(m), 881 (m), 833 (s), 801 (w), 771 (m), 729 (m), 694 (w), 634 (w), 602 (w), 586 (w), 
575 (m), 528 (s); GC-MS (EI, 70 eV): m/z (%): 258 (M+, 100), 257 (89), 221 (55), 195 
(22), 169 (12), 144 (3), 131 (4), 111 (12), 98 (10), 75 (20), 62 (6), 57 (5), 50 (7), 39 (2), 
31 (1); HRMS (ESI) calcd for C14H9ClFN2 [M+H]+: 259.04328 found 259.04323. 
7-Chloro-5-(2,3,4-trimethoxyphenyl)-1,6-naphthyridine (9e): 
Starting with 7 (0.199 g, 1 mmol), 8e (0.276 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 8 
mL), 9e was isolated as white solid (0.221 g, 67%); mp 140 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 3.53 (s, 3H, OCH3), 3.87 (s, 3H, 
OCH3), 3.88 (s, 3H, OCH3), 6.77 (d, J = 8.50 Hz, 1H, ArH), 7.09 (d, J
= 8.50 Hz, 1H, ArH), 7.35 (dd, J = 8.50 Hz, J = 4.16 Hz, 1H, ArH), 7.91 (s, 1H, ArH), 
8.03-8.07 (m, 1H, ArH), 8.97 (dd, J = 4.16 Hz, J = 1.70 Hz, 1H, ArH); 13C NMR (75.46 
MHz, CDCl3), δ = 56.2 (OCH3), 61.1 (OCH3), 61.6 (OCH3), 107.8 (CH), 120.7 (CH), 










(C), 152.2 (C), 155.1 (C), 155.3 (CH), 159.9 (C); IR (ATR, cm−1): ~ν  = 3005 (w), 2955 
(w), 2839 (w), 1601 (m), 1555 (s), 1494 (m), 1469 (m), 1435 (w), 1373 (m), 1300 (s), 
1225 (m), 1165 (w), 1100 (s), 1072 (s), 1023 (m), 976 (m), 924 (w), 877 (m), 799 (w), 
770 (m), 719 (w), 646 (w), 597 (m), 559 (w); GC-MS (EI, 70 eV): m/z (%): 330 (M+, 
100), 329 (49), 313 (53), 294 (90), 279 (84), 268 (28), 257 (22), 251 (21), 241 (12), 229 
(54), 215 (40), 165 (50), 139 (27), 87 (15), 75 (18), 63 (12), 51 (10); HRMS (ESI) calcd 
for C17H16ClN2O3 [M+H]+: 331.0844 found 331.08454. 
7-Chloro-5-(2,3-dimethoxyphenyl)-1,6-naphthyridine (9f): 
Starting with 7 (0.199 g, 1 mmol), 8f (0.24 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 8 
mL), 9f was isolated as white solid (0.288 g, 96%); mp 133–135 °C. 
1H NMR (250.13 MHz, CDCl3): δ = 3.52 (s, 3H, OCH3), 3.92 (s, 3H, 
OCH3), 6.98-7.08 (m, 2H, ArH), 7.16-7.26 (m, 1H, ArH), 7.37 (dd, J = 
8.51 Hz, J = 4.10 Hz, 1H, ArH), 7.97 (s, 1H, ArH), 8.05-8.10 (m, 1H, 
ArH), 9.01 (dd, J = 4.26 Hz, J = 1.73 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 
55.9 (OCH3), 61.4 (OCH3), 113.6 (CH), 120.9 (CH), 121.8 (C), 122.3 (CH), 122.8 (CH), 
124.6 (CH), 131.7 (C), 136.8 (CH), 146.8 (C), 148.1 (C), 151.9 (C), 152.7 (C), 155.4 
(CH), 159.9 (C); IR (ATR, cm−1): ~ν  = 3345 (m), 3333 (m), 2999 (w), 2838 (w), 1603 
(w), 1556 (m), 1468 (s), 1427 (m), 1370 (w), 1259 (s), 1209 (m), 1168 (w), 1107 (w), 
1087 (s), 1031 (m), 982 (s), 878 (w), 859 (m), 795 (m), 749 (s), 696 (m), 588 (w), 559 
(w), 541 (w), 531 (w); MS GC-MS (EI, 70 eV): m/z (%): 300 (M+, 76), 299 (64), 285 
(62), 283 (100), 271 (33), 264 (30), 257 (20), 246 (14), 239 (33), 229 (14), 221 (26), 213 
(29), 193 (22), 177 (25), 165 (67), 152 (27), 125 (12), 102 (14), 99 (10), 89 (19), 77 (11), 
75 (22), 63 (17), 51 (18), 39 (10); HRMS (ESI) calcd for C16H14ClN2O2 [M+H]+: 







Starting with 7 (0.199 g, 1 mmol), 8g (0.176 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 8 
mL), 9g was isolated as brown solid (0.18 g, 70%); mp 105–107 °C. 1H 
NMR (250.13 MHz, CDCl3): δ = 1.99 (s, 3H, CH3), 7.19-7.34 (m, 5H, 
ArH), 7.81-7.90 (m, 2H, ArH), 8.96 (dd, J = 4.26 Hz, J = 1.89 Hz, 1H, 
ArH); 13C NMR (250.13 MHz, CDCl3), δ = 19.8 (CH3), 120.7 (CH), 121.6 (C), 122.5 
(CH), 125.8 (CH), 129.3 (CH), 129.7 (CH), 130.6 (CH), 135.9 (CH), 136.3 (C), 148.2 
(C), 152.3 (C), 155.5 (CH), 156.3 (C), 162.8 (C); IR (ATR, cm−1): ~ν  = 3066 (w), 2992 
(w), 2858 (w), 1600 (m), 1556 (s), 1479 (w), 1368 (m), 1303 (s), 1207 (w), 1143 (w), 
1087 (w), 1063 (m), 1034 (m), 972 (m), 959 (w), 864 (s), 795 (w), 768 (s), 736 (m), 706 
(w), 635 (w), 603 (m), 536 (w); GC-MS (EI, 70 eV): m/z (%): m/z (%): 254 (M+, 30), 253 
(100), 217 (21), 190 (14), 139 (2), 126 (2), 115 (1), 108 (9), 89 (3), 75 (4), 63 (5), 51 (4), 
39 (4); HRMS (ESI) calcd for C15H12ClN2 [M+H]+: 255.06835 found 255.06796. 
7-Chloro-5-(4-chlorophenyl)-1,6-naphthyridine (9h):
Starting with 7 (0.1 g, 0.5 mmol), 8h (0.1 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9h was isolated as light yellow solid (0.045 g, 33%); mp 150–152 
°C. 1H NMR (300.13 MHz, CDCl3): δ = 7.39-7.48 (m, 3H, ArH), 7.55-
7.59 (m, 2H, ArH), 7.92 (s, 1H, ArH), 8.28-8.32 (m, 1H, ArH), 9.01 
(dd, J = 3.97 Hz, J = 1.32 Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 120.7 (C), 
120.9 (CH), 122.6 (CH), 128.9 (2CH), 131.4 (2CH), 135.5 (C), 135.6 (CH), 136.1 (C), 
148.5 (C), 152.9 (C), 155.5 (CH), 160.6 (C); IR (ATR, cm−1): ~ν  = 3076 (w), 2923 (w), 
2852 (w), 1602 (m), 1563 (w), 1551 (m), 1464 (m), 1402 (w), 1304 (m), 1264 (m), 1169 
(w), 1102 (w), 1074 (s), 1013 (m), 966 (m), 875 (m), 852 (w), 835 (s), 794 (w), 771 (s), 
745 (m), 706 (w), 635 (w), 603 (m), 586 (m), 541 (w); GC-MS (EI, 70 eV): m/z (%): 274 
(M+, 100), 273 (69), 239 (74), 203 (43), 176 (22), 150 (11), 137 (8), 119 (10), 111 (7), 
101 (16), 99 (7), 88 (12), 75 (30), 51 (11), 39 (4); HRMS (ESI) calcd for C14H9Cl2N2








Starting with 7 (0.1 g, 0.5 mmol), 8i (0.123 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9i was isolated as white solid (0.1 g, 65%); mp 151–153 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 7.41 (dd, J = 8.69 Hz, J = 4.34 Hz, 
1H, ArH), 7.73 (s, 4H, ArH), 7.93 (s, 1H, ArH), 8.26 (d, J = 8.50 Hz, 
1H, ArH), 9.02 (dd, J = 4.16 Hz, J = 1.70 Hz, 1H, ArH); 13C NMR 
(75.46 MHz, CDCl3), δ = 120.7 (C), 121.4 (CH), 122.7 (CH), 123.9 (CF3, q, 1JCF = 271.25 
Hz), 125.7 (2CH, q, 3JCF = 3.85 Hz), 130.5 (2CH), 131.6 (C, q, 2JCF = 32.46 Hz), 135.3 
(CH), 140.5 (C), 148.5 (C), 152.8 (C), 155.6 (CH), 160.2 (C); 19F NMR (282.40 MHz, 
CDCl3): δ = -62.74 (ArCF3); IR (ATR, cm−1): ~ν  = 3118 (w), 3053 (m), 2931 (w), 2849 
(w), 1603 (m), 1555 (s), 1519 (w), 1470 (m), 1427 (w), 1410 (m), 1372 (w), 1322 (s), 
1264 (w), 1176 (m), 1165 (m), 1107 (s), 1048 (w), 1062 (s), 1039 (w), 1016 (m), 971 
(m), 880 (m), 841 (m), 771 (m), 723 (w), 660 (w), 618 (m), 606 (m), 571 (w), 542 (w); 
GC-MS (EI, 70 eV): m/z (%): 308 (M+, 100), 307 (67), 271 (43), 239 (48), 203 (26), 177 
(10), 126 (4), 102 (5), 88 (4), 75 (13), 51 (5), 39 (1); HRMS (ESI) calcd for C15H9ClF3N2
[M+H]+: 309.04009 found 309.03998. 
7-Chloro-5-(4-methoxyphenyl)-1,6-naphthyridine (9j): 
 Starting with 7 (0.1 g, 0.5 mmol), 8j (0.099 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9j was isolated as white solid (0.126 g, 73%); mp 144–146 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 3.81 (s, 3H, OCH3), 6.98 (d, 3J = 8.89 
Hz, 2H, ArH), 7.36 (dd, J = 8.69 Hz, J = 4.16 Hz, 1H, ArH), 7.56 (d, 3J
= 8.89 Hz, 2H, ArH), 7.84 (s, 1H, ArH), 8.35-8.38 (m, 1H, ArH), 8.97 (dd, J = 4.16 Hz, J
= 1.70 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 55.5 (OCH3), 114.1 (2CH), 
119.9 (CH), 120.7 (C), 122.2 (CH), 129.6 (C), 131.6 (2CH), 136.2 (CH), 148.3 (C), 152.9 
(C), 155.1 (CH), 160.9 (C), 161.6 (C); IR (ATR, cm−1): ~ν  = 3088 (w), 2974 (w), 2844 
(w), 1600 (s), 1574 (w), 1513 (s), 1488 (w), 1467 (m), 1380 (m), 1339 (m), 1250 (s), 
1174 (m), 1110 (w), 1068 (m), 1021 (s), 973 (w), 934 (w), 866 (m), 834 (s), 784 (m), 734 








255 (16), 239 (46), 227 (34), 203 (14), 192 (27), 164 (26), 138 (8), 99 (3), 75 (13), 63 
(12), 51 (6), 39 (5); HRMS (ESI) calcd for C15H12ClN2O [M+H]+: 271.06327 found 
271.06363. 
7-Chloro-5-(4-ethylphenyl)-1,6-naphthyridine (9k):
Starting with 7 (0.1 g, 0.5 mmol), 8k (0.097 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9k was isolated as light brown heavy oil (0.107 g, 79%). 1H NMR 
(300.13 MHz, CDCl3): δ = 1.19 (t, J = 7.55 Hz, 3H, CH3), 2.64 (q, J = 
7.37 Hz, J = 14.92 Hz, 2H, -CH2-), 7.26 (d, 3J = 7.93 Hz, 2H, ArH), 
7.32 (dd, J = 8.69 Hz, J = 4.16 Hz, 1H, ArH), 7.49 (d, 3J = 8.31 Hz, 2H, ArH), 7.83 (s, 
1H, ArH), 8.32-8.35 (m, 1H, ArH), 8.93 (dd, J = 4.16 Hz, J = 1.70 Hz, 1H, ArH); 13C 
NMR (62.89 MHz, CDCl3), δ = 15.5 (CH3), 28.8 (-CH2-), 120.2 (CH), 120.7 (C), 122.2 
(CH), 128.2 (2CH), 130.1 (2CH), 134.5 (C), 136.2 (CH), 146.1 (C), 148.4 (C), 152.9 (C), 
155.2 (CH), 162.1 (C); IR (ATR, cm−1): ~ν  = 3028 (w), 2962 (m), 2870 (w), 1914 (w), 
1726 (w), 1599 (s), 1548 (s), 1513 (w), 1467 (m), 1427 (w), 1366 (m), 1342 (m), 1300 
(m), 1284 (w), 1179 (m), 1074 (s), 1041 (w), 1019 (w), 970 (s), 879 (s), 857 (m), 838 (s), 
769 (m), 707 (w), 661 (w), 641 (w), 618 (m), 602 (m), 573 (w), 554 (w), 531 (w); GC-
MS (EI, 70 eV): m/z (%): 268 (M+, 83), 267 (48), 253 (23), 239 (100), 216 (15), 190 (14), 
151 (5), 126 (4), 108 (10), 89 (6), 77 (6), 75 (9), 63 (7), 39 (5); HRMS (ESI) calcd for 
C16H14ClN2 [M+H]+: 269.084 found 269.08427. 
5-(4-tert-Butylphenyl)-7-chloro-1,6-naphthyridine (9l): 
Starting with 7 (0.1 g, 0.5 mmol), 8l (0.116 g, 1.3 equiv.), Pd(PPh3)4 
(0.029 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane:Toluene (1:1, 4 
mL), 9l was isolated as white solid (0.1 g, 67%); mp 116–118 °C. 1H 
NMR (300.13 MHz, CDCl3): δ = 1.30 (s, 9H, 3CH3), 7.36 (dd, J = 8.69 
Hz, J = 4.16 Hz, 1H, ArH), 7.47 (d, 3J = 8.69 Hz, 2H, ArH), 7.53 (d, 3J
= 8.69 Hz, 2H, ArH), 7.86 (s, 1H, ArH), 8.37-8.41 (m, 1H, ArH), 8.97 
(dd, J = 4.16 Hz, J = 1.70 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 31.3 






(C), 136.3 (CH), 148.4 (C), 152.8 (C), 152.9 (C), 155.2 (CH), 162.1 (C); IR (ATR, cm−1): 
~ν  = 3069 (w), 2962 (m), 2867 (w), 1731 (w), 1600 (s), 1562 (s), 1548 (s), 1514 (w), 
1467 (s), 1404 (w), 1362 (m), 1299 (m), 1264 (m), 1199 (w), 1165 (w), 1122 (m), 1070 
(s), 1017 (w), 971 (m), 880 (m), 865 (m), 836 (s), 823 (w), 774 (m), 735 (w), 703 (w), 
665 (w), 642 (w), 617 (m), 601 (s), 557 (w), 539 (m); GC-MS (EI, 70 eV): m/z (%): 296 
(M+, 32), 281 (100), 239 (12), 205 (6), 177 (4), 127 (4), 108 (7), 95 (4), 75 (4), 63 (2), 51 
(2), 41 (9), 39 (4), 29 (1); HRMS (ESI) calcd for C18H18ClN2 [M+H]+: 297.1153 found 
297.11525. 
68
General procedure for the synthesis of 11a-i: A 1,4-dioxane solution (8 mL) of 7 (1.0 
mmol), arylboronic acid 10 (2.5 equiv.), 2M K2CO3 (2 mL, 1 mL per cross-coupling), 
and Pd(PPh3)4 (5 mol%) was heated at 110 °C for 12 h in a pressure tube. After cooling 
to room temperature, H2O was added and the reaction mixture was extracted with 
CH2Cl2. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The 
residue was purified by column chromatography (gradient elution n-heptane/ethyl 
acetate). 
5,7-Bis(2-methoxyphenyl)-1,6-naphthyridine (11a):
Starting with 7 (0.1 g, 0.5 mmol), 10a (0.19 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (4 
mL), 11a was isolated as light yellow solid (0.122 g, 71%); mp 156–
158 °C. 1H NMR (300.13 MHz, CDCl3): δ = 3.62 (s, 3H, OCH3), 
3.87 (s, 3H, OCH3), 6.95-7.09 (m, 4H, ArH), 7.27-7.33 (m, 2H, 
ArH), 7.37-7.46 (m, 2H, ArH), 7.92-7.96 (m, 1H, ArH), 8.01 (dd, J
= 7.55 Hz, J = 1.70 Hz, 1H, ArH), 8.50 (s, 1H, ArH), 8.97 (dd, J = 4.34 Hz, J = 1.89 Hz, 
1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 55.4 (OCH3), 55.5 (OCH3), 111.1 (CH), 
111.3 (CH), 120.9 (CH), 121.1 (CH), 121.5 (CH), 121.6 (C), 121.9 (CH), 128.1 (C), 
128.5 (C), 129.8 (CH), 130.4 (CH), 131.7 (CH), 131.8 (CH), 136.3 (CH), 150.9 (C), 
152.1 (C), 154.2 (CH), 157.1 (C), 157.4 (C), 158.9 (C); IR (ATR, cm−1): ~ν  = 3067 (w), 
2922 (w), 2834 (w), 1597 (m), 1571 (m), 1518 (w), 1488 (m), 1392 (w), 1330 (m), 1280 
(w), 1281 (s), 1235 (s), 1164 (m), 1125 (w), 1043 (w), 1015 (s), 966 (m), 880 (w), 188 
(w), 771 (m), 751 (s), 705 (w), 655 (m), 585 (w), 574 (w), 558 (w), 541 (w), 533 (w); 
GC-MS (EI, 70 eV): m/z (%): 342 (M+, 100), 341 (79), 311 (27), 297 (25), 281 (26), 237 
(17), 180 (14), 164 (5), 134 (10), 94 (3), 77 (5), 75 (2), 63 (6), 51 (3), 39 (4); HRMS 







Starting with 7 (0.1 g, 0.5 mmol), 10b (0.169 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane 
(4 mL), 11b was isolated as light yellow solid (0.115 g, 74%); mp 
112–114 °C. 1H NMR (250.13 MHz, CDCl3): δ = 2.32 (s, 3H, 
CH3), 2.37 (s, 3H, CH3), 7.21 (d, 3J = 8.12 Hz, 2H, ArH), 7.25-
7.29 (m, 3H, ArH), 7.58 (d, 3J = 8.12 Hz, 2H, ArH), 8.07 (d, 3J = 
8.31 Hz, 2H, ArH), 8.19 (s, 1H, ArH), 8.30-8.34 (m, 1H, ArH), 8.92 (dd, J = 4.16 Hz, J = 
1.70 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.3 (CH3), 21.4 (CH3), 115.9 
(CH), 120.7 (C), 121.5 (CH), 127.2 (2CH), 129.2 (2CH), 129.5 (2CH), 130.2 (2CH), 
135.9 (CH), 136.0 (C), 139.0 (C), 139.1 (2C), 152.5 (C), 153.9 (C), 154.3 (CH), 160.9 
(C); IR (ATR, cm−1): ~ν  = 3128 (w), 3014 (w), 2917 (w), 2857 (w), 2730 (w), 1911 (w), 
1599 (m), 1656 (s), 1513 (m), 1453 (w), 1384 (w), 1365 (m), 1296 (w), 1197 (w), 1181 
(m), 1111 (w), 1031 (w), 968 (m), 877 (m), 860 (w), 817 (s), 786 (w), 766 (s), 721 (s), 
657 (w), 618 (w), 588 (w), 577 (w), 567 (w); GC-MS (EI, 70 eV): m/z (%): 310 (M+, 
100), 309 (89), 295 (59), 266 (3), 217 (5), 190 (7), 147 (11), 115 (5), 91 (5), 65 (4), 51 
(2), 39 (3); HRMS (ESI) calcd for C22H19N2 [M+H]+: 311.15482 found 311.15442. 
5,7-Bis(3,5-dimethylphenyl)-1,6-naphthyridine (11c): 
Starting with 7 (0.1 g, 0.5 mmol), 10c (0.186 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane 
(4 mL), 11c was isolated as light yellow solid (0.16 g, 94%); mp 
174–176 °C. 1H NMR (300.13 MHz, CDCl3): δ = 2.32 (s, 6H, 
2CH3), 2.33 (s, 6H, 2CH3), 6.96 (s, 1H, ArH), 7.06 (s, 1H, ArH), 
7.25-7.29 (m, 3H, ArH), 7.76 (s, 2H, ArH), 8.19 (s, 1H, ArH), 
8.26-8.30 (m, 1H, ArH), 8.94 (dd, J = 4.34 Hz, J = 1.70 Hz, 1H, 
ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (2CH3), 21.5 (2CH3), 116.7 (CH), 120.9 
(C), 121.6 (CH), 125.2 (2CH), 127.9 (2CH), 130.7 (CH), 130.8 (CH), 135.9 (CH), 138.1 
(2C), 138.3 (2C), 138.7 (C), 138.9 (2C), 154.3 (C), 154.4 (CH), 161.4 (C); IR (ATR, 
cm−1): ~ν  = 3034 (w), 2913 (w), 2859 (w), 1596 (m), 1562 (m), 1494 (w), 1335 (w), 1310 






(s), 800 (w), 775 (m), 712 (m), 688 (s), 624 (w), 589 (w), 545 (w), 528 (w); GC-MS (EI, 
70 eV): m/z (%): 338 (M+, 100), 337 (83), 323 (76), 307 (6), 292 (3), 231 (3), 190 (3), 
169 (6), 154 (12), 133 (3), 105 (1), 91 (1), 77 (3), 63 (1), 51 (1), 39 (2); HRMS (ESI) 
calcd for C24H23N2 [M+H]+: 339.18558 found 339.18594. 
5,7-Di(p-tolyl)-1,6-naphthyridine (11d): 
Starting with 7 (0.1 g, 0.5 mmol), 10d (0.188 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane 
(4 mL), 11d was isolated as brown solid (0.114 g, 67%); mp 90–
92 °C. 1H NMR (300.13 MHz, CDCl3): δ = 1.19 (t, J = 4.53 Hz, 
3H, CH3), 1.23 (t, J = 4.34 Hz, 3H, CH3), 2.59-2.71 (m, 4H, 2(-
CH2-)), 7.24 (d, 3J = 8.31 Hz, 2H, ArH), 7.27-7.31 (m, 3H, ArH), 
7.61 (d, 3J = 8.31 Hz, 2H, ArH), 8.10 (d, 3J = 8.31 Hz, 2H, ArH), 
8.21 (s, 1H, ArH), 8.32-8.36 (m, 1H, ArH), 8.93 (dd, J = 4.16 Hz, 
J = 1.70 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 15.5 (CH3), 15.6 (CH3), 28.7 
(-CH2-), 28.8 (-CH2-), 115.9 (CH), 120.7 (C), 121.5 (CH), 127.3 (2CH), 128.0 (2CH), 
128.3 (2CH), 130.3 (2CH), 135.9 (CH), 136.3 (C), 136.4 (C), 145.3 (C), 145.5 (C), 152.5 
(C), 153.9 (C), 154.3 (CH), 160.9 (C); IR (ATR, cm−1): ~ν  = 3069 (w), 3011 (w), 2961 
(m), 2870 (w), 1914 (w), 1599 (s), 1582 (w), 1555 (s), 1513 (m), 1440 (w), 1420 (w), 
1365 (m), 1327 (m), 1181 (m), 1116 (w), 1017 (w), 971 (m), 908 (w), 833 (s), 767 (m), 
701 (w), 655 (w), 609 (w), 560 (w), 552 (w); GC-MS (EI, 70 eV): m/z (%): 338 (M+, 
100), 337 (63), 309 (70), 293 (10), 255 (1), 217 (3), 154 (16), 115 (2), 89 (2), 77 (2), 51 





Starting with 7 (0.1 g, 0.5 mmol), 10e (0.222 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-
Dioxane (4 mL), 11e was isolated as light yellow solid (0.156 
g, 79%); mp 125–127 °C. 1H NMR (300.13 MHz, CDCl3): δ = 
1.28 (s, 9H, 3CH3), 1.32 (s, 9H, 3CH3), 7.28 (dd, J = 8.50 Hz, J
= 4.34 Hz, 1H, ArH), 7.44 (d, 3J = 8.69 Hz, 2H, ArH), 7.49 (d, 
3J = 8.50 Hz, 2H, ArH), 7.64 (d, 3J = 8.69 Hz, 2H, ArH), 8.11 
(d, 3J = 8.69 Hz, 2H, ArH), 8.21 (s, 1H, ArH), 8.36-8.39 (m, 
1H, ArH), 8.94 (dd, J = 4.34 Hz, J = 1.70 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), 
δ = 31.3 (3CH3), 31.4 (3CH3), 34.7 (C), 34.8 (C), 115.9 (CH), 120.7 (C), 121.5 (CH), 
125.5 (2CH), 125.8 (2CH), 127.1 (2CH), 129.9 (2CH), 135.9 (CH), 136.2 (2C), 152.2 
(C), 152.3 (C), 152.5 (C), 153.9 (C), 154.3 (CH), 160.9 (C); IR (ATR, cm−1): ~ν  = 3037 
(w), 2957 (s), 2865 (w), 1918 (w), 1602 (s), 1514 (w), 1468 (m), 1414 (w), 1363 (m), 
1310 (w), 1200 (w), 1128 (w), 1052 (w), 1012 (w), 971 (m), 882 (m), 842 (s), 772 (m), 
725 (m), 645 (w), 631 (w), 609 (w), 559 (s), 543 (w); GC-MS (EI, 70 eV): m/z (%): 394 
(M+, 64), 379 (100), 363 (21), 337 (16), 323 (4), 293 (3), 217 (1), 182 (13), 154 (16), 140 
(1), 115 (1), 91 (1), 57 (3), 41 (7), 39 (1), 29 (1); HRMS (ESI) calcd for C28H31N2
[M+H]+: 395.24818 found 395.24873. 
5,7-Bis(2,3,4-trimethoxyphenyl)-1,6-naphthyridine (11f): 
Starting with 7 (0.1 g, 0.5 mmol), 10f (0.265 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane 
(4 mL), 11f was isolated as brown heavy oil (0.114 g, 49%). 1H 
NMR (300.13 MHz, CDCl3): δ = 3.51 (s, 3H, OCH3), 3.82 (s, 
3H, OCH3), 3.84 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, 
OCH3), 3.88 (s, 3H, OCH3), 6.72 (d, J = 8.88 Hz, 1H, ArH), 6.75 
(d, J = 8.69 Hz, 1H, ArH), 7.14 (d, J = 8.50 Hz, 1H, ArH), 7.29 
(dd, J = 8.31 Hz, J = 4.16 Hz, 1H, ArH), 7.69 (d, J = 8.69 Hz, 
1H, ArH), 8.01-8.04 (m, 1H, ArH), 8.39 (s, 1H, ArH), 8.95 (dd, J = 4.34 Hz, J = 1.89 Hz, 












61.1 (2OCH3), 61.5 (OCH3), 107.6 (CH), 107.7 (CH), 120.7 (CH), 121.5 (C), 121.6 
(CH), 125.8 (CH), 125.9 (C), 126.0 (CH), 126.6 (C), 136.3 (CH), 142.1 (C), 142.6 (C), 
151.5 (C), 151.8 (C), 152.0 (C), 152.5 (C), 154.3 (C), 154.4 (CH), 154.5 (C), 158.4 (C); 
IR (ATR, cm−1): ~ν  = 2934 (w), 2836 (w), 2568 (w), 2248 (w), 1594 (s), 1563 (m), 1494 
(m), 1460 (s), 1410 (m), 1382 (w), 1366 (m), 1332 (m), 1287 (s), 1275 (m), 1224 (m), 
1181 (w), 1130 (w), 1094 (s), 1080 (s), 1010 (m), 904 (m), 828 (w), 800 (m), 725 (s), 692 
(w), 645 (w), 580 (w), 532 (m); GC-MS (EI, 70 eV): m/z (%): 462 (M+, 100), 447 (54), 
431 (23), 415 (11), 401 (15), 387 (12), 331 (6), 255 (8), 224 (24), 194 (20), 165 (15), 151 
(20), 121 (15), 103 (15), 95 (21), 88 (10), 81 (3), 75 (3); HRMS (ESI) calcd for 
C26H27N2O6 [M+H]+: 463.18636 found 463.18707. 
5,7-Βis(4-(trifluoromethyl)phenyl)-1,6-naphthyridine (11g): 
Starting with 7 (0.1 g, 0.5 mmol), 10g (0.236 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-
Dioxane (4 mL), 11g was isolated as white solid (0.135 g, 
64%); mp 180 °C. 1H NMR (300.13 MHz, CDCl3): δ = 7.38 
(dd, J = 8.50 Hz, J = 4.16 Hz, 1H, ArH), 7.64 (d, J = 8.12 Hz, 
2H, ArH), 7.73-7.81 (m, 4H, ArH), 8.22-8.27 (m, 3H, ArH), 
8.31 (s, 1H, ArH), 9.01 (d, J = 2.27 Hz, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 118.2 (CH), 121.2 (C), 122.7 (CH), 124.0 (CF3, q, 1JCF = 272.37 
Hz), 124.2 (CF3, q, 1JCF = 271.91 Hz), 125.6 (2CH, q, 3JCF = 4.12 Hz), 125.8 (2CH, q, 3JCF
= 3.66 Hz), 127.4 (2CH), 130.5 (2CH), 131.0 (C, q, 2JCF = 32.50 Hz), 131.3 (C, q, 2JCF = 
32.96 Hz), 135.0 (CH), 141.8 (2C, q, 5JCF = 1.83 Hz), 152.2 (2C), 154.9 (CH), 159.7 (C);
19F NMR (282.40 MHz, CDCl3): δ = -62.59 (ArCF3), -62.64 (ArCF3); IR (ATR, cm−1): 
~ν  = 3045 (w), 1931 (w), 1606 (m), 1566 (m), 1519 (w), 1422 (w), 1372 (w), 1320 (s), 
1312 (s), 1207 (w), 1156 (m), 1102 (s), 1065 (s), 1013 (m), 985 (w), 885 (w), 843 (s), 
820 (w), 770 (m), 686 (w), 647 (w), 626 (w), 619 (m), 589 (m), 527 (w); GC-MS (EI, 70 
eV): m/z (%): 418 (M+, 100), 417 (76), 350 (10), 279 (4), 199 (4), 175 (5), 150 (4), 125 








Starting with 7 (0.1 g, 0.5 mmol), 10h (0.174 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (4 
mL), 11h was isolated as white solid (0.119 g, 74%); mp 162–164 
°C. 1H NMR (300.13 MHz, CDCl3): δ = 6.98-7.04 (m, 1H, ArH), 
7.09-7.17 (m, 1H, ArH), 7.32-7.45 (m, 5H, ArH), 7.85-7.89 (m, 2H, 
ArH), 8.22 (s, 1H, ArH), 8.27-8.31 (m, 1H, ArH), 8.97 (dd, J = 4.16 
Hz, J = 1.51 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 
114.2 (CH, d, 2JCF = 22.89 Hz), 116.0 (CH, d, 2JCF = 21.06 Hz), 116.2 (CH, d, 2JCF = 
21.06 Hz), 117.2 (CH, d, 2JCF = 22.43 Hz), 117.4 (CH), 120.9 (C), 122.3 (CH), 122.6 
(CH, d, 4JCF = 2.75 Hz), 125.9 (CH, d, 4JCF = 2.75 Hz), 130.1 (CH, d, 3JCF = 8.24 Hz), 
130.3 (CH, d, 3JCF = 8.24 Hz), 135.3 (CH), 140.6 (C, d, 3JCF = 7.32 Hz), 140.9 (C, d, 3JCF
= 7.32 Hz), 152.3 (C), 152.4 (C, d, 4JCF = 2.29 Hz), 154.8 (CH), 159.5 (C, d, 4JCF = 2.29 
Hz), 162.8 (C, d, 1JCF = 247.19 Hz), 163.4 (C, d, 1JCF = 245.36 Hz); 19F NMR (282.40 
MHz, CDCl3): δ = -112.32 (ArF), -112.64 (ArF); IR (ATR, cm−1): ~ν  = 3071 (w), 2975 
(w), 1926 (w), 1852 (w), 1765 (w), 1589 (m), 1561 (s), 1488 (m), 1442 (w), 1368 (m), 
1287 (w), 1217 (m), 1163 (w), 1138 (m), 1038 (w), 968 (w), 940 (m), 882 (w), 872 (s), 
812 (m), 773 (s), 717 (m), 678 (m), 661 (m), 622 (w), 580 (w), 567 (w); GC-MS (EI, 70 
eV): m/z (%): 318 (M+, 95), 317 (100), 290 (6), 269 (4), 221 (7), 195 (4), 125 (4), 112 
(1), 95 (4), 75 (7), 51 (1), 39 (1); HRMS (ESI) calcd for C20H13F2N2 [M+H]+: 319.10413 
found 319.10403. 
5,7-Bis(4-methoxyphenyl)-1,6-naphthyridine (11i): 
Starting with 7 (0.1 g, 0.5 mmol), 10i (0.19 g, 2.5 equiv.), Pd(PPh3)4 (0.029 g, 0.05 
equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (4 mL), 11i was isolated 
as light yellow solid (0.126 g, 73%); mp 125–127 °C. 1H NMR 
(300.13 MHz, CDCl3): δ = 3.79 (s, 3H, OCH3), 3.83 (s, 3H, 
OCH3), 6.95 (d, 3J = 8.88 Hz, 2H, ArH), 7.01 (d, 3J = 8.88 Hz, 
2H, ArH), 7.29 (dd, J = 8.50 Hz, J = 4.16 Hz, 1H, ArH), 7.66 (d, 










1H, ArH), 8.93 (dd, J = 3.97 Hz, J = 1.32 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), 
δ = 55.3 (OCH3), 55.4 (OCH3), 113.9 (2CH), 114.2 (2CH), 115.0 (CH), 120.4 (C), 121.3 
(CH), 128.6 (2CH), 131.4 (C), 131.6 (2CH), 135.9 (CH), 152.6 (2C), 153.5 (2C), 154.3 
(CH), 160.4 (C), 160.6 (C); IR (ATR, cm−1): ~ν  = 3065 (w), 2959 (w), 2916 (m), 2838 
(w), 2551 (w), 2038 (w), 1727 (w), 1600 (s), 1579 (w), 1561 (w), 1511 (s), 1465 (m), 
1388 (w), 1368 (m), 1304 (w), 1244 (s), 1195 (w), 1173 (s), 1113 (w), 1053 (w), 1023 
(s), 969 (m), 879 (w), 826 (s), 787 (m), 765 (m), 714 (w), 657 (w), 617 (w), 604 (w), 581 
(m), 552 (m), 529 (m); GC-MS (EI, 70 eV): m/z (%): 342 (M+, 100), 341 (61), 311 (21), 
299 (15), 255 (16), 229 (8), 203 (1), 171 (6), 134 (6), 114 (5), 101 (2), 89 (2), 76 (2), 63 
(3), 39 (2); HRMS (ESI) calcd for C22H19N2O2 [M+H]+: 343.1441 found 343.1441. 
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General procedure for the synthesis of 13a-d: A 1,4-dioxane solution (8 mL) of 9e,f (1.0 
equiv.), arylboronic acid 12 (1.3 equiv.), 2M K2CO3 (1 mL), and Pd(PPh3)4 (5 mol%) was 
heated at 110 °C for 8 h in a pressure tube. After cooling to room temperature, H2O was 
added and the reaction mixture was extracted with CH2Cl2. The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (gradient elution n-heptane/ethyl acetate). 
7-(3,5-Dimethylphenyl)-5-(2,3,4-trimethoxyphenyl)-1,6-naphthyridine (13a): 
Starting with 9e (0.1 g, 0.3 mmol), 12a (0.058 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane 
(4 mL), 13a was isolated as light yellow solid (0.108 g, 89%); mp 
141–143 °C. 1H NMR (300.13 MHz, CDCl3): δ = 2.34 (s, 6H, 
2CH3), 3.52 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.90 (s, 3H, 
OCH3), 6.80 (d, J = 8.50 Hz, 1H, ArH), 6.99 (s, 1H, ArH), 7.18 
(d, J = 8.50 Hz, 1H, ArH), 7.31 (dd, J = 8.50 Hz, J = 4.16 Hz, 1H, 
ArH), 7.76 (s, 2H, ArH), 8.02-8.05 (m, 1H, ArH), 8.24 (s, 1H, ArH), 8.96 (dd, J = 4.16 
Hz, J = 1.70 Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 21.5 (2CH3), 56.2 
(OCH3), 61.1 (OCH3), 61.6 (OCH3), 107.8 (CH), 117.1 (CH), 121.6 (CH), 121.9 (C), 
125.2 (2CH), 125.9 (C), 126.1 (CH), 130.7 (CH), 136.5 (CH), 138.3 (2C), 139.1 (C), 
142.1 (C), 151.7 (C), 151.8 (C), 154.4 (CH), 154.5 (C), 154.6 (C), 158.9 (C); IR (ATR, 
cm−1): ~ν  = 2916 (w), 2839 (w), 1598 (m), 1562 (m), 1494 (w), 1460 (m), 1382 (w), 1366 
(m), 1335 (w), 1279 (m), 1225 (m), 1164 (w), 1131 (w), 1094 (s), 1047 (w), 1034 (m), 
1015 (w), 980 (m), 941 (w), 912 (w), 875 (m), 850 (m), 796 (w), 771 (m), 694 (w), 674 
(m), 606 (w), 587 (w), 568 (w), 540 (w), 534 (w); GC-MS (EI, 70 eV): m/z (%): 400 (M+, 
74), 399 (60), 385 (100), 383 (36), 353 (23), 339 (25), 283 (8), 255 (15), 235 (23), 192 
(9), 163 (5), 134 (23), 121 (10), 88 (2), 77 (3), 39 (1); HRMS (ESI) calcd for C25H25N2O3








Starting with 9e (0.1 g, 0.3 mmol), 12b (0.053 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane 
(4 mL), 13b was isolated as light brown solid (0.109 g, 64%); mp 
137–139 °C. 1H NMR (300.13 MHz, CDCl3): δ = 2.34 (s, 3H, 
CH3), 3.53 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.89 (s, 3H, 
OCH3), 6.77 (d, J = 8.69 Hz, 1H, ArH), 7.15 (d, J = 8.50 Hz, 1H, 
ArH), 7.23 (d, J = 7.93 Hz, 2H, ArH), 7.29 (dd, J = 8.50 Hz, J = 
4.34 Hz, 1H, ArH), 8.01-8.07 (m, 3H, ArH), 8.23 (s, 1H, ArH), 8.95 (dd, J = 4.16 Hz, J = 
1.70 Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 21.3 (CH3), 56.2 (OCH3), 61.2 
(OCH3), 61.7 (OCH3), 107.7 (CH), 116.4 (CH), 121.5 (CH), 121.9 (C), 125.9 (C), 126.0 
(CH), 127.2 (2CH), 129.5 (2CH), 136.3 (C), 136.5 (CH), 139.0 (C), 142.2 (C), 151.7 (C), 
151.9 (C), 154.1 (C), 154.5 (CH), 154.6 (C), 158.9 (C); IR (ATR, cm−1): ~ν  = 3076 (w), 
3016 (w), 2970 (w), 2839 (w), 1597 (m), 1513 (w), 1465 (m), 1408 (m), 1330 (w), 1291 
(m), 1234 (m), 1129 (w), 1093 (s), 1053 (m), 1025 (w), 1012 (m), 986 (m), 927 (w), 871 
(m), 819 (s), 743 (w), 686 (m), 642 (w), 564 (w), 557 (w), 531 (w); GC-MS (EI, 70 eV): 
m/z (%): 386 (M+, 73), 385 (55), 371 (100), 355 (27), 339 (18), 325 (24), 295 (7), 269 
(14), 221 (25), 186 (11), 142 (13), 128 (28), 91 (3), 75 (1), 51 (2), 39 (3); HRMS (ESI) 
calcd for C24H23N2O3 [M+H]+: 387.17032 found 387.17041. 
7-(4-tert-Butylphenyl)-5-(2,3,4-trimethoxyphenyl)-1,6-naphthyridine (13c): 
Starting with 9e (0.1 g, 0.3 mmol), 12c (0.069 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-
Dioxane (4 mL), 13c was isolated as light yellow heavy oil 
(0.07 g, 54%). 1H NMR (250.13 MHz, CDCl3): δ = 1.29 (s, 9H, 
3CH3), 3.53 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.89 (s, 3H, 
OCH3), 6.77 (d, J = 8.67 Hz, 1H, ArH), 7.15 (d, J = 8.51 Hz, 
1H, ArH), 7.27-7.32 (m, 1H, ArH), 7.45 (d, J = 8.51 Hz, 2H, 
ArH), 8.01-8.05 (m, 1H, ArH), 8.09 (d, J = 8.36 Hz, 2H, ArH), 
8.25 (s, 1H, ArH), 8.95 (dd, J = 4.26 Hz, J = 1.73 Hz, 1H, ArH); 13C NMR (62.89 MHz, 












116.4 (CH), 121.5 (CH), 121.8 (C), 125.8 (2CH), 125.9 (C), 126.0 (CH), 127.0 (2CH), 
136.2 (C), 136.5 (CH), 142.1 (C), 151.7 (C), 151.8 (C), 152.2 (C), 154.1 (C), 154.4 (CH), 
154.6 (C), 158.9 (C); IR (ATR, cm−1): ~ν  = 3053 (w), 2958 (m), 2866 (w), 1737 (w), 
1601 (s), 1564 (m), 1513 (w), 1497 (m), 1462 (s), 1409 (m), 1366 (m), 1332 (w), 1270 
(m), 1233 (m), 1178 (w), 1130 (w), 1094 (s), 1021 (w), 982 (m), 897 (w), 840 (m), 815 
(w), 747 (w), 735 (w), 692 (m), 623 (w), 605 (w), 542 (w); GC-MS (EI, 70 eV): m/z (%): 
428 (M+, 62), 413 (100), 397 (25), 367 (20), 311 (12), 263 (8), 207 (19), 178 (12), 156 
(10), 128 (29), 114 (22), 96 (4), 57 (13), 41 (13), 29 (6); HRMS (ESI) calcd for 
C27H29N2O3 [M+H]+: 429.21727 found 429.21749. 
5-(2,3-Dimethoxyphenyl)-7-o-tolyl-1,6-naphthyridine (13d):
Starting with 9f (0.1 g, 0.3 mmol), 12d (0.053 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (4 
mL), 13d was isolated as light yellow heavy oil (0.06 g, 47%). 1H 
NMR (250.13 MHz, CDCl3): δ = 2.40 (s, 3H, CH3), 3.43 (s, 3H, 
OCH3), 3.87 (s, 3H, OCH3), 6.98-7.04 (m, 2H, ArH), 7.13 (d, J = 
7.88 Hz, 1H, ArH), 7.22-7.25 (m, 3H, ArH), 7.34 (dd, J = 8.51 Hz, J
= 4.26 Hz, 1H, ArH), 7.49-7.53 (m, 1H, ArH), 7.97 (s, 1H, ArH), 
8.05-8.09 (m, 1H, ArH), 8.98 (dd, J = 4.26 Hz, J = 1.73 Hz, 1H, ArH); 13C NMR (62.89 
MHz, CDCl3), δ = 20.6 (CH3), 55.9 (OCH3), 61.3 (OCH3), 113.1 (CH), 120.9 (CH), 
121.4 (C), 122.0 (CH), 123.2 (CH), 124.5 (CH), 125.9 (CH), 128.4 (CH), 130.1 (CH), 
130.8 (CH), 133.1 (C), 136.2 (C), 136.7 (CH), 140.1 (C), 146.9 (C), 150.9 (C), 152.7 (C), 
154.6 (CH), 156.8 (C), 158.7 (C); IR (ATR, cm−1): ~ν  = 3056 (w), 2929 (m), 2835 (w), 
1601 (m), 1567 (s), 1463 (s), 1425 (m), 1366 (m), 1300 (w), 1260 (m), 1230 (w), 1205 
(w), 1132 (w), 1075 (s), 1026 (w), 1002 (w), 984 (m), 904 (w), 884 (m), 791 (w), 766 (s), 
728 (s), 703 (w), 677 (w), 652 (w), 613 (w), 587 (m), 572 (w); GC-MS (EI, 70 eV): m/z
(%): 356 (M+, 98), 355 (100), 339 (18), 325 (21), 309 (17), 269 (9), 242 (13), 219 (16), 
154 (11), 140 (19), 121 (5), 102 (2), 99 (1), 89 (3), 75 (2), 63 (2), 51 (2), 39 (2); HRMS 






6.4 Regioselective Palladium-Catalysed Cross-Coupling Reactions of 2,6-
dichloroquinoxaline. 
General procedure for synthesis of 16a-t: A THF solution (8 mL) of 14 (1.0 mmol), 
arylboronic acid 15 (1.3 equiv.), K3PO4 (2 equiv.), and Pd(PPh3)4 (5 mol%) was heated at 
90 °C for 8 h. After cooling to room temperature, H2O was added and the reaction 
mixture was extracted with CH2Cl2. The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by column chromatography (gradient 
elution n-heptane/ethyl acetate). 
6-Chloro-2-o-tolylquinoxaline (16a):
Starting with 14 (0.1 g, 0.5 mmol), 15a (0.088 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16a was isolated as white solid (0.098 g, 77%); mp 
121-123 oC. 1H NMR (300.13 MHz, CDCl3): δ = 2.38 (s, 3H, CH3), 7.25-7.36 (m, 3H, 
ArH), 7.44-7.48 (m, 1H, ArH), 7.65 (dd, J = 9.07 Hz, J = 2.26 Hz, 1H, ArH), 7.98-8.06 
(m, 2H, ArH), 8.92 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 20.4 (CH3), 126.4 
(CH), 128.1 (CH), 129.6 (CH), 129.9 (CH), 130.8 (CH), 131.2 (CH), 131.3 (CH), 135.5 
(C), 136.6 (C), 136.7 (C), 140.5 (C), 141.3 (C), 146.7 (CH), 155.1 (C); IR (ATR, cm−1): 
~ν  = 3074 (w), 3043 (w), 2986 (w), 2930 (w), 2746 (w), 1606 (m), 1568 (w), 1539 (m), 
1445 (w), 1417 (w), 1385 (w), 1335 (w), 1268 (w), 1175 (m), 1124 (w), 1065 (m), 1037 
(s), 960 (s), 936 (w), 901 (s), 870 (m), 827 (s), 785 (m), 754 (s), 726 (s), 701 (m), 679 
(w), 639 (w), 579 (s), 553 (m), 540 (w), 528 (w); GC-MS (EI, 70 eV): m/z (%): 254 (M+, 
35), 253 (100), 218 (12), 190 (3), 165 (4), 127 (3), 116 (8), 110 (2), 100 (1), 90 (4), 75 







Starting with 14 (0.1 g, 0.5 mmol), 15b (0.088 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16b was isolated as white solid (0.085 g, 67%); mp 
125-127 oC. 1H NMR (300.13 MHz, CDCl3): δ = 2.41 (s, 3H, 
CH3), 7.26 (d, 3J = 7.55 Hz, 1H, ArH), 7.37 (t, J = 7.74 Hz, 1H, ArH), 7.63 (dd, J = 8.88 
Hz, J = 2.27 Hz, 1H, ArH), 7.87 (d, 3J = 7.54 Hz, 1H, ArH), 7.92 (s, 1H, ArH), 7.98-8.02 
(m, 2H, ArH), 9.22 (s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 20.5 (CH3), 123.6 
(CH), 127.0 (CH), 127.1 (CH), 128.1 (CH), 129.8 (CH), 130.22 (CH), 130.23 (CH), 
134.1 (C), 135.3 (C), 138.0 (C), 139.8 (C), 140.8 (C), 143.3 (CH), 151.1 (C); IR (ATR, 
cm−1): ~ν  = 3024 (w), 2960 (w), 2856 (w), 1952 (w), 1841 (w), 1711 (w), 1606 (w), 1588 
(m), 1537 (m), 1494 (w), 1470 (w), 1453 (m), 1330 (w), 1314 (m), 1224 (w), 1169 (m), 
1135 (m), 1060 (w), 996 (w), 962 (s), 923 (w), 912 (s), 869 (m), 831 (s), 789 (s), 738 (w), 
692 (s), 673 (m), 643 (w), 617 (w), 585 (s), 547 (w), 529 (w); GC-MS (EI, 70 eV): m/z 
(%): 254 (M+, 100), 239 (4), 227 (18), 219 (5), 192 (10), 165 (11), 127 (4), 110 (7), 91 
(4), 75 (12), 51 (2), 39 (2); HRMS (EI) calcd for C15H11ClN2 [M+]: 254.06053 found 
254.060317. 
6-Chloro-2-p-tolylquinoxaline (16c): 
Starting with 14 (0.1 g, 0.5 mmol), 15c (0.088 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16c was isolated as white solid (0.096 g, 75%); 
mp 136 oC. 1H NMR (300.13 MHz, CDCl3): δ = 2.38 (s, 3H, CH3), 7.29 (d, 3J = 7.93 Hz, 
2H, ArH), 7.63 (dd, J = 9.06 Hz, J = 2.08 Hz, 1H, ArH), 7.97-8.02 (m, 4H, ArH), 9.22 (s, 
1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (CH3), 127.4 (2CH), 128.0 (CH), 
129.9 (2CH), 130.7 (CH), 131.2 (CH), 133.52 (C), 134.94 (C), 140.7 (C), 140.8 (C), 
141.7 (C), 144.1 (CH), 151.9 (C); IR (ATR, cm−1): ~ν  = 3063 (w), 2916 (w), 2854 (w), 
2722 (w), 1607 (m), 1576 (w), 1536 (m), 1476 (m), 1413 (m), 1359 (w), 1315 (m), 1300 
(w), 1260 (w), 1170 (s), 1136 (w), 1125 (w), 1064 (m), 1044 (m), 1018 (w), 958 (m), 918 
(m), 890 (m), 813 (s), 778 (w), 712 (m), 642 (w), 629 (w), 569 (s), 544 (w); GC-MS (EI, 








(10), 63 (3), 50 (2), 39 (1); HRMS (EI) calcd for C15H11ClN2 [M+]: 254.06053 found 
254.060639. 
6-Chloro-2-(2,6-dimethylphenyl)quinoxaline (16d): 
Starting with 14 (0.1 g, 0.5 mmol), 15d (0.097 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16d was isolated as brownish heavy oil (0.050 g, 
37%). 1H NMR (300.13 MHz, CDCl3): δ = 2.00 (s, 6H, 2CH3), 
7.07-7.10 (m, 2H, ArH), 7.17-7.23 (m, 1H, ArH), 7.65 (dd, J = 8.88 Hz, J = 2.27 Hz, 1H, 
ArH), 7.98-8.08 (m, 2H, ArH), 8.72 (s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 
20.4 (2CH3), 128.1 (2CH), 128.3 (CH), 129.1 (CH), 130.8 (CH), 131.3 (CH), 135.7 (C), 
136.3 (2C), 136.7 (C), 140.9 (C), 141.5 (C), 147.2 (CH), 155.7 (C); IR (ATR, cm−1): 
~ν  = 3063 (w), 3020 (w), 2919 (w), 2855 (w), 2735 (w), 2516 (w), 2392 (w), 2230 (w), 
1932 (w), 1865 (w), 1748 (w), 1667 (w), 1602 (m), 1546 (m), 1505 (w), 1474 (s), 1451 
(w), 1377 (w), 1293 (m), 1199 (w), 1169 (s), 1131 (w), 1091 (w), 1062 (m), 1042 (s), 
1029 (w), 990 (w), 960 (m), 914 (w), 899 (s), 877 (w), 829 (s), 786 (w), 768 (s), 731 (m), 
673 (m), 626 (m), 584 (s), 560 (w), 541 (m); GC-MS (EI, 70 eV): m/z (%): 268 (M+, 39), 
267 (100), 253 (6), 232 (6), 190 (2), 133 (3), 116 (3), 103 (6), 89 (2), 77 (4), 63 (2), 39 
(1); HRMS (EI) calcd for C16H14ClN2 [M+H]+: 269.084 found 269.08432. 
6-Chloro-2-(3,5-dimethylphenyl)quinoxaline (16e): 
Starting with 14 (0.1 g, 0.5 mmol), 15e (0.097 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16e was isolated as white solid (0.12 g, 90%); 
mp 178-179 oC. 1H NMR (300.13 MHz, CDCl3): δ = 2.35 (s, 
6H, 2CH3), 7.06 (s, 1H, ArH), 7.59 (dd, J = 8.88 Hz, J = 2.27 
Hz, 1H, ArH), 7.66 (s, 2H, ArH), 7.95-7.99 (m, 2H, ArH), 9.17 (s, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 21.4 (2CH3), 125.3 (2CH), 128.0 (CH), 130.7 (CH), 131.2 
(CH), 132.1 (CH), 134.9 (C), 136.3 (C), 138.8 (2C), 140.8 (C), 141.7 (C), 144.4 (CH), 
152.2 (C); IR (ATR, cm−1): ~ν  = 3042 (w), 3010 (w), 2916 (w), 2858 (w), 2735 (w), 1936 








1416 (w), 1398 (w), 1371 (w), 1312 (m), 1258 (w), 1172 (s), 1119 (w), 1088 (m), 997 
(m), 966 (m), 948 (w), 867 (m), 844 (w), 828 (s), 782 (m), 721 (w), 706 (s), 674 (m), 626 
(m), 590 (m), 550 (w), 542 (m); GC-MS (EI, 70 eV): m/z (%): 268 (M+, 100), 241 (13), 
226 (4), 206 (4), 190 (6), 134 (3), 116 (13), 100 (2), 89 (2), 75 (8), 50 (1), 39 (1); HRMS 
(EI) calcd for C16H13ClN2 [M+]: 268.07618 found 268.076349. 
6-Chloro-2-(2,4,6-trimethylphenyl)quinoxaline (16f): 
Starting with 14 (0.12 g, 0.6 mmol), 15f (0.165 g, 1.3 equiv.), 
Pd(PPh3)4 (0.035 g, 0.05 equiv.), K3PO4 (0.254 g, 2 equiv.), 
THF (4 mL), 16f was isolated as yellowish solid (0.163 g, 
96%); mp 100 oC. 1H NMR (300.13 MHz, CDCl3): δ = 1.97 
(s, 6H, 2CH3), 2.25 (s, 3H, CH3), 6.90 (s, 2H, ArH), 7.62 (dd, J = 8.88 Hz, J = 2.27 Hz, 
1H, ArH), 7.96-8.06 (m, 2H, ArH), 8.70 (s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ
= 19.2 (2CH3), 20.1 (CH3), 127.2 (CH), 127.8 (2CH), 129.7 (CH), 130.1 (CH), 132.9 (C), 
134.5 (C), 135.1 (2C), 137.8 (C), 139.9 (C), 140.3 (C), 146.4 (CH), 154.8 (C); IR (ATR, 
cm−1): ~ν  = 3076 (w), 3042 (m), 2964 (w), 2916 (m), 2854 (w), 1818 (w), 1727 (w), 1610 
(m), 1567 (w), 1539 (m), 1470 (w), 1446 (m), 1417 (w), 1373 (m), 1330 (w), 1317 (w), 
1295 (m), 1266 (w), 1222 (w), 1163 (m), 1125 (m), 1042 (m), 978 (w), 964 (m), 911 (w), 
892 (s), 846 (s), 828 (s), 788 (s), 739 (w), 688 (m), 634 (w), 588 (m), 572 (m), 543 (m), 
530 (w); GC-MS (EI, 70 eV): m/z (%): 282 (M+, 40), 281 (100), 267 (9), 246 (4), 204 
(1), 144 (2), 128 (2), 115 (5), 100 (1), 75 (4), 50 (1), 39 (1); HRMS (ESI) calcd for 
C17H16ClN2 [M+H]+: 283.09869 found 283.10003. 
6-Chloro-2-(2-methoxyphenyl)quinoxaline (16g): 
Starting with 14 (0.1 g, 0.5 mmol), 15g (0.099 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16g was isolated as white solid (0.097 g, 72%); mp 
143 oC. 1H NMR (300.13 MHz, CDCl3): δ = 3.83 (s, 3H, 
OCH3), 6.98 (d, 3J = 8.31 Hz, 1H, ArH), 7.08 (dt, J = 7.55, J = 0.94 Hz, 1H, ArH), 7.38-
7.44 (m, 1H, ArH), 7.61 (dd, J = 8.88 Hz, J = 2.46 Hz, 1H, ArH), 7.81 (dd, J = 7.55 Hz, J









CDCl3), δ = 54.6 (OCH3), 110.4 (CH), 120.5 (CH), 125.1 (C), 126.9 (CH), 129.7 (2CH), 
130.5 (CH), 130.7 (CH), 133.9 (C), 140.2 (C), 140.3 (C), 147.1 (CH), 151.3 (C), 156.4 
(C); IR (ATR, cm−1): ~ν  = 3069 (w), 2973 (w), 2838 (w), 1939 (w), 1754 (w), 1600 (s), 
1544 (w), 1493 (m), 1459 (s), 1392 (w), 1296 (w), 1239 (s), 1173 (m), 1117 (m), 1060 
(s), 1020 (m), 962 (m), 930 (m), 901 (m), 876 (m), 834 (s), 777 (w), 741 (s), 702 (m), 685 
(w), 641 (m), 611 (w), 583 (m), 571 (w), 557 (w), 541 (w); GC-MS (EI, 70 eV): m/z (%): 
270 (M+, 100), 253 (55), 241 (48), 213 (17), 178 (14), 165 (27), 151 (8), 118 (11), 110 
(14), 103 (9), 90 (11), 75 (24), 63 (11), 39 (4); HRMS (ESI) calcd for C15H12ClN2O 
[M+H]+: 271.06327 found 271.06367. 
6-Chloro-2-(4-methoxyphenyl)quinoxaline (16h): 
Starting with 14 (0.1 g, 0.5 mmol), 15h (0.099 g, 1.3 
equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 
equiv.), THF (4 mL), 16h was isolated as yellowish white 
solid (0.086 g, 63%); mp 124-146 oC. 1H NMR (300.13 MHz, CDCl3): δ = 3.81 (s, 3H, 
OCH3), 6.98 (d, 3J = 9.07 Hz, 2H, ArH), 7.58 (dd, J = 9.07 Hz, J = 2.46 Hz, 1H, ArH), 
7.92-7.98 (m, 2H, ArH), 8.06 (d, 3J = 8.88 Hz, 2H, ArH), 9.18 (s, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 55.4 (OCH3), 114.6 (2CH), 128.0 (CH), 128.8 (C), 128.9 
(2CH), 130.6 (CH), 131.1 (CH), 134.6 (C), 140.8 (C), 141.4 (C), 143.8 (CH), 151.5 (C), 
161.6 (C); IR (ATR, cm−1): ~ν  = 3048 (m), 3015 (w), 2930 (w), 2894 (w), 2039 (w), 1915 
(w), 1882 (w), 1651 (w), 1604 (s), 1580 (w), 1519 (m), 1463 (w), 1398 (w), 1315 (s), 
1269 (w), 1250 (s), 1183 (w), 1167 (s), 1114 (m), 1070 (w), 1024 (s), 955 (m), 921 (m), 
898 (m), 823 (s), 783 (m), 727 (w), 689 (m), 633 (m), 570 (s), 545 (w); GC-MS (EI, 70 
eV): m/z (%): 270 (M+, 100), 255 (17), 243 (10), 227 (8), 200 (7), 192 (4), 133 (11), 110 








Starting with 14 (0.12 g, 0.6 mmol), 15i (0.142 g, 1.3 
equiv.), Pd(PPh3)4 (0.035 g, 0.05 equiv.), K3PO4 (0.254 g, 2 
equiv.), THF (4 mL), 16i was isolated as white solid (0.118 
g, 65%); mp 124 oC. 1H NMR (300.13 MHz, CDCl3): δ = 
3.69 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 7.00 (dd, J = 8.12 Hz, 1.51 Hz, 1H, ArH), 7.15 
(t, J = 7.93, 1H, ArH), 7.38 (dd, J = 7.74 Hz, J = 1.51 Hz, 1H, ArH), 7.62 (dd, J = 8.88 
Hz, J = 2.27 Hz, 1H, ArH), 7.98-8.04 (m, 2H, ArH), 9.27 (s, 1H, ArH); 13C NMR (62.89 
MHz, CDCl3), δ = 56.0 (OCH3), 61.4 (OCH3), 114.3 (CH), 122.7 (CH), 124.8 (CH), 
128.0 (CH), 130.8 (CH), 130.9 (CH), 131.2 (C), 135.3 (C), 141.2 (C), 141.4 (C), 147.6 
(C), 147.8 (CH), 151.9 (C), 153.1 (C); IR (ATR, cm−1): ~ν  = 2996 (w), 2951 (m), 2840 
(m), 1582 (m), 1542 (m), 1484 (m), 1466 (s), 1428 (m), 1397 (w), 1320 (m), 1266 (s), 
1234 (m), 1185 (w), 1175 (m), 1138 (w), 1110 (m), 1086 (m), 1041 (s), 994 (s), 934 (m), 
918 (m), 850 (m), 834 (s), 811 (w), 783 (m), 765 (m), 741 (s), 690 (m), 679 (m), 635 (w), 
623 (m), 597 (s), 565 (w), 534 (m); GC-MS (EI, 70 eV): m/z (%): 300 (M+, 100), 285 
(47), 283 (91), 271 (34), 257 (23), 242 (13), 213 (11), 179 (18), 165 (26), 142 (6), 120 
(7), 110 (13), 100 (7), 92 (5), 75 (20), 63 (6), 50 (6), 39 (2); HRMS (EI) calcd for 
C16H13ClN2O2 [M+]: 300.06601 found 300.065686. 
6-Chloro-2-(2,6-dimethoxyphenyl)quinoxaline (16j): 
Starting with 14 (0.12 g, 0.5 mmol), 15j (0.142 g, 1.3 equiv.), 
Pd(PPh3)4 (0.035 g, 0.05 equiv.), K3PO4 (0.254 g, 2 equiv.), 
THF (4 mL), 16j was isolated as yellow solid (0.175 g, 97%); 
mp 135-137 oC. 1H NMR (300.13 MHz, CDCl3): δ = 3.78 (s, 
6H, 2(OCH3)), 6.93-6.94 (m, 2H, ArH), 7.40 (d, J = 2.83 Hz, 1H, ArH), 7.61 (dd, J = 
8.88 Hz, J = 2.27 Hz, 1H, ArH), 7.98-8.02 (m, 2H, ArH), 9.29 (s, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 55.9 (OCH3), 56.3 (OCH3), 113.0 (CH), 115.9 (CH), 117.5 
(CH), 126.6 (C), 127.9 (CH), 130.7 (2CH), 135.1 (C), 141.1 (C), 141.3 (C), 148.0 (CH), 
151.8 (C), 152.0 (C), 154.3 (C); IR (ATR, cm−1): ~ν  = 3079 (w), 2985 (w), 2831 (w), 
1621 (w), 1586 (m), 1538 (m), 1497 (s), 1464 (w), 1425 (m), 1394 (w), 1336 (w), 1304 












(w), 883 (m), 832 (s), 795 (s), 786 (m), 732 (s), 700 (m), 683 (w), 653 (w), 618 (w), 600 
(w), 593 (w), 541 (w), 534 (w); GC-MS (EI, 70 eV): m/z (%): 300 (M+, 100), 285 (64), 
283 (88), 269 (14), 257 (12), 242 (16), 214 (7), 179 (13), 165 (24), 148 (13), 120 (7), 110 
(11), 100 (5), 75 (14), 63 (5), 50 (4), 39 (1); HRMS (EI) calcd for C16H13ClN2O2 [M+]: 
300.06601 found 300.065903. 
6-Chloro-2-(2,3,4-trimethoxyphenyl)quinoxaline (16k): 
Starting with 14 (0.12 g, 0.6 mmol), 15k (0.165 g, 1.3 
equiv.), Pd(PPh3)4 (0.035 g, 0.05 equiv.), K3PO4 (0.254 g, 2 
equiv.), THF (4 mL), 16k was isolated as yellowish solid 
(0.105 g, 53%); mp 106-108 oC. 1H NMR (300.13 MHz, 
CDCl3): δ = 3.79 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 6.78 (d, 3J = 
8.69 Hz, 1H, ArH), 7.55-7.61 (m, 2H, ArH), 7.94-8.00 (m, 2H, ArH), 9.24 (s, 1H, ArH);
13C NMR (75.46 MHz, CDCl3), δ = 56.2 (OCH3), 61.0 (OCH3), 61.6 (OCH3), 108.2 
(CH), 123.8 (C), 125.9 (CH), 128.0 (CH), 130.6 (CH), 130.8 (CH), 134.9 (C), 141.1 (C), 
141.2 (C), 142.3 (C), 147.6 (CH), 151.7 (C), 152.5 (C), 155.7 (C); IR (ATR, cm−1): 
~ν  = 3052 (w), 2943 (m), 2848 (w), 1601 (s), 1542 (m), 1494 (w), 1460 (m), 1433 (w), 
1414 (s), 1335 (w), 1309 (m), 1280 (m), 1210 (m), 1210 (m), 1171 (m), 1133 (w), 1106 
(s), 1087 (m), 1014 (s), 969 (m), 949 (w), 928 (m), 902 (m), 853 (m), 823 (m), 774 (s), 
700 (w), 689 (w), 681 (w), 648 (m), 629 (w), 597 (m), 568 (w), 544 (m); GC-MS (EI, 70 
eV): m/z (%): 330 (M+, 100), 315 (51), 313 (40), 299 (12), 287 (14), 272 (15), 257 (13), 
229 (12), 215 (15), 203 (10), 201 (26), 178 (10), 163 (14), 153 (11), 135 (8), 110 (6), 100 
(7), 75 (10), 51 (2), 39 (6); HRMS (EI) calcd for C17H15ClN2O3 [M+]: 330.07657 found 
330.076374. 
6-Chloro-2-(3-fluorophenyl)quinoxaline (16l): 
Starting with 14 (0.1 g, 0.5 mmol), 15l (0.09 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16l was isolated as white solid (0.03 g, 23%); 
mp 172-173 oC. 1H NMR (300.13 MHz, CDCl3): δ = 7.13-












ArH), 7.85-7.89 (m, 2H, ArH), 8.00-8.05 (m, 2H, ArH), 9.23 (s, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 113.5 (CH, d, 2JCF = 23.35 Hz), 116.4 (CH, d, 2JCF = 21.06 Hz), 
122.0 (CH, d, 4JCF = 2.75 Hz), 127.1 (CH), 129.8 (CH, d, 3JCF = 8.24 Hz), 129.9 (CH), 
130.6 (CH), 134.7 (C), 137.6 (C, d, 3JCF = 7.78 Hz), 139.7 (C), 141.0 (C), 142.8 (CH), 
149.5 (C, d, 4JCF = 2.75 Hz), 162.4 (C, d, 1JCF = 247.19 Hz); 19F NMR (282.40 MHz, 
CDCl3): δ = -111.56 (ArF); IR (ATR, cm−1): ~ν  = 3087 (w), 3065 (w), 2923 (w), 2850 
(w), 1953 (w), 1815 (w), 1704 (w), 1590 (m), 1495 (w), 1435 (m), 1402 (w), 1314 (m), 
1203 (m), 1134 (w), 1066 (w), 1050 (w), 975 (s), 939 (w), 865 (s), 831 (s), 789 (s), 695 
(s), 670 (s), 616 (w), 596 (m), 549 (w); GC-MS (EI, 70 eV): m/z (%): 258 (M+, 100), 231 
(31), 196 (21), 169 (4), 129 (4), 110 (15), 100 (4), 75 (23), 63 (1), 50 (4); HRMS (EI) 
calcd for C14H8ClFN2 [M+]: 258.03546 found 258.035713. 
6-Chloro-2-(4-fluorophenyl)quinoxaline (16m): 
Starting with 14 (0.1 g, 0.5 mmol), 15m (0.09 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16m was isolated as yellowish white solid (0.08 
g, 62%); mp 165-168 oC. 1H NMR (300.13 MHz, CDCl3): δ
= 7.13-7.21 (m, 2H, ArH), 7.64 (dd, J = 9.07 Hz, J = 2.46 Hz, 1H, ArH), 7.96-8.02 (m, 
2H, ArH), 8.07-8.14 (m, 2H, ArH), 9.20 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ
= 116.3 (2CH, d, 2JCF = 21.52 Hz), 128.1 (CH), 129.5 (2CH, d, 3JCF = 8.70 Hz), 130.7 
(CH), 131.4 (CH), 132.5 (C, d, 4JCF = 3.20 Hz), 135.3 (C), 140.7 (C), 141.7 (C), 143.7 
(CH), 150.8 (C), 164.4 (C, d, 1JCF = 251.31 Hz); 19F NMR (282.40 MHz, CDCl3): δ = -
110.01 (ArF); IR (ATR, cm−1): ~ν  = 3054 (w), 3012 (w), 2914 (w), 1600 (s), 1558 (w), 
1514 (m), 1478 (m), 1445 (w), 1359 (w), 1305 (m), 1237 (s), 1162 (m), 1105 (w), 1047 
(m), 1014 (w), 957 (m), 901 (m), 872 (m), 828 (s), 790 (m), 720 (m), 691 (m), 638 (w), 
626 (w), 571 (s); GC-MS (EI, 70 eV): m/z (%): 258 (M+, 100), 233 (11), 231 (33), 196 
(20), 169 (5), 129 (5), 121 (8), 110 (13), 100 (4), 75 (22), 63 (1), 50 (4); HRMS (EI) 







Starting with 14 (0.1 g, 0.5 mmol), 15n (0.082 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), THF 
(4 mL), 16n was isolated as yellow solid (0.056 g, 45%); mp 
154-156 oC. 1H NMR (300.13 MHz, CDCl3): δ = 7.11-7.14 (m, 
1H, ArH), 7.48 (dd, J = 5.10 Hz, J = 1.13 Hz, 1H, ArH), 7.59 (dd, J = 8.88 Hz, J = 2.46 
Hz, 1H, ArH), 7.77 (dd, J = 3.78 Hz, J = 1.13 Hz, 1H, ArH), 7.89-7.96 (m, 2H, ArH), 
9.13 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 127.2 (CH), 128.1 (CH), 128.6 
(CH), 130.2 (CH), 130.3 (CH), 131.4 (CH), 134.8 (C), 140.6 (C), 141.5 (C), 141.8 (C), 
142.8 (CH), 147.5 (C); IR (ATR, cm−1): ~ν  = 3095 (w), 3064 (w), 3011 (w), 2007 (w), 
1941 (w), 1887 (w), 1746 (w), 1693 (w), 1593 (m), 1541 (s), 1474 (m), 1433 (w), 1414 
(m), 1369 (w), 1311 (m), 1269 (w), 1176 (s), 1131 (m), 1062 (s), 1002 (s), 942 (s), 872 
(m), 832 (s), 789 (m), 747 (w), 709 (s), 692 (w), 630 (w), 615 (w), 588 (s), 558 (m); GC-
MS (EI, 70 eV): m/z (%): 246 (M+, 100), 219 (29), 184 (12), 140 (10), 110 (11), 100 (3), 
84 (2), 75 (12), 58 (3), 39 (2); HRMS (EI) calcd for C12H7ClN2S [M+]: 246.00130 found 
246.001467. 
6-Chloro-2-(4-ethylphenyl)quinoxaline (16o): 
Starting with 14 (0.1 g, 0.5 mmol), 15o (0.098 g, 1.3 
equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 
equiv.), THF (4 mL), 16o was isolated as white solid (0.13 
g, 96%); mp 104 oC. 1H NMR (300.13 MHz, CDCl3): δ = 1.21 (t, 3J = 7.74 Hz, 3H, CH3), 
2.65 (q, J = 7.55 Hz, J = 15.12 Hz, 2H, -CH2-), 7.29 (d, 3J = 8.50 Hz, 2H, ArH), 7.59 (dd, 
J = 9.07 Hz, J = 2.27 Hz, 1H, ArH), 7.94-8.02 (m, 4H, ArH), 9.19 (s, 1H, ArH); 13C 
NMR (75.46 MHz, CDCl3), δ = 15.4 (CH3), 28.8 (-CH2-), 127.5 (2CH), 128.1 (CH), 
128.8 (2CH), 130.8 (CH), 131.2 (CH), 133.8 (C), 134.9 (C), 140.8 (C), 141.7 (C), 144.1 
(CH), 147.1 (C), 151.9 (C); IR (ATR, cm−1): ~ν  = 3068 (w), 3039 (w), 2955 (m), 2865 
(w), 1607 (s), 1537 (s), 1504 (w), 1477 (s), 1445 (w), 1416 (m), 1334 (w), 1313 (s), 1281 
(m), 1225 (w), 1173 (s), 1127 (w), 1053 (s), 1014 (m), 957 (s), 922 (m), 998 (s), 871 (m), 
825 (s), 805 (w), 782 (w), 750 (w), 720 (m), 689 (m), 660 (w), 641 (w), 628 (m), 582 (s), 









(4), 190 (7), 163 (2), 116 (18), 110 (8), 89 (7), 84 (1), 75 (11), 63 (3), 51 (2), 39 (1); 
HRMS (EI) calcd for C16H13ClN2 [M+]: 268.07618 found 268.076421. 
2-(4-tert-Butylphenyl)-6-chloroquinoxaline (16p): 
Starting with 14 (0.1 g, 0.5 mmol), 15p (0.106 g, 1.3 equiv.), Pd(PPh3)4 (0.029 g, 0.05 
equiv.), K3PO4 (0.212 g, 2 equiv.), THF (4 mL), 16p was 
isolated as white solid (0.115 g, 77%); mp 99-102 oC. 1H 
NMR (300.13 MHz, CDCl3): δ = 1.30 (s, 9H, 3CH3), 7.50 
(d, 3J = 8.69 Hz, 2H, ArH), 7.60 (dd, J = 9.07 Hz, J = 2.46 
Hz, 1H, ArH), 7.95-8.04 (m, 4H, ArH), 9.21 (s, 1H, ArH); 13C NMR (75.46 MHz, 
CDCl3), δ = 31.2 (3CH3), 34.9 (C), 126.2 (2CH), 127.3 (2CH), 128.1 (CH), 130.8 (CH), 
131.2 (CH), 133.6 (C), 134.9 (C), 140.9 (C), 141.7 (C), 144.1 (CH), 151.9 (C), 153.9 (C); 
IR (ATR, cm−1): ~ν  = 3093 (w), 3063 (w), 2955 (m), 2867 (w), 1601 (m), 1569 (w), 1537 
(m), 1504 (w), 1474 (m), 1455 (w), 1404 (m), 1392 (w), 1360 (m), 1333 (w), 1316 (m), 
1302 (w), 1270 (m), 1244 (w), 1200 (m), 1174 (m), 1147 (w), 1111 (w), 1093 (m), 1045 
(m), 1012 (m), 975 (w), 957 (s), 920 (s), 897 (s), 879 (m), 841 (s), 826 (s), 799 (w), 739 
(m), 694 (w), 672 (m), 660 (w), 640 (w), 623 (w), 577 (s), 539 (m); GC-MS (EI, 70 eV): 
m/z (%): 296 (M+, 31), 281 (100), 265 (5), 253 (11), 218 (1), 203 (1), 163 (4), 140 (2), 
116 (7), 110 (4), 75 (5), 39 (1); HRMS (EI) calcd for C18H17ClN2 [M+]: 296.10748 found 
296.107517. 
6-Chloro-2-(4-(trifluoromethyl)phenyl)quinoxaline (16q): 
Starting with 14 (0.1 g, 0.5 mmol), 15q (0.123 g, 1.3 
equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 
equiv.), THF (4 mL), 16q was isolated as white solid 
(0.081 g, 52%); mp 128-130 oC. 1H NMR (300.13 MHz, 
CDCl3): δ = 7.67 (dd, J = 8.88 Hz, J = 2.27 Hz, 1H, ArH), 7.75 (d, 3J = 8.12 Hz, 2H, 
ArH), 8.01-8.06 (m, 2H, ArH), 8.23 (d, 3J = 8.12 Hz, 2H, ArH), 9.26 (s, 1H, ArH); 13C 
NMR (75.46 MHz, CDCl3), δ = 123.9 (CF3, q, 1JCF = 272.35 Hz), 126.1 (2CH, q, 3JCF = 
3.30 Hz), 127.8 (2CH), 128.2 (CH), 132.2 (C, q, 2JCF = 32.46 Hz), 130.9 (CH), 131.7 









(282.40 MHz, CDCl3): δ = -62.81 (ArCF3); IR (ATR, cm−1): ~ν  = 3043 (w), 1928 (w), 
1809 (w), 1617 (w), 1604 (m), 1538 (m), 1519 (w), 1478 (m), 1414 (m), 1326 (s), 1260 
(w), 1195 (w), 1174 (w), 1157 (m), 1107 (s), 1068 (s), 1015 (m), 960 (m), 927 (m), 899 
(m), 850 (m), 832 (s), 800 (w), 774 (w), 745 (w), 678 (w), 651 (m), 636 (w), 624 (w), 598 
(s), 568 (m), 544 (w); GC-MS (EI, 70 eV): m/z (%): 308 (M+, 100), 281 (24), 246 (9), 
226 (8), 212 (2), 177 (4), 152 (6), 136 (2), 110 (17), 100 (4), 75 (20), 50 (3); HRMS (EI) 
calcd for C15H8ClF3N2 [M+]: 308.03226 found 308.031777. 
6-Chloro-2-(4-vinylphenyl)quinoxaline (16r): 
Starting with 14 (0.1 g, 0.5 mmol), 15r (0.096 g, 1.3 
equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 
equiv.), THF (4 mL), 16r was isolated as yellow solid 
(0.04 g, 30%); mp 113-115 oC. 1H NMR (300.13 MHz, CDCl3): δ = 5.29 (d, J = 11.33 
Hz, 1H, -CH2-), 5.79 (d, J = 17.56 Hz, 1H, -CH2-), 6.65-6.75 (m, 1H, -CH-), 7.49 (d, 3J = 
8.31 Hz, 2H, ArH), 7.61 (dd, J = 8.88 Hz, J = 2.27 Hz, 1H, ArH), 7.95-8.00 (m, 2H, 
ArH), 8.06 (d, 3J = 8.50 Hz, 2H, ArH), 9.21 (s, 1H, ArH); 13C NMR (75.46 MHz, 
CDCl3), δ = 114.6 (-CH2-), 125.9 (2CH), 126.6 (2CH), 127.0 (CH), 129.7 (CH), 130.3 
(CH), 134.1 (C), 134.5 (C), 135.1 (CH), 138.6 (C), 139.8 (C), 140.7 (C), 142.9 (CH), 
150.3 (C); IR (ATR, cm−1): ~ν  = 3046 (w), 2921 (m), 2851 (w), 1606 (m), 1568 (w), 1536 
(m), 1475 (m), 1445 (w), 1411 (m), 1333 (w), 1314 (m), 1210 (w), 1172 (s), 1132 (w), 
1047 (m), 987 (w), 957 (m), 899 (m), 844 (w), 825 (s), 782 (w), 731 (m), 675 (w), 605 
(w), 572 (s), 544 (w); GC-MS (EI, 70 eV): m/z (%): 266 (M+, 100), 238 (14), 204 (10), 
177 (3), 129 (12), 102 (8), 75 (11), 63 (2), 50 (2); HRMS (EI) calcd for C16H11ClN2 [M+]: 
266.06053 found 266.060883. 
6-Chloro-2-(2-chlorophenyl)quinoxaline (16s): 
Starting with 14 (0.12 g, 0.5 mmol), 15s (0.121 g, 1.3 equiv.), 
Pd(PPh3)4 (0.035 g, 0.05 equiv.), K3PO4 (0.254 g, 2 equiv.), 
THF (4 mL), 16s was isolated as white solid (0.129 g, 78%); mp 
177 oC. 1H NMR (300.13 MHz, CDCl3): δ = 7.34-7.40 (m, 2H, ArH), 7.44-7.49 (m, 1H, 









(75.46 MHz, CDCl3), δ = 126.5 (CH), 127.2 (CH), 129.3 (CH), 129.8 (CH), 129.9 (CH), 
130.3 (CH), 130.9 (CH), 131.5 (C), 134.9 (C), 135.1 (C), 139.8 (C), 140.6 (C), 145.9 
(CH), 151.5 (C); IR (ATR, cm−1): ~ν  = 3091 (w), 3047 (m), 2982 (w), 1921 (w), 1807 
(w), 1621 (w), 1598 (s), 1543 (m), 1504 (w), 1476 (s), 1447 (w), 1429 (m), 1397 (w), 
1356 (w), 1324 (w), 1311 (m), 1265 (w), 1248 (m), 1176 (s), 1147 (w), 1137 (m), 1093 
(w), 1075 (m), 1040 (s), 1031 (w), 961 (s), 935 (s), 921 (w), 898 (s), 862 (w), 833 (s), 
802 (w), 791 (m), 748 (s), 723 (m), 686 (m), 676 (m), 642 (w), 615 (w), 579 (m), 538 
(m); GC-MS (EI, 70 eV): m/z (%): 274 (M+, 100), 247 (20), 241 (30), 239 (93), 212 (21), 
177 (31), 137 (18), 110 (20), 102 (12), 100 (9), 88 (2), 75 (36), 63 (2), 51 (4), 50 (7); 
HRMS (EI) calcd for C14H8Cl2N2 [M+]: 274.00591 found 274.005460. 
6-Chloro-2-(3-chlorophenyl)quinoxaline (16t): 
Starting with 14 (0.1 g, 0.5 mmol), 15t (0.1 g, 1.3 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), K3PO4 (0.212 g, 2 equiv.), 
THF (4 mL), 16t was isolated as white solid (0.035 g, 25%); 
mp 167 oC. 1H NMR (300.13 MHz, CDCl3): δ = 7.41-7.43 (m, 2H, ArH), 7.65 (dd, J = 
8.88 Hz, J = 2.27 Hz, 1H, ArH), 7.93-8.04 (m, 3H, ArH), 8.13-8.14 (m, 1H, ArH), 9.20 
(s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 125.4 (CH), 127.6 (CH), 128.1 (CH), 
130.4 (2CH), 130.9 (CH), 131.6 (CH), 135.4 (C), 135.7 (C), 138.1 (C), 140.7 (C), 142.0 
(C), 143.7 (CH), 150.4 (C); IR (ATR, cm−1): ~ν  = 3080 (w), 3048 (m), 1937 (w), 1822 
(w), 1712 (w), 1602 (w), 1537 (m), 1475 (m), 1371 (w), 1311 (s), 1258 (w), 1175 (m), 
1106 (w), 1065 (m), 1048 (w), 966 (s), 940 (m), 904 (m), 873 (w), 831 (m), 791 (s), 755 
(m), 700 (s), 671 (m), 638 (w), 586 (m), 547 (w), 530 (w); GC-MS (EI, 70 eV): m/z (%): 
275 (M+, 17), 274 (100), 247 (18), 239 (26), 212 (21), 177 (23), 137 (14), 110 (18), 100 







General procedure for the synthesis of 18a-f: A 1,4-dioxane solution (8 mL) of 14 (1.0 
equiv.), arylboronic acid 17 (2.5 equiv.), 2M K2CO3 (2 mL), and Pd(PPh3)4 (5 mol%) was 
heated at 120 °C for 12 h. After cooling to room temperature, H2O was added and the 
reaction mixture was extracted with CH2Cl2. The organic layer was dried (Na2SO4), 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(gradient elution n-heptane/ethyl acetate). 
2,6-Di(o-tolyl)quinoxaline (18a): 
Starting with 14 (0.1 g, 0.5 mmol), 17a (0.169 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-
Dioxane (4 mL), 18a was isolated as as white solid (0.1 g, 
64%); mp 139 oC. 1H NMR (300.13 MHz, CDCl3): δ = 2.28 
(s, 3H, CH3), 2.41 (s, 3H, CH3), 7.22-7.33 (m, 7H, ArH), 7.47-7.50 (m, 1H, ArH), 7.71 
(dd, J = 8.69 Hz, J = 2.08 Hz, 1H, ArH), 8.02-8.12 (m, 2H, ArH), 8.95 (s, 1H, ArH); 13C 
NMR (62.89 MHz, CDCl3), δ = 20.4 (CH3), 20.6 (CH3), 126.1 (CH), 126.4 (CH), 128.0 
(CH), 128.9 (CH), 129.1 (CH), 129.4 (CH), 129.9 (CH), 130.0 (CH), 130.6 (CH), 131.3 
(CH), 132.2 (CH), 135.4 (C), 136.6 (C), 137.2 (C), 140.5 (C), 140.9 (C), 141.0 (C), 143.7 
(C), 146.2 (CH), 154.9 (C); IR (ATR, cm−1): ~ν  = 3092 (w), 3019 (w), 2921 (w), 2854 
(w), 2735 (w), 1954 (w), 1822 (w), 1551 (w), 1567 (w), 1539 (m), 1494 (w), 1481 (m), 
1434 (m), 1349 (w), 1314 (m), 1268 (w), 1164 (m), 1060 (m), 1029 (m), 977 (w), 961 
(m), 848 (s), 791 (w), 757 (s), 728 (s), 705 (w), 666 (m), 626 (m), 600 (w), 564 (w), 546 
(w), 535 (w); GC-MS (EI, 70 eV): m/z (%): 310 (M+, 48), 309 (100), 190 (2), 165 (8), 
153 (4), 115 (10), 89 (3), 75 (1), 65 (2), 51 (1), 39 (1); HRMS (ESI) calcd for C22H19N2





Starting with 14 (0.1 g, 0.5 mmol), 17b (0.169 g, 2.5 
equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 
mL), 1,4-Dioxane (4 mL), 18b was isolated as as white 
solid (0.08 g, 51%); mp 203-205 oC. 1H NMR (300.13 
MHz, CDCl3): δ = 2.35 (s, 3H, CH3), 2.37 (s, 3H, CH3), 7.25 (d, 3J = 7.93 Hz, 2H, ArH), 
7.29 (d, 3J = 7.93 Hz, 2H, ArH), 7.60 (d, 3J = 8.12 Hz, 2H, ArH), 7.95 (dd, J = 8.69 Hz, J
= 1.89 Hz, 1H, ArH), 8.03 (d, 3J = 8.12 Hz, 2H, ArH), 8.08-8.21 (m, 2H, ArH), 9.24 (s, 
1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 21.2 (CH3), 21.5 (CH3), 126.1 (CH), 127.3 
(2CH), 127.4 (2CH), 129.7 (CH), 129.80 (CH), 129.83 (2CH), 129.9 (2CH), 134.1 (C), 
136.9 (C), 137.5 (C), 138.1 (C), 140.5 (C), 141.7 (C), 142.0 (C), 143.6 (CH), 151.5 (C); 
IR (ATR, cm−1): ~ν  = 3020 (w), 2913 (w), 2856 (w), 2726 (w), 1614 (m), 1503 (w), 1402 
(w), 1322 (w), 1275 (w), 1186 (w), 1167 (m), 1118 (w), 1054 (m), 975 (w), 931 (m), 849 
(w), 816 (s), 723 (m), 691 (w), 606 (m), 587 (w), 554 (w); GC-MS (EI, 70 eV): m/z (%): 
310 (M+, 100), 295 (2), 268 (1), 166 (14), 139 (1), 116 (15), 91 (1), 63 (1); HRMS (EI) 
calcd for C22H18N2 [M+]: 310.14645 found 310.146793. 
2,6-Bis(3,5-dimethylphenyl)quinoxaline (18c): 
Starting with 14 (0.1 g, 0.5 mmol), 17c (0.186 g, 2.5 
equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 
mL), 1,4-Dioxane (4 mL), 18c was isolated as as 
yellow solid (0.16 g, 94%); mp 190-192 oC. 1H NMR 
(300.13 MHz, CDCl3): δ = 2.33 (s, 6H, 2CH3), 2.36 (s, 
6H, 2CH3), 6.97 (s, 1H, ArH), 7.05 (s, 1H, ArH), 7.29 
(s, 2H, ArH), 7.70 (s, 2H, ArH), 7.93 (dd, J = 8.69 Hz, J = 2.08 Hz, 1H, ArH), 8.01-8.19 
(m, 2H, ArH), 9.20 (s, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 20.4 (4CH3), 124.3 
(2CH), 124.4 (2CH), 125.4 (CH), 128.6 (CH), 128.7 (CH), 128.9 (CH), 130.8 (CH), 
135.7 (C), 137.6 (2C), 137.7 (2C), 138.6 (C), 140.5 (C), 140.7 (C), 141.3 (C), 142.9 
(CH), 150.8 (C); IR (ATR, cm−1): ~ν  = 3012 (w), 2913 (m), 2854 (w), 2734 (w), 1597 
(m), 1538 (w), 1435 (w), 1373 (w), 1316 (m), 1286 (w), 1217 (w), 1164 (m), 1087 (m), 






(w), 544 (w); GC-MS (EI, 70 eV): m/z (%): 338 (M+, 100), 311 (2), 296 (1), 180 (7), 154 
(2), 130 (8), 115 (4), 77 (1); HRMS (EI) calcd for C24H22N2 [M+]: 338.17775 found 
338.177487. 
2,6-Bis(2-methoxyphenyl)quinoxaline (18d): 
Starting with 14 (0.1 g, 0.5 mmol), 17d (0.19 g, 2.5 equiv.), 
Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-
Dioxane (4 mL), 18d was isolated as yellow solid (0.085 g, 
49%); mp 128-129 oC. 1H NMR (300.13 MHz, CDCl3): δ = 
3.75 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 6.93-6.97 (m, 2H, ArH), 6.99-7.09 (m, 2H, 
ArH), 7.26-7.40 (m, 3H, ArH), 7.82 (dd, J = 7.55 Hz, J = 1.70 Hz, 1H, ArH), 7.89 (dd, J
= 8.69 Hz, J = 2.08 Hz, 1H, ArH), 8.05-8.18 (m, 2H, ArH), 9.25 (s, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 55.5 (OCH3), 55.6 (OCH3), 111.4 (CH), 111.5 (CH), 121.1 
(CH), 121.5 (CH), 126.7 (C), 128.6 (CH), 129.0 (CH), 129.4 (C), 129.5 (CH), 131.1 
(CH), 131.3 (CH), 131.6 (CH), 132.1 (CH), 140.0 (C), 140.9 (C), 141.8 (C), 147.3 (CH), 
151.8 (C), 156.6 (C), 157.4 (C); IR (ATR, cm−1): ~ν  = 3066 (w), 3024 (w), 2938 (w), 
2838 (w), 1599 (m), 1489 (m), 1440 (w), 1336 (w), 1268 (m), 1233 (s), 1163 (m), 1116 
(m), 1060 (m), 1039 (w), 1016 (s), 960 (m), 904 (m), 842 (w), 828 (m), 784 (m), 741 (s), 
695 (w), 666 (m), 617 (m), 576 (m), 562 (w), 541 (w); GC-MS (EI, 70 eV): m/z (%): 342 
(M+, 100), 341 (58), 325 (48), 313 (29), 297 (10), 270 (4), 237 (19), 207 (3), 193 (4), 164 
(6), 139 (15), 131 (7), 118 (8), 90 (4), 77 (3), 63 (3), 39 (1); HRMS (EI) calcd for 
C22H18N2O2 [M+]: 342.13628 found 342.135862. 
2,6-Bis(4-ethylphenyl)quinoxaline (18e): 
Starting with 14 (0.1 g, 0.5 mmol), 17e (0.188 g, 
2.5 equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M 
K2CO3 (2 mL), 1,4-Dioxane (4 mL), 18e was 
isolated as white solid (0.08 g, 47%); mp 150 oC. 
1H NMR (300.13 MHz, CDCl3): δ = 1.223 (t, 3J = 7.18 Hz, 3H, CH3), 1.224 (t, 3J = 7.55 
Hz, 3H, CH3), 2.65 (q, J = 7.55 Hz, J = 15.12 Hz, 2H, -CH2-), 2.67 (q, J = 7.55 Hz, J = 








7.62 (d, 3J = 8.31 Hz, 2H, ArH), 7.95 (dd, J = 8.68 Hz, J = 2.08 Hz, 1H, ArH), 8.05 (d, 3J
= 8.31 Hz, 2H, ArH), 8.08-8.21 (m, 2H, ArH), 9.23 (s, 1H, ArH); 13C NMR (62.89 MHz, 
CDCl3), δ = 15.4 (CH3), 15.5 (CH3), 28.6 (-CH2-), 28.8 (-CH2-), 126.1 (CH), 127.4 
(2CH), 127.5 (2CH), 128.6 (2CH), 128.7 (2CH), 129.7 (CH), 129.8 (CH), 134.3 (C), 
137.1 (C), 141.6 (C), 141.7 (C), 142.0 (C), 143.7 (CH), 144.4 (C), 146.7 (C), 151.5 (C); 
IR (ATR, cm−1): ~ν  = 3025 (w), 2931 (w), 2874 (w), 1614 (m), 1513 (w), 1452 (m), 1300 
(w), 1203 (w), 1165 (m), 1121 (w), 1057 (m), 1015 (m), 960 (m), 914 (w), 829 (s), 798 
(w), 684 (w), 633 (w), 609 (m), 590 (w), 553 (w); GC-MS (EI, 70 eV): m/z (%): 338 
(M+, 100), 323 (55), 308 (13), 190 (2), 154 (13), 115 (5), 102 (1), 90 (1), 51 (1); HRMS 
(EI) calcd for C24H18N2 [M+]: 338.17775 found 338.177824. 
2,6-Bis(4-tert-butylphenyl)quinoxaline (18f): 
Starting with 14 (0.1 g, 0.5 mmol), 17f (0.223 g, 
2.5 equiv.), Pd(PPh3)4 (0.029 g, 0.05 equiv.), 2M 
K2CO3 (2 mL), 1,4-Dioxane (4 mL), 18f was 
isolated as white solid (0.052 g, 26%); mp 265-
267 oC. 1H NMR (300.13 MHz, CDCl3): δ = 1.32 
(s, 18H, 6CH3), 7.47 (d, 3J = 8.50 Hz, 2H, ArH), 7.52 (d, 3J = 8.69 Hz, 2H, ArH), 7.65 (d, 
3J = 8.50 Hz, 2H, ArH), 7.97 (dd, J = 8.69 Hz, J = 2.08 Hz, 1H, ArH), 8.06 (d, 3J = 8.50 
Hz, 2H, ArH), 8.09-8.23 (m, 2H, ArH), 9.25 (s, 1H, ArH); 13C NMR (62.89 MHz, 
CDCl3), δ = 31.2 (3CH3), 31.3 (3CH3), 34.7 (C), 34.9 (C), 126.0 (2CH), 126.1 (CH), 
126.2 (2CH), 127.1 (2CH), 127.2 (2CH), 129.7 (CH), 129.8 (CH), 134.1 (C), 136.8 (C), 
141.6 (C), 141.7 (C), 141.9 (C), 143.7 (CH), 151.3 (C), 151.5 (C), 153.5 (C); IR (ATR, 
cm−1): ~ν  = 3062 (w), 2964 (m), 2863 (w), 2707 (w), 1614 (m), 1504 (w), 1455 (m), 1361 
(m), 1301 (w), 1265 (m), 1202 (w), 1138 (w), 1047 (m), 976 (w), 930 (m), 890 (m), 823 
(s), 742 (w), 694 (w), 640 (w), 610 (m), 566 (s), 545 (w); GC-MS (EI, 70 eV): m/z (%): 
394 (M+, 63), 380 (31), 379 (100), 363 (10), 335 (3), 295 (2), 182 (11), 154 (10), 102 (1), 




General procedure for the synthesis of 20a-g: A 1,4-dioxane solution (8 mL) of 16 (1.0 
equiv.), arylboronic acid 19 (1.3 equiv.), 2M K2CO3 (2 mL), and Pd(PPh3)4 (5 mol%) was 
heated at 120 °C for 8 h. After cooling to room temperature, H2O was added and the 
reaction mixture was extracted with CH2Cl2. The organic layer was dried (Na2SO4), 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(gradient elution n-heptane/ethyl acetate). 
6-(3,5-Dimethylphenyl)-2-p-tolylquinoxaline (20a): 
Starting with 16c (0.05 g, 0.2 mmol), 19a (0.039 g, 1.3 
equiv.), Pd(PPh3)4 (0.012 g, 0.05 equiv.), 2M K2CO3 (1 
mL), 1,4-Dioxane (3 mL), 20a was isolated as light 
yellow solid (0.045 g, 70%); mp 168oC. 1H NMR 
(300.13 MHz, CDCl3): δ = 2.34 (s, 6H, 2CH3), 2.37 (s, 
3H, CH3), 6.99 (s, 1H, ArH), 7.28 (s, 1H, ArH), 7.30 (s, 3H, ArH), 7.95 (dd, J = 8.69 Hz, 
J = 2.08 Hz, 1H, ArH), 8.03 (d, 3J = 8.12 Hz, 2H, ArH), 8.08 (d, 3J = 8.69 Hz, 1H, ArH), 
8.20 (d, J = 2.07 Hz, 1H, ArH), 9.23 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 
21.4 (3CH3), 125.4 (2CH), 126.4 (CH), 127.4 (2CH), 129.6 (CH), 129.7 (CH), 129.8 
(2CH), 129.9 (CH), 134.0 (C), 138.6 (2C), 139.7 (C), 140.4 (C), 141.6 (C), 141.7 (C), 
142.3 (C), 143.6 (CH), 151.5 (C); IR (ATR, cm−1): ~ν  = 3030 (w), 2913 (m), 2727 (w), 
1601 (m), 1555 (w), 1463 (w), 1427 (w), 1370 (w), 1276 (w), 1184 (w), 1164 (w), 1075 
(w), 1049 (m), 960 (m), 929 (w), 881 (w), 818 (s), 776 (w), 717 (m), 682 (m), 640 (w), 
624 (w), 614 (s), 569 (w), 555 (w), 536 (w); GC-MS (EI, 70 eV): m/z (%): 324 (M+, 100), 
309 (5), 297 (5), 180 (42), 162 (20), 130 (27), 115 (11), 77 (1), 65 (1), 63 (1); HRMS 





Starting with 16c (0.05 g, 0.2 mmol), 19b (0.046 g, 
1.3 equiv.), Pd(PPh3)4 (0.012 g, 0.05 equiv.), 2M 
K2CO3 (1 mL), 1,4-Dioxane (3 mL), 20b was 
isolated as light yellow solid (0.054 g, 78%); mp 
185-187oC. 1H NMR (300.13 MHz, CDCl3): δ = 1.31 
(s, 9H, 3CH3), 2.37 (s, 3H, CH3), 7.28 (d, 3J = 7.93 Hz, 2H, ArH), 7.46 (d, 3J = 8.69 Hz, 
2H, ArH), 7.65 (d, 3J = 8.50 Hz, 2H, ArH), 7.95 (dd, J = 8.88 Hz, J = 1.89 Hz, 1H, ArH), 
8.03 (d, 3J = 8.31 Hz, 2H, ArH), 8.09 (d, J = 8.69 Hz, 1H, ArH), 8.22 (d, J = 1.51 Hz, 1H, 
ArH), 9.23 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (CH3), 31.3 (3CH3), 
34.7 (C), 126.0 (2CH), 126.1 (CH), 127.1 (2CH), 127.4 (2CH), 129.7 (CH), 129.8 (CH), 
129.9 (2CH), 134.0 (C), 136.7 (2C), 140.4 (2C), 141.7 (C), 141.9 (C), 143.6 (CH), 151.3 
(C); IR (ATR, cm−1): ~ν  = 3061 (w), 3032 (w), 2902 (w), 2865 (w), 1916 (w), 1614 (m), 
1514 (w), 1450 (m), 1397 (w), 1362 (m), 1269 (w), 1186 (w), 1166 (m), 1143 (w), 1109 
(w), 1048 (w), 1009 (w), 958 (m), 925 (m), 889 (w), 842 (w), 819 (s), 740 (w), 718 (m), 
687 (w), 672 (w), 628 (w), 606 (m), 564 (w), 558 (m), 547 (m); GC-MS (EI, 70 eV): m/z
(%): 352 (M+, 100), 309 (25), 297 (9), 178 (10), 152 (7), 141 (15), 65 (1), 39 (1); HRMS 
(ESI) calcd for C25H25N2 [M+H]+ : 353.20123 found 353.20151. 
6-(2-Methoxyphenyl)-2-p-tolylquinoxaline (20c): 
Starting with 16c (0.05 g, 0.2 mmol), 19c (0.04 g, 1.3 
equiv.), Pd(PPh3)4 (0.012 g, 0.05 equiv.), 2M K2CO3 (1 
mL), 1,4-Dioxane (3 mL), 20c was isolated as light 
yellow solid (0.03 g, 47%); mp 125-127oC. 1H NMR 
(300.13 MHz, CDCl3): δ = 2.35 (s, 3H, CH3), 3.77 (s, 3H, 
OCH3), 6.94-7.04 (m, 2H, ArH), 7.26-7.33 (m, 3H, ArH), 7.39 (dd, J = 7.55 Hz, J = 1.70 
Hz, 1H, ArH), 7.91 (dd, J = 8.69 Hz, J = 1.89 Hz, 1H, ArH), 8.01-8.17 (m, 4H, ArH), 
9.21 (s, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (CH3), 55.6 (OCH3), 111.4 
(CH), 121.1 (CH), 127.4 (2CH), 128.6 (CH), 129.0 (CH), 129.3 (C), 129.5 (CH), ), 129.9 
(2CH), ), 131.1 (CH), ), 132.6 (CH), 134.1 (C), 139.9 (C), 140.4 (C), 141.4 (C), 141.5 







(w), 2834 (w), 1613 (w), 1567 (w), 1518 (w), 1464 (m), 1415 (w), 1322 (w), 1283 (w), 
1243 (m), 1182 (w), 1119 (m), 1059 (w), 1025 (m), 977 (w), 932 (m), 900 (m), 833 (s), 
823 (s), 754 (s), 716 (w), 636 (w), 616 (w), 609 (m), 576 (w), 543 (w); GC-MS (EI, 70 
eV): m/z (%): 326 (M+, 100), 311 (20), 284 (20), 182 (9), 163 (12), 139 (12), 131 (5), 115 
(2), 102 (1), 63 (1), 39 (1); HRMS (ESI) calcd for C22H19N2O [M+H]+ : 327.14919 found 
327.15004. 
6-(4-Fluorophenyl)-2-(4-methoxyphenyl)quinoxaline (20d): 
Starting with 16h (0.08 g, 0.3 mmol), 19d (0.054 g, 
1.3 equiv.), Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M 
K2CO3 (1 mL), 1,4-Dioxane (3 mL), 20d was 
isolated as white solid (0.074 g, 76%); mp 187-189 
oC. 1H NMR (300.13 MHz, CDCl3): δ = 3.84 (s, 3H, 
OCH3), 7.02 (d, 3J = 9.07 Hz, 2H, ArH), 7.13 (t, J = 8.69 Hz, 2H, ArH), 7.62-7.69 (m, 
2H, ArH), 7.90 (dd, J = 8.69 Hz, J = 2.08 Hz, 1H, ArH), 8.07-8.16 (m, 4H, ArH), 9.23 (s, 
1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 55.5 (OCH3), 114.6 (2CH), 116.0 (2CH, d, 
2JCF = 22.01 Hz), 126.4 (CH), 128.9 (2CH), 129.1 (2CH, d, 3JCF = 8.25 Hz), 129.3 (C), 
129.6 (CH), 129.8 (CH), 135.9 (C, d, 4JCF = 3.30 Hz), 140.8 (C), 141.4 (C), 141.6 (C), 
143.6 (CH), 151.3 (C), 161.5 (C), 163.0 (C, d, 1JCF = 247.59 Hz); 19F NMR (282.40 MHz, 
CDCl3): δ = -114.27 (ArF); IR (ATR, cm−1): ~ν  = 3062 (w), 3014 (w), 2970 (w), 2843 
(w), 1600 (m), 1545 (w), 1510 (m), 1454 (w), 1401 (w), 1306 (w), 1253 (m), 1226 (m), 
1178 (w), 1115 (w), 1100 (w), 1027 (m), 960 (m), 902 (w), 890 (w), 826 (s), 785 (w), 
720 (w), 696 (w), 640 (m), 631 (w), 589 (m), 554 (w), 534 (m); GC-MS (EI, 70 eV): m/z 
(%): 330 (M+, 100), 315 (14), 287 (10), 260 (2), 195 (2), 170 (12), 120 (20), 103 (1), 90 








Starting with 16m (0.07 g, 0.3 mmol), 19e (0.058 g, 1.3 
equiv.), Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 
mL), 1,4-Dioxane (3 mL), 20e was isolated as white 
solid (0.055 g, 63%); mp 163-165 oC. 1H NMR (300.13 
MHz, CDCl3): δ = 2.34 (s, 6H, 2CH3), 6.99 (s, 1H, 
ArH), 7.16 (t, J = 8.69 Hz, 2H, ArH), 7.29 (s, 2H, ArH), 7.95 (dd, J = 8.69 Hz, J = 1.89 
Hz, 1H, ArH), 8.04-8.20 (m, 4H, ArH), 9.19 (s, 1H, ArH); 13C NMR (62.89 MHz, 
CDCl3), δ = 20.4 (2CH3), 115.2 (2CH, d, 2JCF = 21.97 Hz), 124.4 (2CH), 125.4 (CH), 
128.3 (CH), 128.5 (2CH, d, 3JCF = 8.24 Hz), 128.8 (CH), 129.2 (CH), 131.9 (C, d, 4JCF = 
3.20 Hz), 137.6 (2C), 138.6 (C), 140.5 (C), 140.7 (C), 141.6 (C), 142.2 (CH), 149.3 (C), 
163.2 (C, d, 1JCF = 250.85 Hz); 19F NMR (282.40 MHz, CDCl3): δ = -110.61 (ArF); IR 
(ATR, cm−1): ~ν  = 3339 (s), 2919 (w), 2859 (w), 2735 (w), 1599 (m), 1538 (w), 1469 (w), 
1410 (w), 1343 (w), 1298 (w), 1264 (w), 1225 (m), 1142 (w), 1048 (m), 960 (m), 911 
(w), 839 (m), 827 (s), 789 (w), 722 (m), 684 (m), 634 (w), 612 (s), 573 (w), 552 (w), 541 
(w); GC-MS (EI, 70 eV): m/z (%): 328 (M+, 100), 313 (3), 180 (13), 164 (3), 130 (9), 
115 (5), 94 (1), 75 (1); HRMS (EI) calcd for C22H17FN2 [M+]: 328.13703 found 
328.136677. 
6-(3,5-Dimethylphenyl)-2-(thiophen-2-yl)quinoxaline (20f): 
 Starting with 16n (0.05 g, 0.2 mmol), 19f (0.039 g, 1.3 
equiv.), Pd(PPh3)4 (0.012 g, 0.05 equiv.), 2M K2CO3 (1 
mL), 1,4-Dioxane (3 mL), 20f was isolated as yellow solid 
(0.058 g, 91%); mp 152oC. 1H NMR (300.13 MHz, 
CDCl3): δ = 2.33 (s, 3H, CH3), 2.34 (s, 3H, CH3), 6.98 (s, 
1H, ArH), 7.10-7.13 (m, 1H, ArH), 7.29 (s, 2H, ArH), 7.46 (dd, J = 5.10 Hz, J = 1.13 Hz, 
1H, ArH), 7.77 (dd, J = 3.78 Hz, J = 1.13 Hz, 1H, ArH), 7.90-8.16 (m, 3H, ArH), 9.15 (s, 
1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (2CH3), 125.3 (2CH), 126.4 (CH), 
126.8 (CH), 128.5 (CH), 129.2 (CH), 129.7 (CH), 129.8 (CH), 130.2 (CH), 138.6 (3C), 
139.6 (C), 141.4 (C), 141.6 (C), 142.2 (C), 142.4 (CH), 147.0 (C); IR (ATR, cm−1): 







1454 (w), 1517 (m), 1371 (w), 1321 (m), 1238 (w), 1161 (w), 1132 (m), 1064 (w), 1006 
(m), 935 (w), 919 (m), 891 (w), 819 (s), 786 (w), 775 (m), 750 (w), 703 (m), 682 (s), 625 
(w), 615 (s), 606 (w), 561 (w), 537 (w); GC-MS (EI, 70 eV): m/z (%): 316 (M+, 100), 301 
(4), 180 (19), 158 (7), 130 (14), 115 (5), 69 (1), 63 (1), 57 (1); HRMS (ESI) calcd for 
C20H17N2S [M+H]+ : 317.11070 found 317.11119. 
2-(4-Ethylphenyl)-6-p-tolylquinoxaline (20g): 
Starting with 16o (0.07 g, 0.3 mmol), 19g (0.053 g, 
1.3 equiv.), Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M 
K2CO3 (1 mL), 1,4-Dioxane (3 mL), 20g was 
isolated as yellowish solid (0.046 g, 54%); mp 152-
154 oC. 1H NMR (300.13 MHz, CDCl3): δ = 1.21 (t, 3J = 7.55 Hz, 3H, CH3), 2.33 (s, 3H, 
CH3), 2.65 (q, J = 7.73 Hz, J = 15.29 Hz, 2H, -CH2-), 7.22 (d, 3J = 7.74 Hz, 2H, ArH), 
7.29 (d, 3J = 8.31 Hz, 2H, ArH), 7.57 (d, 3J = 8.12 Hz, 2H, ArH), 7.92 (dd, J = 8.69 Hz, J
= 2.07 Hz, 1H, ArH), 8.02-8.18 (m, 4H, ArH), 9.21 (s, 1H, ArH); 13C NMR (62.89 MHz, 
CDCl3), δ = 15.4 (CH3), 21.2 (CH3), 28.8 (-CH2-), 126.1 (CH), 127.3 (2CH), 127.5 
(2CH), 128.7 (2CH), 129.7 (2CH), 129.8 (2CH), 134.3 (C), 136.8 (C), 138.1 (C), 141.6 
(C), 141.7 (C), 141.9 (C), 143.7 (CH), 146.7 (C), 151.5 (C); IR (ATR, cm−1): ~ν  = 3021 
(w), 2962 (m), 2854 (w), 2729 (w), 1915 (w), 1822 (w), 1727 (w), 1613 (m), 1513 (w), 
1452 (m), 1336 (w), 1276 (w), 1209 (w), 1165 (m), 1080 (w), 1015 (w), 960 (m), 932 
(m), 894 (w), 835 (m), 817 (s), 788 (w), 722 (w), 665 (w), 608 (m), 588 (w), 554 (w), 542 
(w); GC-MS (EI, 70 eV): m/z (%): 324 (M+, 100), 309 (36), 254 (1), 166 (8), 154 (7), 





6.5 Regioselective Palladium-Catalysed Cross-Coupling Reactions of 2,4-Dichloro-
1-(trifluoromethyl)benzene 
General procedure for the synthesis of 23a-m: A 1,4-dioxane solution (8 mL) of 21 (1.0 
equiv.), arylboronic acid 22 (1.3 equiv.), 2M K2CO3 (1 mL per cross coupling), and 
Pd(PPh3)4 (5 mol%) was heated at 80 °C for 6 h. After cooling to room temperature, H2O 
was added and the reaction mixture was extracted with CH2Cl2. The organic layer was 
dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (gradient elution n-heptane/ethyl acetate). 
  
3'-Chloro-2-methyl-4'-(trifluoromethyl)biphenyl (23a): 
Starting with 21 (0.215 g, 1 mmol), 22a (0.176 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23a was 
isolated  as colorless oil (0.251 g, 93%). 1H NMR (300.13 MHz, CDCl3): δ
= 2.31 (s, 3H, CH3), 7.21-7.24 (m, 1H), 7.28-7.37 (m, 4H), 7.52 (s, 1H, 
ArH), 7.76 (d, 3J = 7.93 Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 
20.3 (CH3), 123.1 (CF3, q, 1JCF = 272.89 Hz), 126.1 (CH), 126.8 (C, q, 2JCF
= 31.91 Hz), 127.3 (CH, q, 3JCF = 4.95 Hz), 127.6 (CH), 128.5 (CH), 129.4 (CH), 130.7 
(CH), 132.1 (CH), 135.2 (2C), 139.1 (C), 147.2 (C); 19F NMR (282.40 MHz, CDCl3): δ = 
-62.27 (ArCF3); IR (ATR, cm−1): ~ν  = 3214 (w), 3063 (w), 3021 (w), 2956 (w), 2926 (w), 
2865 (w), 2741 (w), 1921 (w), 1804 (w), 1609 (m), 11602 (m), 1556 (m), 1504 (w), 1481 
(w), 1455 (w), 1383 (m), 1312 (s), 1280 (w), 1248 (m), 1173 (m), 1126 (s), 1102 (s), 
1054 (w), 1027 (s), 964 (w), 945 (w), 892 (m), 867 (w), 838 (s), 786 (w), 760 (s), 738 
(m), 724 (m), 681 (m), 661 (w) , 641 (m), 599 (w), 594 (w) , 565 (w), 551 (w), 536 (w); 
GC-MS (EI, 70 eV): m/z (%): 270 (M+, 100), 235 (11), 215 (27), 165 (80), 139 (3), 115 






Starting with 21 (0.215 g, 1 mmol), 22b (0.176 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23b was 
isolated  as colorless oil (0.257 g, 95%). 1H NMR (300.13 MHz, CDCl3): δ
= 2.48 (s, 3H, CH3), 7.27-7.30 (m, 1H), 7.39-7.43 (m, 3H), 7.56-7.59 (m, 
1H), 7.75-7.78 (m, 2H); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (CH3), 
123.1 (CF3, q, 1JCF = 272.83 Hz), 124.3 (CH), 125.2 (CH), 126.8 (C, q, 2JCF = 31.59 Hz), 
127.8 (CH, q, 3JCF = 5.04 Hz), 127.9 (CH), 129.0 (CH), 129.6 (CH), 129.9 (CH), 132.6 
(C, q, 4JCF = 2.29 Hz), 138.2 (C), 138.9 (2C), 146.3 (C);19F NMR (282.40 MHz, CDCl3): 
δ = -62.19 (ArCF3); IR (ATR, cm−1): ~ν  = 3214 (w), 3027 (w), 2952 (w), 2923 (w), 2864 
(w), 2736 (w), 1922 (w), 1883 (w), 1853 (w), 1791 (w), 1698(w), 1674 (w), 1605 (m), 
1557 (m), 1503 (m), 1480 (w), 1456 (w), 1427 (w), 1377 (m), 1312 (s), 1299 (w), 
1273(w), 1254 (w), 1175 (m), 1126 (s), 1104 (s), 999 (w), 961 (w), 910 (w), 880 (m), 835 
(s), 781 (s), 736 (m), 721 (w), 698 (m) , 684 (w), 633 (m), 596 (w) , 569 (w), 540 (w); 
GC-MS (EI, 70 eV): m/z (%): 270 (M+, 100), 251 (5), 235 (12), 215 (9), 201 (6), 183 (2), 
165 (33), 125 (1), 91 (2), 69 (2), 39 (1); HRMS (EI) calcd for C14H10ClF3 [M+]: 
270.04176 found 270.041311. 
3-Chloro-4'-methyl-4-(trifluoromethyl)biphenyl (23c): 
Starting with 21 (0.215 g, 1 mmol), 22c (0.176 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23c was 
isolated  as white solid (0.262 g, 97%); mp 55-57 °C. 1H NMR (300.13 MHz, 
CDCl3): δ = 2.44 (s, 3H, CH3), 7.31 (d, 3J = 8.49 Hz, 2H, ArH), 7.50 (d, 3J = 
8.12 Hz, 2H, ArH), 7.56 (d, 3J = 8.12 Hz, 1H, ArH), 7.74 (d, 3J = 8.69 Hz, 
2H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.2 (CH3), 123.1 (CF3, q, 1JCF
= 275.65 Hz), 124.9 (CH), 126.6 (C, q, 2JCF = 31.36 Hz), 127.0 (2CH), 127.9 (CH, q, 3JCF
= 5.50 Hz), 129.6 (CH), 129.9 (2CH), 132.6 (C, q, 3JCF = 1.65 Hz), 135.4 (C), 138.9 (C), 
146.1 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.19 (ArCF3); IR (ATR, cm−1): 
~ν  = 3070 (w), 3040 (w), 3029 (m), 2921 (m), 2858 (w), 2739 (w), 1916 (w), 1797 (w), 
1769 (w), 1602 (s), 1551 (m), 1520 (w), 1489 (m), 1413 (w), 1379 (m), 1356 (w), 1313 






1040 (w), 1026 (m), 1014 (w), 959 (m), 904 (w), 887 (m), 845 (w), 836 (m), 808 (s), 785 
(m), 740 (m), 717 (w), 676 (m), 643 (w), 624 (w), 588 (m), 561 (m), 547 (w); GC-MS 
(EI, 70 eV): m/z (%): 270 (M+, 100), 235 (14), 215 (8), 165 (32), 139 (2), 99 (1), 87 (1), 
75 (1), 63 (1), 51 (1), 39 (1); HRMS (EI) calcd for C14H10ClF3 [M+]: 270.04176 found 
270.041119. 
3'-Chloro-2,6-dimethyl-4'-(trifluoromethyl)biphenyl (23d): 
Starting with 21 (0.215 g, 1 mmol), 22d (0.194 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23d was 
isolated  as colorless oil (0.102 g, 36%). 1H NMR (300.13 MHz, CDCl3): δ
= 1.95 (s, 6H, 2CH3), 7.03-7.15 (m, 4H, ArH), 7.25 (s, 1H, ArH), 7.66 (d, 
3J = 7.93 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 20.7 (2CH3), 
123.0 (CF3, q, 1JCF = 272.83 Hz), 126.8 (C, q, 2JCF = 31.59 Hz), 127.60 (2CH), 127.64 
(CH), 127.7 (CH, q, 3JCF = 5.49 Hz), 128.0 (CH), 132.0 (CH), 132.4 (C, q, 3JCF = 1.83 
Hz), 135.5 (2C), 138.9 (C), 146.6 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.28 
(ArCF3); IR (ATR, cm−1): ~ν  = 3064 (w), 3022 (w), 2953 (w), 2923 (w), 2855 (w), 2739 
(w), 1928 (w), 1858 (w), 1787 (w), 1607 (m), 1559 (m), 1500 (w), 1464 (m), 1445 (w), 
1384 (m), 1312 (s), 1285 (w), 1251 (m), 1240 (w), 1173 (m), 1126 (s), 1101 (s), 1054 
(w), 1028 (s), 988 (w), 964 (w), 919 (w), 889 (m), 834 (s), 769 (s), 758 (w),752 (w), 718 
(m), 667 (m), 646 (m) , 595 (w), 566 (m), 553 (w); GC-MS (EI, 70 eV): m/z (%): 284 
(M+, 100), 269 (25), 249 (73), 234 (28), 180 (22), 165 (38), 152 (4), 139 (1), 105 (1), 89 
(2), 39 (1); HRMS (EI) calcd for C15H12ClF3 [M+]: 284.05741 found 284.056674. 
3-Chloro-3',5'-dimethyl-4-(trifluoromethyl)biphenyl (23e): 
Starting with 21 (0.215 g, 1 mmol), 22e (0.194 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23e was 
isolated  as colorless oil (0.204 g, 72%). 1H NMR (300.13 MHz, CDCl3): δ
= 2.43 (s, 6H, 2CH3), 7.11 (s, 1H, ArH), 7.22 (s, 2H, ArH), 7.56 (d, 3J = 
8.49 Hz, 1H, ArH), 7.73-7.76 (m, 2H, ArH); 13C NMR (62.89 MHz, 
CDCl3), δ = 21.3 (2CH3), 123.1 (CF3, q, 1JCF = 272.83 Hz), 125.1 (2CH), 125.2 (CH), 






132.5 (C, q, 3JCF = 1.83 Hz), 138.2 (C), 138.7 (2C), 146.4 (C); 19F NMR (282.40 MHz, 
CDCl3): δ = -62.19 (ArCF3); IR (ATR, cm−1): ~ν  = 3016 (w), 2922 (w), 2856 (w), 1602 
(m), 1562 (w), 1554 (m), 1501 (w), 1493 (w), 1479 (w), 1467 (w), 1443 (w), 1432 (w), 
1409 (w), 1379 (w), 1315 (s), 1264 (w), 1212 (w), 1177 (m), 1132 (s), 1108 (m), 1040 
(w), 1026 (m), 997 (w), 963 (w), 895 (w), 885 (w), 853 (w), 831 (m), 775 (w), 723 (w), 
698 (w), 667 (w), 661 (w), 636 (w), 540 (w); GC-MS (EI, 70 eV): m/z (%): 284 (M+, 
100), 269 (23), 249 (11), 234 (14), 165 (18), 152 (2), 105 (1), 51 (1); HRMS (EI) calcd 
for HRMS (EI) calcd for C15H12ClF3 [M+]: 284.05741 found 284.057528. 
3-Chloro-4'-ethyl-4-(trifluoromethyl)biphenyl (23f): 
Starting with 21 (0.215 g, 1 mmol), 22f (0.195 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23f was 
isolated  as colorless oil (0.14 g, 49%). 1H NMR (300.13 MHz, CDCl3): δ = 
1.21 (t, J = 7.55 Hz, 3H, CH3), 2.63 (q, J = 7.55 Hz, J = 15.11 Hz, 2H), 7.22 
(d, 3J = 8.50 Hz, 2H, ArH), 7.41-7.48 (m, 3H), 7.63-7.66 (m, 2H); 13C NMR 
(75.46 MHz, CDCl3), δ = 15.5 (CH3), 28.6 (-CH2-), 123.1 (CF3, q, 1JCF = 
272.90 Hz), 124.9 (CH), 127.0 (C, q, 2JCF = 34.66 Hz), 127.1 (2CH), 127.9 (CH, q, 3JCF = 
5.50 Hz), 128.7 (2CH), 129.7 (CH), 132.6 (C, q, 3JCF = 1.65 Hz), 135.6 (C), 145.2 (C), 
146.1 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.19 (ArCF3); IR (ATR, cm−1): 
~ν  = 3026 (w), 2966 (w), 2932 (w), 2874 (m), 1907 (w), 1579 (w), 1605 (m), 1576 (w), 
1552 (m), 1523 (w), 1488 (w), 1461 (w), 1455 (w), 1420 (m), 1382 (m), 1312 (s), 1293 
(w), 1254 (w), 1175 (m), 1127 (s), 1103(s), 1059 (w), 1042 (w), 1025 (m), 1015 (m), 962 
(w),  887 (m), 820 (s), 772 (w), 736 (m) , 699 (w), 674 (m), 644(w), 624 (w), 594 (m), 
561 (m), 532 (w); GC-MS (EI, 70 eV): m/z (%): 284 (M+, 50), 271 (32), 269 (100), 249 
(4), 233 (7), 165 (19), 117 (1), 77 (1), 63 (1), 39 (1); HRMS (EI) calcd for C15H12ClF3





Starting with 21 (0.215 g, 1 mmol), 22g (0.198 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23g was 
isolated  as heavy oil (0.16 g, 56%). 1H NMR (300.13 MHz, CDCl3): δ = 
3.75 (s, 3H, OCH3), 6.91-6.99 (m, 2H, ArH), 7.21 (dd, J = 7.55 Hz, J = 
1.89 Hz, 1H, ArH), 7.28-7.34 (m, 1H, ArH), 7.42-7.45 (m, 1H, ArH), 
7.60-7.64 (m, 2H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 55.5 (OCH3), 111.4 (CH), 
121.0 (CH), 123.1 (CF3, q, 1JCF = 272.83 Hz), 126.5 (C, q, 2JCF = 31.59 Hz), 127.0 (CH, q, 
3JCF = 5.49 Hz), 127.7 (CH, C), 130.0 (CH), 130.6 (CH), 131.7 (C, q, 3JCF = 1.83 Hz), 
132.3 (CH), 143.7 (C), 156.4 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.25 (ArCF3); 
IR (ATR, cm−1): ~ν  = 3069 (w), 3002 (w), 2941 (w), 2836 (w), 1605 (m), 1581 (w), 1555 
(w), 1504 (m), 1482 (m), 1463 (m), 1435 (m), 1386 (m), 1311 (s), 1277 (w), 1251 (m), 
1238 (m), 1175 (m), 1120 (s), 1103 (s), 1056 (w), 1025 (s), 1003 (w), 963 (w), 935 (w), 
889 (m), 851 (w), 833 (m), 784 (m), 748 (s), 731 (w), 682 (m), 635 (m), 615 (w), 593 
(w), 574 (w) , 566 (w), 554 (m); GC-MS (EI, 70 eV): m/z (%): 286 (M+, 100), 267 (7), 
251 (19), 236 (59), 217 (13), 202 (21), 152 (4), 139 (12), 118 (19), 99 (3), 87 (7), 39 (2); 
HRMS (EI) calcd for C14H10ClF3O [M+]: 286.03688 found 286.036464. 
3'-Chloro-2,3-dimethoxy-4'-(trifluoromethyl)biphenyl (23h): 
Starting with 21 (0.215 g, 1 mmol), 22h (0.237 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23h was 
isolated  as colorless oil (0.235 g, 74%). 1H NMR (300.13 MHz, CDCl3): 
δ = 3.53 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 6.78-6.81 (m, 1H, ArH), 
6.85 (dd, J = 8.31 Hz, J = 1.51 Hz, 1H, ArH, ArH), 6.98-7.03 (m, 1H, 
ArH), 7.42-7.45 (m, 1H, ArH), 7.59-7.61 (m, 2H, ArH); 13C NMR (62.89 MHz, CDCl3), 
δ = 55.9 (OCH3), 60.8 (OCH3), 112.9 (CH), 122.0 (CH), 123.1 (CF3, q, 1JCF = 272.89 Hz), 
124.5 (CH), 126.8 (C, q, 2JCF = 31.91 Hz), 127.2 (CH, q, 3JCF = 4.95 Hz), 127.6 (CH), 
131.8 (C, q, 3JCF = 1.65 Hz), 132.1 (CH), 132.9 (C), 143.5 (C), 146.6 (C), 153.3 (C); 19F 
NMR (282.40 MHz, CDCl3): δ = -62.23 (ArCF3); IR (ATR, cm−1): ~ν  = 3030 (w), 2966 
(m), 2933 (w), 2874 (w), 1907 (w), 1606 (m), 1579 (w), 1516 (w), 1474 (m), 1415 (w), 









1029 (m), 1014 (m), 965 (w), 904 (m), 842 (w), 825 (s), 774 (w),  731 (w), 717 (m), 677 
(w), 657 (m), 632 (m), 598 (m), 581 (w), 554 (m); GC-MS (EI, 70 eV): m/z (%): 316 
(M+, 100), 301 (17), 266 (92), 251 (12), 223 (10), 204 (8), 169 (6), 141 (2), 126 (2), 99 
(1), 69 (3); HRMS (EI) calcd for C15H12ClF3O2 [M+]: 316.04724 found 316.046783. 
3'-Chloro-2,3,4-trimethoxy-4'-(trifluoromethyl)biphenyl (23i): 
Starting with 21 (0.215 g, 1 mmol), 22i (0.276 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23i was 
isolated  as colorless oil (0.207 g, 60%). 1H NMR (300.13 MHz, CDCl3): 
δ = 3.61 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 6.63 (d, 
J = 8.69 Hz, 1H, ArH), 6.89 (d, J = 8.69 Hz, 1H, ArH), 7.34 (d, J = 8.12 
Hz, 1H, ArH), 7.56-7.59 (m, 2H, ArH); 13C NMR (75.46 MHz, CDCl3), 
δ = 55.9 (OCH3), 60.9 (OCH3), 61.1 (OCH3), 107.7 (CH), 122.5 (CF3, q, 1JCF = 272.89 
Hz), 124.6 (CH), 125.6 (C), 126.2 (C, q, 2JCF = 31.36 Hz), 127.1 (CH, q, 3JCF = 5.50 Hz), 
127.3 (CH), 131.8 (CH), 142.7 (C), 143.4 (C), 151.4 (C), 153.5 (C), 154.3 (C); 19F NMR 
(282.40 MHz, CDCl3): δ = -62.18 (ArCF3); IR (ATR, cm−1): ~ν  = 2995 (w), 2938 (w), 
2837 (w), 1740 (w), 1596 (s), 1552 (m), 1509 (m), 1484 (m), 1462 (m), 1434 (w), 1416 
(m), 1378 (m), 1313 (w), 1304 (s), 1293 (w), 1257 (w), 1234 (m), 1211 (m), 1175 (s), 
1127 (m), 1104 (s), 1084 (s), 1025 (w), 1009 (s), 927 (m), 883 (m),  838 (m), 794 (s), 759 
(w), 737 (m), 697 (w), 689 (w), 654 (w), 621 (w), 603 (w) , 585 (w), 539 (w); GC-MS 
(EI, 70 eV): m/z (%): 346 (M+, 100), 331 (16), 296 (31), 288 (19), 217 (29), 182 (6), 167 
(2), 132 (1), 99 (2), 69 (2); HRMS (EI) calcd for C16H14ClF3O3 [M+]: 346.05781 found 
346.056833. 
2,3'-Dichloro-4'-(trifluoromethyl)biphenyl (23j): 
Starting with 21 (0.215 g, 1 mmol), 22j (0.202 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23j was 
isolated  as colorless oil (0.135 g, 47%). 1H NMR (300.13 MHz, CDCl3): 
δ = 7.24-7.29 (m, 3H, ArH), 7.35-7.38 (m, 1H, ArH), 7.40-7.43 (m, 1H, 
ArH), 7.51 (s, 1H, ArH), 7.66 (d, 3J = 8.12 Hz, 1H, ArH); 13C NMR 










127.1 (CH), 127.2 (CH, q, 3JCF = 5.49 Hz), 127.8 (CH), 129.7 (CH), 130.2 (CH), 130.9 
(CH), 132.0 (C, q, 3JCF = 1.83 Hz), 132.2 (C), 132.3 (CH), 137.7 (C), 144.3 (C); 19F NMR 
(282.40 MHz, CDCl3): δ = -62.40 (ArCF3); IR (ATR, cm−1): ~ν  = 3061 (w), 2924 (w), 
2854 (w), 1923 (w), 1807 (w), 1607 (m), 1569 (m), 1556 (w), 1503 (m), 1468 (m), 1435 
(m), 1385 (m), 1311 (s), 1264 (w), 1244 (w), 1174 (m), 1125 (s), 1103 (m), 1077 (m), 
1050 (w), 1037(s), 1027 (m), 981 (w), 962 (w), 947 (w), 891 (m),  865 (w), 834 (s), 756 
(m), 749 (m) , 740 (w), 731 (w), 705(m), 671 (m), 636 (m), 598 (w), 562 (w) , 557(w), 
542 (w); GC-MS (EI, 70 eV): m/z (%): 290 (M+, 100), 271 (5), 255 (4), 235 (10), 220 
(25), 201 (5), 186 (12), 170 (4), 150 (5), 123 (1), 99 (2), 50 (1); HRMS (EI) calcd for 
C13H7Cl2F3 [M+]: 289.98714 found 289.987078. 
3-Chloro-4'-fluoro-4-(trifluoromethyl)biphenyl (23k): 
Starting with 21 (0.215 g, 1 mmol), 22k (0.181 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23k was 
isolated  as white solid (0.127 g, 46%); mp 67-69 °C. 1H NMR (300.13 MHz, 
CDCl3): δ = 7.02-7.11 (m, 2H, ArH), 7.37-7.48 (m, 3H, ArH), 7.58 (s, 1H, 
ArH), 7.63 (d, 3J = 8.31 Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 
116.2 (2CH, d, 2JCF = 22.01 Hz), 123.0 (CF3, q, 1JCF = 272.90 Hz), 125.0 (CH), 
128.0 (CH, q, 3JCF = 4.95 Hz), 128.9 (2CH, d, 3JCF = 8.25 Hz), 127.0 (C, q, 2JCF = 31.91 
Hz), 129.8 (CH), 132.8 (C, q, 3JCF = 1.65 Hz), 134.4 (C, d, 4JCF = 3.30 Hz), 145.1 (C), 
163.3 (CF, d, 1JCF = 249.24 Hz); 19F NMR (282.40 MHz, CDCl3): δ = -62.28 (ArCF3), -
112.95 (ArF); IR (ATR, cm−1): ~ν  = 3075 (w), 3049 (w), 2924 (w), 2856 (w), 1890 (w), 
1605 (m), 1598 (m), 1561 (w), 1521 (w), 1495 (m), 1489 (m), 1421 (w), 1383 (m), 1313 
(s), 1290 (w), 1232 (s), 1179 (w), 1160 (w), 1126 (s), 1105 (s), 1059(w), 1038 (w), 1024 
(m), 1014 (w), 959 (w), 884 (m),  839 (w), 820 (s), 804 (m), 764 (w) , 738 (m), 712 (w), 
701(w), 675 (m), 712 (w), 701 (w), 675 (m), 637 (w),  619 (w), 593 (m), 560 (m), 546 
(w); GC-MS (EI, 70 eV): m/z (%): 274 (M+, 100), 238 (4), 219 (15), 170 (19), 120 (1), 







Starting with 21 (0.215 g, 1 mmol), 22l (0.246 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23l was 
isolated  as colorless oil (0.114 g, 35%). 1H NMR (300.13 MHz, CDCl3): δ = 
7.47-7.50 (m, 1H, ArH), 7.59-7.72 (m, 6H, ArH); 13C NMR (75.46 MHz, 
CDCl3), δ = 122.8 (CF3, q, 1JCF = 272.90 Hz), 124.0 (CF3, q, 1JCF = 271.80 
Hz), 125.4 (CH), 127.6 (2CH), 126.1 (2CH, q, 3JCF = 3.85 Hz), 128.2 (CH, q, 
3JCF = 5.50 Hz), 130.1 (CH), 130.9 (2C, q, 2JCF = 32.46 Hz), 133.0 (C, q, 3JCF = 1.65 Hz), 
141.8 (C), 144.6 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.45 (ArCF3), -62.69 
(ArCF3); IR (ATR, cm−1): ~ν  = 2934 (w), 1924 (w), 1737 (w), 1607 (m), 1557 (m), 1492 
(w), 1421 (w), 1381 (m), 1313 (s), 1257 (w), 1165 (w), 1105 (s), 1069 (s), 1038 (w), 
1025 (m), 1014 (m), 964 (w), 956 (w), 890 (m), 850 (w), 824 (s), 771 (w), 742 (w), 732 
(w), 693 (m), 653 (m),  625 (w), 598 (m), 558 (w), 543 (w); GC-MS (EI, 70 eV): m/z 
(%): 324 (M+, 100), 305 (18), 274 (8), 220 (14), 170 (3), 144 (1), 112 (2), 99 (1), 75 (1), 
69 (2); HRMS (EI) calcd for C14H7ClF6 [M+]: 324.01350 found 324.013171. 
3-Chloro-3',4-bis(trifluoromethyl)biphenyl (23m): 
Starting with 21 (0.215 g, 1 mmol), 22a (0.246 g, 1.3 equiv.), Pd(PPh3)4 
(0.058 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (8 mL), 23a was 
isolated  as colorless oil (0.103 g, 32%). 1H NMR (300.13 MHz, 
CDCl3): δ = 7.49-7.61 (m, 3H, ArH), 7.64-7.74 (m, 4H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 122.8 (CF3, q, 1JCF = 273.29 Hz), 123.9 (CF3, q, 
1JCF = 272.37 Hz), 123.9 (CH, q, 3JCF = 4.12 Hz), 124.7 (CH, q, 3JCF = 
3.66 Hz), 125.3 (CH), 125.4 (CH, q, 3JCF = 3.66 Hz), 129.7 (CH), 130.0 (CH), 130.5 
(CH), 131.5 (C, q, 2JCF = 32.04 Hz), 131.7 (C, q, 2JCF = 32.50 Hz), 133.1 (C, q, 3JCF = 
1.83 Hz), 139.1 (C), 144.6 (C); 19F NMR (282.40 MHz, CDCl3): δ = -62.43 (ArCF3), -
62.72 (ArCF3); IR (ATR, cm−1): ~ν  = 3071 (w), 3051 (w), 2926 (w), 1608 (m), 1565 (w), 
1510 (w), 1503 (w), 1484 (w), 1443 (m), 1412 (w), 1385 (m), 1334 (m), 1314 (s), 1289 
(w), 1267 (m), 1255 (m), 1167 (m), 1120 (s), 1104 (s), 1074 (m), 1049(m), 1026 (m), 
1001 (w), 963 (w), 922 (w), 908 (w),  885 (m), 862 (m), 837 (m), 798 (s) , 782 (w), 762 








GC-MS (EI, 70 eV): m/z (%): 324 (M+, 100), 305 (15), 274 (6), 220 (13), 170 (3), 145 
(1), 109 (1), 99 (1), 75 (1), 69 (2); HRMS (EI) calcd for C14H7ClF6 [M+]: 324.01350 
found 324.013577. 
General procedure for the synthesis of 25a-d: A 1,4-Dioxane solution (8 mL) of 21 (1.0 
equiv.), arylboronic acid 24 (2.5 equiv.), 2M K2CO3 (2 mL), and Pd(PPh3)4 (5 mol%) was 
heated at 110 °C for 8 h. After cooling to room temperature, H2O was added and the 
reaction mixture was extracted with CH2Cl2. The organic layer was dried (Na2SO4), 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(gradient elution n-heptane/ethyl acetate). 
4-Trifluoromethyl-1,3-bis(2-methylphenyl)-benzene (25a):
Starting with 21 (0.215 g, 1 mmol), 24a (0.337 g, 2.5 equiv.), 
Pd(PPh3)4 (0.058 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (8 
mL), 25a was isolated as colorless oil (0.186 g, 57%). 1H NMR 
(300.13 MHz, CDCl3): δ = 2.01 (s, 3H, CH3), 2.20 (s, 3H, CH3), 7.09-
7.19 (m, 9H), 7.34 (qd, J = 8.12 Hz, J = 0.94 Hz, 1H, ArH), 7.70 (d, 3J
= 7.93 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 20.1 (CH3), 20.4 (CH3), 124.2 
(CF3, q, 1JCF = 273.74 Hz), 124.9 (CH), 125.9 (CH), 126.0 (CH, q, 3JCF = 5.04 Hz), 127.2 
(C, q, 2JCF = 29.76 Hz), 127.91 (CH), 127.98 (CH), 128.0 (CH), 129.5 (CH), 129.6 
(2CH), 130.6 (CH), 132.4 (CH), 135.2 (C), 135.9 (C), 138.9 (C), 140.2 (C), 140.5 (C, q, 
4JCF = 2.29 Hz), 145.1 (C); 19F NMR (282.40 MHz, CDCl3): δ = -58.80 (ArCF3); IR 
(ATR, cm−1): ~ν  = 3061 (w), 3020 (w), 2953 (w), 2923 (w), 2858 (w), 2738 (w), 2620 
(w), 2576 (w), 1917 (w), 1806 (w), 1727 (w), 1609 (m), 1601 (m), 1564 (m), 1507 (w), 
1479 (m), 1455 (m), 1390 (m), 1310 (s), 1256 (w), 1168 (s), 1116 (s), 1070 (m), 1044 
(w), 1030 (m), 1009 (m),  985 (w), 964 (w), 943 (w), 908 (s), 866 (w), 839 (s), 768 (m), 
754 (s), 739 (m), 724 (s), 692 (m), 653 (m), 639 (m), 630 (m), 597 (m), 557 (m), 539 (m); 
GC-MS (EI, 70 eV): m/z (%): 326 (M+, 100), 311 (9), 285 (5), 257 (19), 242 (10), 215 





Starting with 21 (0.215 g, 1 mmol), 24b (0.337 g, 2.5 equiv.), 
Pd(PPh3)4 (0.058 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (8 
mL), 25b was isolated as colorless oil (0.126 g, 39%). 1H NMR 
(300.13 MHz, CDCl3): δ = 2.32 (s, 3H, CH3), 2.33 (s, 3H, CH3), 7.05-
7.14 (m, 4H), 7.19-7.35 (m, 4H), 7.46 (s, 1H), 7.54-7.58 (m, 1H), 7.69 
(d, 3J = 8.31 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.4 (CH3), 21.5 (CH3), 
124.3 (CF3, q, 1JCF = 273.74 Hz), 124.4 (CH), 125.7 (CH), 126.1 (CH), 126.5 (CH, q, 3JCF
= 5.04 Hz), 127.1 (C, q, 2JCF = 30.21 Hz), 127.7 (CH), 128.0 (CH), 128.4 (CH), 128.8 
(CH), 128.9 (CH), 129.7 (CH), 130.7 (CH), 137.4 (C), 138.6 (C), 139.4 (C), 139.9 (C), 
141.9 (C, q, 4JCF = 1.83 Hz), 144.2 (C); 19F NMR (282.40 MHz, CDCl3): δ = -56.54 
(ArCF3); IR (ATR, cm−1): ~ν  = 3030 (m), 2922 (m), 2853 (w), 2732 (w), 1943 (w), 1876 
(w), 1788 (w), 1726 (w), 1603 (m), 1585 (w), 1567 (m), 1479 (m), 1454 (w), 1379 (m), 
1309 (s), 1267 (w), 1165 (m), 1117 (s), 1096 (w), 1078 (m), 1031 (s), 999 (w), 962 (w), 
895 (w), 881 (w), 835 (m),  783 (s), 758 (w), 734 (w), 703 (s), 694 (w), 643 (m), 611 (w), 
589 (m), 563 (w); GC-MS (EI, 70 eV): m/z (%): 326 (M+, 100), 305 (11), 291 (5), 257 
(3), 165 (3), 128 (1), 91 (1); HRMS (EI) calcd for C21H17F3 [M+]: 326.12769 found 
326.127119. 
4-Trifluoromethyl-1,3-bis(4-methylphenyl)-benzene (25c): 
Starting with 21 (0.215 g, 1 mmol), 24c (0.337 g, 2.5 equiv.), 
Pd(PPh3)4 (0.058 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (8 
mL), 25c was isolated as colorless oil (0.196 g, 60%). 1H NMR (300.13 
MHz, CDCl3): δ = 2.29 (s, 3H, CH3), 2.32 (s, 3H, CH3), 7.11-7.20 (m, 
6H, ArH), 7.37-7.44 (m, 3H, ArH), 7.51-7.55 (m, 1H, ArH), 7.66 (d, 3J
= 8.12 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.2 (CH3), 
21.3 (CH3), 124.4 (CF3, q, 1JCF = 274.20 Hz), 125.4 (CH), 126.6 (CH, q, 3JCF = 5.49 Hz), 
126.8 (CH), 127.0 (C, q, 2JCF = 30.21 Hz), 127.1 (2CH), 128.6 (CH), 128.89 (CH, q, 5JCF
= 1.37 Hz),), 129.5 (CH), 129.7 (2CH), 130.6 (CH), 136.6 (C), 136.7 (C), 137.0 (C), 
138.2 (C), 141.9 (C), 144.0 (C); 19F NMR (282.40 MHz, CDCl3): δ = -56.47 (ArCF3); IR 




(m), 1798 (w), 1732 (w), 1652 (w), 1607 (s), 1578 (w), 1561 (w), 1515 (m), 1500 (w), 
1490 (m), 1455 (w), 1417 (w), 1383 (m), 1348 (w), 1307 (s), 1281 (w), 1264 (w), 1211 
(w), 1170 (s), 1118 (s), 1111 (s), 1075 (s), 1029 (s), 1008 (m), 963 (w), 945 (w), 901 (m), 
841 (m), 809 (s), 801 (m), 779 (w), 758 (m), 738 (w), 720 (m), 698 (w), 679 (w), 653 
(w), 641 (w), 626 (w), 606 (w), 586 (m), 565 (w), 540 (m); GC-MS (EI, 70 eV): m/z (%): 
326 (M+, 100), 286 (1), 257 (4), 215 (2), 165 (3), 91 (2); HRMS (EI) calcd for C21H17F3
[M+]: 326.12769 found 326.127380. 
4-Trifluoromethyl-1,3-bis(4-fluorophenyl)-benzene (25d):
Starting with 21 (0.215 g, 1 mmol), 24d (0.348 g, 2.5 equiv.), 
Pd(PPh3)4 (0.058 g, 0.05 equiv.), 2M K2CO3 (2 mL), 1,4-Dioxane (8 
mL), 25d was isolated as colorless oil (0.165 g, 49%). 1H NMR 
(300.13 MHz, CDCl3): δ = 6.99-7.09 (m, 4H, ArH), 7.24-7.28 (m, 2H, 
ArH), 7.39 (s, 1H, ArH), 7.48-7.57 (m, 3H, ArH), 7.71 (d, 3J = 8.12 
Hz, 1H, ArH); 13C NMR (75.46 MHz, CDCl3), δ = 114.9 (2CH, d, 2JCF
= 22.01 Hz), 116.0 (2CH, d, 2JCF = 21.46 Hz), 124.2 (CF3, q, 1JCF = 273.45 Hz), 125.9 
(CH), 126.8 (CH, q, 3JCF = 5.50 Hz), 127.4 (C, q, 2JCF = 30.26 Hz), 128.9 (2CH, d, 3JCF = 
8.25 Hz), 130.6 (2CH), 130.7 (C, q, 3JCF = 1.65 Hz), 135.4 (C, d, 4JCF = 3.30 Hz), 135.6 
(C, d, 4JCF = 3.30 Hz), 140.9 (C, q, 3JCF = 1.65 Hz), 143.2 (C), 162.6 (CF, d, 1JCF = 247.04 
Hz), 163.1 (CF, d, 1JCF = 248.14 Hz); 19F NMR (282.40 MHz, CDCl3): δ = -56.73 
(ArCF3), -113.77 (ArF), -114.50 (ArF); IR (ATR, cm−1): ~ν  = 3046 (w), 2923 (w), 2854 
(w), 1894 (w), 1608 (m), 1568 (w), 1511 (m), 1490 (m), 1405 (w), 1384 (w), 1309 (s), 
1264 (w), 1224 (m), 1174 (w), 1117 (s), 1095 (w), 1076 (m), 1030 (m), 1010 (w), 961 
(w), 903 (w), 822 (s), 790 (m), 721 (m), 679 (m), 635 (w), 621 (w), 605 (w), 585 (w), 563 
(m), 542 (m); GC-MS (EI, 70 eV): m/z (%): 334 (M+, 100), 313 (7), 264 (9), 244 (6), 219 






General procedure for the synthesis of 27a-d: A 1,4-dioxane solution (8 mL) of 23 (1.0 
equiv.), arylboronic acid 26 (1.3 equiv.), 2M K2CO3 (1 mL), and Pd(PPh3)4 (5 mol%) was 
heated at 110 °C for 8 h. After cooling to room temperature, H2O was added and the 
reaction mixture was extracted with CH2Cl2. The organic layer was dried (Na2SO4), 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(gradient elution n-heptane/ethyl acetate). 
1-(4'- Methylphenyl)-3-(4''-fluorophenyl)-4-trifluoromethylbenzene (27a): 
Starting with 23c (0.12 g, 0.4 mmol), 26a (0.072 g, 1.3 equiv.), 
Pd(PPh3)4 (0.023 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (4 
mL), 27a was isolated as colorless oil (0.037 g, 25%). 1H NMR 
(300.13 MHz, CDCl3): δ = 2.33 (s, 3H, CH3), 6.99-7.07 (m, 2H, ArH), 
7.17-7.29 (m, 4H, ArH), 7.43-7.46 (m, 3H, ArH), 7.59 (d, 3J = 8.31 
Hz, 1H, ArH), 7.70 (d, 3J = 8.12 Hz, 1H, ArH); 13C NMR (75.46 MHz, 
CDCl3), δ = 21.2 (CH3), 114.8 (2CH, d, 2JCF = 21.46 Hz), 124.3 (CF3, q, 1JCF = 273.45 
Hz), 125.8 (CH), 126.7 (CH, q, 3JCF = 4.95 Hz), 127.1 (2CH), 127.5 (C, q, 2JCF = 30.81 
Hz), 129.7 (2CH), 130.5 (CH), 130.7 (2CH, d, 3JCF = 8.25 Hz), 135.8 (C, d, 4JCF = 3.30 
Hz), 136.4 (C), 140.8 (C, q, 3JCF = 2.20 Hz), 138.3 (C), 144.2 (C), 162.5 (CF, d, 1JCF = 
247.04 Hz); 19F NMR (282.40 MHz, CDCl3): δ = -56.64 (ArCF3), -114.74 (ArF); IR 
(ATR, cm−1): ~ν  = 3028 (w), 2923 (w), 2859 (w), 2733 (w), 1901 (w), 1741 (w), 1606 
(m), 1563 (w), 1512 (m), 1490 (m), 1417 (w), 1308 (s), 1282 (w), 1224 (m), 1172 (m), 
1117 (s), 1076 (m), 1030 (m), 1010 (w), 962 (w), 837 (m), 810 (s), 783 (w), 741 (w), 702 
(w), 639 (w), 624 (w), 587 (w), 564 (w), 542 (w); GC-MS (EI, 70 eV): m/z (%): 330 (M+, 
100), 289 (3), 261 (7), 246 (5), 220 (2), 183 (2), 165 (10), 144 (3), 109 (1), 91 (3), 89 (1), 





1-(4'- Methylphenyl)-3-(4''-methoxyphenyl)-4-trifluoromethylbenzene (27b): 
Starting with 23c (0.08 g, 0.3 mmol), 26b (0.059 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (4 
mL), 27b was isolated as colorless oil (0.06 g, 59%). 1H NMR (300.13 
MHz, CDCl3): δ = 2.31 (s, 3H, CH3), 3.76 (s, 3H, OCH3), 6.86 (d, 3J = 
8.69 Hz, 2H, ArH), 7.15-7.24 (m, 4H, ArH), 7.39-7.44 (m, 3H, ArH), 
7.52-7.55 (m, 1H, ArH), 7.68 (d, 3J = 8.12 Hz, 1H, ArH); 13C NMR 
(62.89 MHz, CDCl3), δ = 21.1 (CH3), 55.3 (OCH3), 113.3 (2CH), 
124.4 (CF3, q, 1JCF = 273.74 Hz), 125.3 (CH), 126.6 (CH, q, 3JCF = 5.49 Hz), 127.0 (C, q, 
2JCF = 29.76 Hz), 127.1 (2CH), 129.7 (2CH), 130.2 (2CH, q, 5JCF = 1.37 Hz), 130.7 (CH), 
132.3 (C), 136.5 (C), 138.2 (C), 141.6 (C, q, 3JCF = 1.83 Hz), 144.0 (C), 159.2 (C); 19F 
NMR (282.40 MHz, CDCl3): δ = -56.56 (ArCF3); IR (ATR, cm−1): ~ν  = 3030 (w), 3000 
(w), 2934 (w), 2836 (w), 1607 (m), 1562 (w), 1510 (m), 1463 (w), 1385 (w), 1307 (s), 
1291 (w), 1243 (m), 1170 (m), 1116 (s), 1107 (s), 1076 (m), 1029 (s), 1004 (w), 962 (w), 
930 (m), 809 (s), 762 (w), 679 (w), 624 (w), 606 (w), 587 (w), 573 (w), 545 (w); GC-MS 
(EI, 70 eV): m/z (%): 342 (M+, 100), 279 (5), 264 (6), 249 (3), 233 (2), 215 (2), 171 (4), 
124 (1), 91 (2), 65 (1), 39 (1); HRMS (EI) calcd for C21H17F3O [M+]: 342.12260 found 
342.122754. 
1-(4'- Methylphenyl)-3-(3'',5''-dimethylphenyl)-4-trifluoromethylbenzene (27c): 
Starting with 23c (0.08 g, 0.3 mmol), 26c (0.058 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (4 
mL), 27c was isolated as colorless oil (0.065 g, 64%). 1H NMR 
(300.13 MHz, CDCl3): δ = 2.28 (s, 6H, 2CH3), 2.31 (s, 3H, CH3), 6.92 
(s, 2H, ArH), 6.96 (s, 1H, ArH), 7.17 (d, 3J = 8.50 Hz, 2H, ArH), 7.42-
7.45 (m, 3H, ArH), 7.53-7.56 (m, 1H, ArH), 7.68 (d, 3J = 8.31 Hz, 1H, 
ArH); 13C NMR (62.89 MHz, CDCl3), δ = 21.1 (CH3), 21.3 (2CH3), 
124.4 (CF3, q, 1JCF = 271.91 Hz), 125.3 (CH), 126.4 (C, q, 2JCF = 30.67 Hz), 126.6 (CH, q, 
3JCF = 5.49 Hz), 126.8 (2CH, q, 5JCF = 1.37 Hz), 127.1 (2CH), 129.3 (CH), 129.7 (2CH), 
130.5 (CH), 136.6 (C), 137.2 (2C), 138.2 (C), 139.9 (C), 142.1 (C, q, 3JCF = 1.83 Hz), 





~ν  = 3023 (w), 2952 (w), 2919 (m), 2862 (w), 2735 (w), 1917 (w), 1598 (m), 1562 (w), 
1470 (w), 1381 (w), 1307 (s), 1281 (m), 1192 (w), 1161 (m), 1119 (s), 1095 (w), 1027 
(m), 964 (w), 900 (w), 858 (m), 811 (s), 772 (w), 717 (w), 704 (m), 659 (w), 646 (w), 633 
(w), 589 (m), 541 (w); GC-MS (EI, 70 eV): m/z (%): 340 (M+, 100), 305 (7), 271 (4), 256 
(5), 239 (5), 170 (4), 162 (5), 141 (1), 127 (3), 105 (3), 91 (2), 77 (1), 65 (1), 51 (1), 39 
(1); HRMS (EI) calcd for C22H19F3 [M+]: 340.14334 found 340.143000. 
1-(4'-Methylphenyl)-3-(4''-ethylphenyl)-4-trifluoromethylbenzene (27d):
Starting with 23c (0.08 g, 0.3 mmol), 26d (0.059 g, 1.3 equiv.), 
Pd(PPh3)4 (0.017 g, 0.05 equiv.), 2M K2CO3 (1 mL), 1,4-Dioxane (4 
mL), 27d was isolated as colorless oil (0.04 g, 40%). 1H NMR (300.13 
MHz, CDCl3): δ = 1.21 (t, J = 7.55 Hz, 3H, CH3), 2.31 (s, 3H, CH3), 
2.63 (q, J = 7.74 Hz, J = 15.30 Hz, 2H, -CH2-), 7.16-7.23 (m, 6H, 
ArH), 7.41-7.46 (m, 3H, ArH), 7.54-7.57 (m, 1H, ArH), 7.68 (d, 3J = 
8.31 Hz, 1H, ArH); 13C NMR (62.89 MHz, CDCl3), δ = 15.4 (CH3), 
21.1 (CH3), 28.6 (-CH2-), 124.4 (CF3, q, 1JCF = 274.20 Hz), 125.3 (2CH), 126.6 (CH, q, 
3JCF = 5.50 Hz), 127.1 (2CH), 127.3 (2CH), 128.5 (C), 128.9 (CH, q, 4JCF = 1.83 Hz), 
129.6 (2CH), 126.9 (C, q, 2JCF = 30.21 Hz), 130.6 (CH), 136.5 (C), 137.3 (C), 141.9 (C, 
q, 3JCF = 1.83 Hz), 143.6 (C), 143.9 (C); 19F NMR (282.40 MHz, CDCl3): δ = -56.50 
(ArCF3); IR (ATR, cm−1): IR (ATR, cm−1): ~ν  = 3025 (w), 2928 (w), 2872 (w), 2731 (w), 
2620 (w), 2431 (w), 2302 (w), 1905 (w), 1728 (w), 1665 (w), 1606 (m), 1514 (w), 1454 
(w), 1384 (w), 1307 (s), 1265 (w), 1170 (m), 1112 (s), 1075 (m), 1029 (m), 1008 (w), 963 
(w), 902 (w), 833 (w), 809 (s), 773 (w), 718 (w), 640 (w), 626 (w), 608 (w), 587 (w), 541 
(w); GC-MS (EI, 70 eV): m/z (%): 340 (M+, 98), 325 (100), 305 (5), 270 (6), 241 (4), 189 
(2), 162 (14), 127 (3), 105 (4), 91 (4), 65 (2), 51 (1), 39 (1); HRMS (EI) calcd for 
C22H19F3 [M+]: 340.14334 found 340.142981. 
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 Appendix: Crystal Data and Structure Refinement
Table 14.  Crystal data and structure refinement for 9f. 
Identification code  is_n15 
Empirical formula  C16H13ClN2O2
Formula weight  300.73 
Temperature  173 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.)  P21/n  
Space group (Hall)  -P 2yn 
Unit cell dimensions a = 8.9306 (3) Å α= 90.00° 
b = 24.0720 (7) Å β= 105.2530 (10)° 
c = 13.6808 (4) Å γ = 90.00° 
Volume 2837.46 (15) Å3
Z 8 
Density (calculated) 1.408 Mg/m3
Absorption coefficient 0.28 mm-1
F(000) 1248 
Crystal size 0.38 x 0.27 x 0.17 mm 
Θ range for data collection 2.5° to 30.0°. 
Index ranges -12h12, -32k33, -14l19 
Reflections collected 32140 
Independent reflections 8276 [R(int) = 0.0254] 
Completeness to Θ = 30.00° 99.8% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.955 and 0.903 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 6331 / 0 / 383 
Goodness-of-fit on F2 1.040 
Final R indices [F2>2σ(F2)] R1 = 0.0456, wR = 0.0981 
R indices (all data) R1 = 0.0655, wR(F2) = 0.1063 
Largest diff. peak and hole 0.302 and -0.379 e.Å-3
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Table 15.  Crystal data and structure refinement for 11c. 
Identification code  is_n10
Empirical formula  C24H22N2
Formula weight  338.44 
Temperature  173 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.) P21/n  
Space group (Hall)  -P 2yn 
Unit cell dimensions a = 15.4248 (5) Å α= 90.00° 
b = 15.6793 (6) Å β= 110.744 (2)° 
c = 16.1729 (6) Å γ = 90.00° 
Volume 3657.8 (2) Å3
Z 8 
Density (calculated) 1.229 Mg/m3
Absorption coefficient 0.07 mm-1
F(000) 1440 
Crystal size 0.54 x 0.25 x 0.22 mm 
Θ range for data collection 1.6° to 28.00° 
Index ranges -18h20, -20k20, -21l21 
Reflections collected 36789 
Independent reflections 8834 
Completeness to Θ = 28.00° 99.9% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.984 and 0.962 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 6452 / 0 / 477 
Goodness-of-fit on F2 1.08 
Final R indices [F2>2σ( F2)] R1 = 0.046, wR = 0.1292 
R indices (all data) R1 = 0.0657, wR(F2) = 0.1400 
Largest diff. peak and hole 0.317 and -0.200 e.Å-3
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Table 16.  Crystal data and structure refinement for 16g. 
Identification code  av_q3
Empirical formula  C15H11ClN2O
Formula weight  270.71 
Temperature  173 K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group (H.-M.)  P -1 
Space group (Hall)  -P 1 
Unit cell dimensions a = 3.8558 (10) Å α= 62.043 (10)° 
b = 13.376 (3 Å β= 89.839 (11)° 
c = 13.951 (3) Å γ = 84.563 (10)° 
Volume 632.0 (3) Å3
Z 2 
Density (calculated) 1.423 Mg/m3
Absorption coefficient 0.29 mm-1
F(000) 280 
Crystal size 1.11 x 0.21 x 0.14 mm 
Θ range for data collection 1.7° to 30.0° 
Index ranges -5h5, -18k18, -19l19 
Reflections collected 11308 
Independent reflections 3632 
Completeness to Θ = 30.0° 98.2% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.960 and 0.736 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3267  / 0 / 173 
Goodness-of-fit on F2 1.040 
Final R indices [F2>2σ( F2)] R1 = 0.0373, wR = 0.0979 
R indices (all data) R1 = 0.0419, wR(F2) = 0.1011 
Largest diff. peak and hole 0.346 and -0.368 e.Å-3
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Table 17.  Crystal data and structure refinement for 20e. 
Identification code  av_q19
Empirical formula  C22H17FN2
Formula weight  328.38 
Temperature  173 K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group (H.-M.)  P -1 
Space group (Hall)  -P 1 
Unit cell dimensions a = 7.3626 (3) Å α= 88.380 (2)° 
b = 11.8575 (4) Å β= 85.796 (2)° 
c = 18.6843 (7) Å γ = 88.122 (2)° 
Volume 1625.37 (11) Å3
Z 4 
Density (calculated) 1.342 Mg/m3
Absorption coefficient 0.09 mm-1
F(000) 688 
Crystal size 0.30 x 0.12 x 0.05 mm 
Θ range for data collection 1.7° to 28.1° 
Index ranges -9h9, -15k15, -24l24 
Reflections collected 36045 
Independent reflections 7929 
Completeness to Θ = 28.1° 99.6% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.996 and 0.974 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 5345 / 0 / 455 
Goodness-of-fit on F2 1.07 
Final R indices [F2>2σ( F2)] R1 = 0.045, wR = 0.1128 
R indices (all data) R1 = 0.0760, wR(F2) = 0.124 
Largest diff. peak and hole 0.27 and -0.23 e.Å-3
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Table 18.  Crystal data and structure refinement for 23c. 
Identification code  av_a133a 
Empirical formula  C14H10ClF3
Formula weight  270.67 
Temperature  173 K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group (H.-M.)  P -1 
Space group (Hall)  -P 1 
Unit cell dimensions a = 9.3940 (7) Å α= 97.508 (4)° 
b = 9.4551 (7) Å β= 91.207 (4)° 
c = 13.7991 (9) Å γ = 102.301 (4)° 
Volume 1185.73 (15) Å3
Z 4 
Density (calculated) 1.516 Mg/m3
Absorption coefficient 0.34 mm-1
F(000) 552 
Crystal size 0.28 x 0.25 x 0.03 mm 
Θ range for data collection 5.5° to 64.9° 
Index ranges -12h12, -12k12, -18l18 
Reflections collected 26270 
Independent reflections 6257 
Completeness to Θ = 28.1° 99.4% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.990 and 0.912 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3390 / 8 / 353 
Goodness-of-fit on F2 0.97 
Final R indices [F2>2σ(F2)] R1 = 0.041, wR = 0.1070 
R indices (all data) R1 = 0.0929, wR(F2) = 0.121 
Largest diff. peak and hole 0.42 and -0.25 e.Å-3
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Abbreviations
Ac  Acetyl  
M+  Molecular ion  
calcd  Calculated  
CI  Chemical Ionization  
COSY  Correlation Spectroscopy 
DEPT  Distortionless Enhancement by Polarization Transfer  
HSQC  Heteronuclear Single Quantum Correlation 
EI  Electron Impact   
GC  Gas Chromatography  
EI-MS  Electron Impact Mass Spectrum  
HMBC Heteronuclear Multiple Bond Correlation  
HRMS  High Resolution Mass Spectrometry  
IR  Infrared Spectroscopy  
MS  Mass Spectrometry  
mp  Melting point  
NMR  Nuclear Magnetic Resonance  
NOESY Nuclear Overhauser and Exchange Spectroscopy 
ORTEP Oak Ridge Thermal Ellipsoid Plot   
Ph  Phenyl  
ppm  Parts per million  
Rf  Retention factor  
THF  Tetrahydrofuran  
TLC  Thin Layer Chromatography  
TMS   Tetramethylsilane  
Tol  Tolyl (p-MeC6H4) 
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